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Abstract
Paclitaxel has established an evolving role in the management of ovarian cancer. However, 
the emergence of resistance to paclitaxel is likely to become an increasing problem, and thus a 
reason for failure of therapy of ovarian cancer. Understanding of the molecular pathways 
involved in the development of resistance to paclitaxel may provide suitable targets for novel 
therapies to help to circumvent resistance to paclitaxel. Three main mechanisms have been 
shown to be involved in paclitaxel resistance: (a) altered paclitaxel uptake, (b) altered 
paclitaxel-microtubules interaction, (c) alterations in apoptosis regulating proteins that control 
the induction o f cell death.
The realization that most chemotherapeutic agents- including paclitaxel- induce cell death by 
a genetically programmed process termed apoptosis together with the demonstration that 
alteration of apoptosis regulating proteins such as bcl-2 family of proteins or p53 may induce 
chemoresistance to paclitaxel has led to intense research in this area. Almost all these studies 
were in vitro with an obvious lack of in vivo studies. Hence, these apoptosis regulating 
proteins were the focus of the present in vivo study as they may either represent oncogenes 
responsible for acquired resistance, or alternatively potential targets for molecular 
intervention to circumvent resistance to paclitaxel.
The first part o f the study compared the alterations in apoptosis regulating proteins between 
CHI paclitaxel sensitive xenografts (CHl/TS) and acquired paclitaxel resistant xenografts 
(CHl/TR). These xenografts were established from a CHI paclitaxel sensitive cell line treated 
with paclitaxel which then acquired resistance in vitro. Following the confirmation of the 
sensitivity pattern of both tumours to paclitaxel in vivo, it was demonstrated that there was no 
paclitaxel uptake defect in CHl/TR tumours that may contribute to paclitaxel resistance. Flow 
cytometric and apoptosis studies provided an insight into the mechanism of action of 
paclitaxel. They confirmed the response pattern with paclitaxel inducing mitotic arrest, G2/M 
phase arrest, and apoptosis in CHl/TS tumours. In contrast, these parameters were unaltered 
in the CHl/TR tumours, consistent with its resistant phenotype. There were clear differences 
in the induction of apoptosis regulating proteins between the paclitaxel sensitive and resistant 
tumours. Following the treatment of CHf/TS tumours with paclitaxel, there was a significant
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early induction o f p53, and p21 with evidence of inactivation (phosphorylation) of survival 
promoting (anti-apoptotic) protein bcl-2, and down regulation of anti-apoptotic protein bcl-xl. 
These changes were not significantly altered in CHl/TR tumours.
Subsequently, these xenografts were treated with cisplatin to compare and contrast its effect 
to that of paclitaxel. The first difference demonstrated was that both CHl/TS and CHl/TR 
tumours displayed complete and partial response, respectively, to cisplatin. In contrast to 
paclitaxel, the main cell cycle alterations to cisplatin were accumulation of cells in S phase, 
and late G2 arrest. These cell cycle alterations were shown to be associated with induction of 
apoptosis. More importantly, it was observed that cisplatin was able to induce p53 and down 
regulate bcl-xl in CHl/TR tumours suggesting that these pathway are intact. This suggested 
that CHl/TR tumours acquired resistance to paclitaxel was not due to inherent defect in the 
expression of apoptosis regulating proteins, but instead due to an upstream defect possibly at 
the level of paclitaxel-microtubule interaction. This is consistent with previous in vitro studies 
that have shown that successfiii polymerization of microtubules is required for induction of 
cell death, induction of p53 and p21 and phosphorylation o f bcl-2. Taking all these 
observations into consideration, it could postulated that resistance to paclitaxel in CHl/TR 
tumours that was reflected in the lack of significant alteration in apoptosis regulating protein 
was due to unsuccessful microtubule-paclitaxel interaction which is supported by the lack of 
G2/M arrest and induction of apoptosis. The paclitaxel-microtubule interaction will be the 
focus of a subsequent study.
The second part o f this study demonstrated in vivo that the overexpression of a single 
apoptosis regulating protein resulted in the modulation of response to chemotherapy. 
Xenografts of CHI paclitaxel sensitive cells overexpressing the anti-apoptotic protein bcl-xl 
were established and treated with paclitaxel and cisplatin. The overexpression of bcl-xl 
protein resulted in development of chemoresistance to paclitaxel and cisplatin. This 
observation was particularly important because it demonstrated that these proteins do control 
a common pathway controlling cell death, and further underline their importance as possible 
targets for moletmlar therapy.
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1.1 Developm ent of chemotherapy treatment for ovarian cancer 
1.1,1. Introduction
I
.Epithelial ovarian cancer is the sixth most common neoplasm among women worldwide and
contributing factors to the poor outcome (Trope C, 1997).
the leading cause of death jfrom gynaecological cancers, with an incidence rate of about 15 per 
100,000 women in the western world. Despite the improvement in the management of ovarian 
cancer, it still has a poor prognosis. The fact that up to 64% o f patients present with advanced 
disease (FIGO stage III and IV) and the development of chemoresistance are the two main
The present standard management of advanced ovarian cancer consists of aggressive surgical
cytoreduction followed by chemotherapy. Surgery is the cornerstone of management and it is
.supported mainly by retrospective data that show a clear inverse correlation between volume 
of residual disease and both response to chemotherapy and survival (Hacker NF, 1983). 
Ovarian cancer is chemotherapy sensitive with 70% to 80% of patients responding to 
platinum-based chemotherapy. Furthermore, 20% of patients with suboptimally debulked 
disease (residual disease greater than or equal to 1 cm) and 50% with optimally debulked 
disease (residual disease less than 1 cm) will achieve complete pathological response as 
determined by second look lapratomy (Kristensen GB, 1997).
The evolution of chemotherapeutic regimens for management of ovarian has progressed
‘through phases. Before 1978 the standard chemotherapy following surgery was single 
alkalyting agent (melphalan) or a combination of an alkalyting agent (cyclophosphamide) and 
doxorubicin (AC) (Tobias IS, 1976). Subsequently, two chemotherapeutic agents dominated 
the management of ovarian cancer, cisplatin and paclitaxel.
ft
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1.1.2 Cfinicaf development of cisplatin-based chemotherapy
Following the demonstration of activity of cisplatin (P) in ovarian cancer, it was added to 
cyclophosphamide and doxorubicin (CAP). The Gynecologic Oncology Group (GOG) study 
47 randomized patients with large volume advanced disease to receive either AC or CAP 
regimen (Omura G, 1986). The addition of cisplatin to the regimen resulted in improvement 
in complete and overall response rate, duration of response and survival in patients with 
measurable disease. Subsequently, the Netherlands joint study group confirmed the 
superiority of cisplatin containing regimen over non-platinum containing regimens with 
improvement in survival (Neijt JP, 1991). A large meta-analysis further substantiated the 
superiority of platinum compound containing regimens (Advanced Ovarian Cancer Trialists 
Group, 1991).
These studies established platinum-based chemotherapy as the treatment of choice and 
subsequent trials were aimed at improving the therapeutic index and reduction of toxicity. The 
first modification was to assess the role of doxorubicin. The GOG study 52 randomized 
patients with small volume stage HI disease to receive either CAP or cyclophosphamide and 
cisplatin only (Omura GA, 1989). There was no difference between the two regimens in terms 
of response or survival with reduced toxicity for cisplatin combination. Four other trails 
reached the same conclusion and established the cisplatin and cyclophosphamide combination 
as the regimen of choice (Bertelsen K, 1987; Conte PF, 1986; Hemadi Z, 1988) ((Gruppo 
Interegionale Coopérative Oncologico Ginecologia, 1987).
The second modification was to assess the role of escalating cisplatin dose intensity. Although 
not completely a close issue today, high dose cisplatin did not offer any significant outcome 
advantage for patients with advanced ovarian cancer (McGuire WP, 1998). The GOG study 
randomized 97 patients to receive either cisplatin 50 mg/m^or cyclophosphamide 500 mg/m^ 
every 3 weeks for eight cycles or cisplatin 100 mg/m^ and cyclophosphamide 1000 mg/m^ 
every 3 weeks for four cycles. There was no statistically significant difference in terms of 
response or survival between the two regimens (McGuire WP, 1995). In contrast, a Scottish 
study randomized patients to receive cyclophosphamide 750 mg/m^ and either 50 mg/m^ or
18
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100 mg/m of cisplatin for 6 cycles. An improvement in response rate and overall survival 
.was reported for higher dose (Kaye SB, 1992). However, the study design allowed the high 
dose arm to receive double dose intensity, but also double total dose. Thus, it was concluded 
that the total dose was a key issue in determining efficacy as opposed to total dose intensity 
and more mature data suggest overall survival curves are beginning to converge (Kaye SB,
1996b).
The third modification in platinum-based regimens was the introduction of less toxic platinum j
compound, carboplatinum. Four randomized trials have compared cisplatin-based
combination and carboplatin-based combination (Alberts DS, 1992; Hannigan EV, 1993;
Swenerton K, 1992; Ten Bokkel Huinink WW, 1988). There was no difference in response or
overall survival, however carboplatinum had a more favourable toxicity profile. Recently the
second international collaborative ovarian study (IC0N2) randomized patients to receive
.cyclophosphamide, doxorubicin, and cisplatin combination or carboplatin alone. There was no 
difference in response or survival between the two arms (International Collaborative Ovarian 
Neoplasm Study, 1998). I
Unfortunately, most patients with advanced ovarian cancer responding to platinum-based
.chemotherapy will ultimately relapse developing recurrent disease that is usually resistant to 
further chemotherapy (acquired resistance). In addition, 20-30% of patients with advanced 
tumours will not respond to chemotherapy (innate resistance) and these patients have poor 
prognosis with survival less than 6 to 12 months (McGuire WP, 1998). Hence, the need for 
development and incorporation of new drugs in the management of ovarian cancer has been 
an intense area of research over the last two decades. In the 1990s the taxanes, in particular 
paclitaxel, were developed and have now become incorporated in primary therapy. In fact, 
paclitaxel and platinum based regimen has already been shown to improve outcome in the 
management of advanced ovarian cancer in terms of response and survival (McGuire WP,
1996; Stuart G, 1998). The success of paclitaxel in management of ovarian cancer is probably 
due to its unique mechanism of action targeting the microtubules and cytotoxicity, which is 
different from DNA damaging agent such as platinum drugs. Is
1.1.3 Clinical development of paclitaxel-based chemotherapy
Following the demonstration of activity of paclitaxel in ovarian cancer in phase I studies, five 
phase II trials were conducted in total o f 198 patients with progressive, relapsed ovarian 
cancer treated with cisplatin. There was an overall response rate o f 29%, which was certainly 
encouraging in this group of patients with resistant disease (Einzig AI, 1992; Kohn EC, 1994; 
McGuire WP, 1989; Thigpen JT, 1994).
The next step was to explore the dosing and scheduling of paclitaxel and to develop 
paclitaxel-based regimens. A joint NCI-Canada/ European trial in patients who received up to 
2 prior platinum based regimens, compared 2 doses (135 vs. 175 mg/m^) and 2 infusion times 
(3 vs. 24hours) in a bifactorial randomized design (Eisenhauer EA, 1994). In 382 evaluable 
patients the overall response rate was 17.3% (12% in platinum-refractory patients). There was 
no statistical difference between those randomized to high versus low dose (response rate 
20% vs. 15%) or long versus short infusion (19 vs. 16%). There was a statistically significant 
advantage to the higher dose and to shorter infiision in terms of time to progression, but no 
difference in survival or quality of life. This trial provided some important observation on 
toxicity. The frequency of hypersensitivity and significant cardiac toxicity were low (<1%) in 
all groups regardless of schedule. The myelosupression was significantly less common with 3 
hour infusion. The incidence of peripheral neuropathy did not appear to be schedule- 
dependent, although there was a trend towards more neurotoxicity with higher paclitaxel dose.
The demonstration that paclitaxel is non-cross resistant with cisplatin gave the rational for the 
use of paclitaxel in combination with cisplatin in adjuvant setting in order to improve the 
outcome. So far three randomized trials have been reported, one reported in full and two in 
abstract form (tablel-1). The GOG study 111 randomized 410 suboptimally debulked patients 
to receive either paclitaxel 135mg/m^ over 24hours plus cisplatin 75mg/m^ or 
cyclophosphamide 750mg/m^ and the same dose of cisplatin. The paclitaxel arm was superior 
in terms of response rate (77% vs. 64%, p<0.01), median time to progression (18 vs. 13 
months, p=0.0001) and median overall survival (37.5 vs. 24.4 months, p=0.0001)(McGuire 
WP, 1996). Recently, the results of an intergoup collaborative trial conducted in Europe and
20
Canda has become available. This study differed from the GOG study in that 35% of patients
had low volume disease at entry, the paclitaxel was administered at 175 mg/m^ over 3 hours,
'and second look surgery was not required to assess pathological response. The paclitaxel arm
; =:
had improved response rate (77% vs. 66%, p=0.02), clinical CR rate (57% vs. 43%, p=0.01), 
progression free survival (16.6 vs. 12 months, p-0.0001), median survival (35 vs. 25 months) 
(Stuart G, 1998). Finally, the GOG study 132 also recently reported the results of a large 
study in 615 patients with bulky ovarian cancer randomized to receive cisplatin alone (100 
mg/m^), paclitaxel alone (200 mg/m over 24 hours), or paclitaxel (135mg/m^ over 24 hours) 
and cisplatin (75 mg/m^) combination (Muggia FM, 1997). As shown in table 1, the 
paclitaxel alone arm was inferior to the other two arms in terms of response and survival. The 
response rate and median survival were similar in cisplatin only arm and paclitaxel and 
cisplatin combination, however the toxicity was less in the combination regimen. However, in 
this trail there has been cross over between in large number o f patients and at an early stage of 
treatment. Thus the interpretation of these results is difficult since most patients received both 
drugs.
More recently, a panel of oncologist treating ovarian cancer in United Kingdom published a
consensus statement on standard management of ovarian cancer. It was recommended based
on current evidence including the GOG 132 study that combination of paclitaxel and platinum 
.compound is the regimen of choice for majority of patients with advanced ovarian cancer 
(Adams M, 1998).
Unfortunately, both the innate and acquired resistance to paclitaxel are now well recognized. 
Thus, the understanding of molecular pathways of mechanisms of action and resistance of 
paclitaxel has become an intense area of research over the last few years with the aim o f 
developing therapies to defined molecular targets that will help to overcome resistance.
Resistance to paclitaxel can be broadly into proximal and distal mechanisms.
The proximal mechanisms include altered drug uptake and drug targets (microtubules). The 
distal mechanisms involve the alteration or modification of several proteins that regulate cell 
death or apoptosis. The concept of programmed cell death (apoptosis) has gained huge
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interest over the two decades, particularly with demonstration that most chemotherapeutic 
agents induce cell death by apoptosis (Hannun YA, 1997). It now recognized that the 
alteration of apoptosis regulating proteins such as bcl-2 family o f proteins or p53 may induce 
chemoresistance to paclitaxel (Haidar S, 1995; Wahl AF, 1996). If so, these apoptosis 
regulating proteins may provide molecular targets to help to circumvent resistance to 
paclitaxel.
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Trial Overall
response(%)
Clinical CR 
(%)
Median time to
progression
(months)
Median survival 
(months)
GOG-111
CP 66 31 13.0 24.4
TP 73 51 18.0 37.5
Intrgroup study
CP 66 36 12.0 25
TP 77 50 16.6 38
GOG-132
P alone. 67 NA 16.4 30.2
T alone. 46 NA 11.4 26
TP 67 NA 14.1 26.6
Table 1-1: Three randomized trials comparing paclitaxel and cisplatin based regimens. 
C= cyclophosphamide, P= cisplatin, and T= paclitaxel. For drug doses and delivery see 
text.
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1.2 Paclitaxel
1.2.1 Discovery and development
The history of paclitaxel started around the turn of the century, when a British official in the 
Indian subcontinent noted that parts of the European yew, Taxus baccata, were used in a 
clarified butter preparation for the treatment of cancer (Song JI, 1991). Subsequent 
development of paclitaxel was conducted in the National Cancer Institute (NCI) in a program 
evaluating plants for anti-cancer activity. Initially, in 1963, crude bark extracts of the related 
pacific yew, Taxus brevifolia, were provided to NCI by Untied States forest service. The 
crude alcohol extract was shown to be cytotoxic against several murine tumours. The pure 
form of the active component (Paclitaxel) was isolated in 1966 and two years later; Wani et al 
described paclitaxel unique chemical structure (figurel-1) (Wani MC, 1971). However, 
further development was delayed because of modest activity of the drug in preclinical model 
systems, scarce supply, poor solubility, and apparent similarities in mechanism of action to 
vinca alkaloids. Interest was revived in 1979 when the unique mechanism o f action of 
paclitaxel was discovered (Schiff PB, 1979). Unlike other microtubule targeting drugs, which 
inhibit the polymerization of microtubules, paclitaxel was shown to promote the assembly of 
tubulin and stabilize the resulting microtubules. Under the auspices of the NCI, paclitaxel 
underwent phase I and phase II studies in the early eighties. In 1989, paclitaxel was 
recognized as an important clinical advance when activity in platinum resistant ovarian cancer 
was demonstrated (McGuire WP, 1989). Paclitaxel has been commercially available since 
early 1993 and activity of the drug has been demonstrated now against ovarian cancer, breast 
cancer, lung cancer, malignant melanoma, head and neck cancer, and lymphoma.
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1.2.2 Chemical structure and pharmacological properties
Paclitaxel (C4 H51 014, M.W. 853.9) possesses ataxane nucleus built from a diterpene 
carbon skeleton (figure 1-2). The taxane nucleus consists o f three rings (Kingston DG, 1994). 
Six membered A- and C-rings are fused at an almost perpendicular angle with an eight 
membered B-ring. The C13 side chain of paclitaxel, 2R- 3S N-benzoyl-3- phenyliserine 
methylester is esterified with C13-0H of taxane nucleus. This C-13 side chain seems to be 
mandatory for its anti-tumour activity because analogs of paclitaxel that do not possess it are 
not cytotoxic (Arbuck SG, 1993). Intramolecular hydrogen bonds between estercarbonyl, 2- 
OH and 3-NH stabilize the side chain into well-defined confirmation.
Paclitaxel is highly lipophilic and insoluble in water, but soluble in Cremophol EL, 
polyethylene glycols 300 and 400, chloroform, acetone, ethanol and methanol. Paclitaxel used 
in clinical practice is formulated in 50% CremophorEL and 50% dehydrated alcohol (Verweij 
J, 1994). In early phase I studies the pharmacokinetic of paclitaxel showed linear 
biexponential disposition profile whereby the area under the plasma concentration versus time 
curve (AUC) is linearly related to dosage. Subsequent studies demonstrated non-linear 
pharmacokinetics whereby there was an unproportional increase in maximally reached plasma 
concentration and area under the curve, when increasing dosage of paclitaxel was given by 3- 
hr infusion suggesting triexponential disposition. There was an initial rapid decline 
representing significant elimination of drug from the circulation and tissue distribution and a 
prolonged terminal phase representing a slow reflux of paclitaxel into the circulation (Huizing 
MT, 1995).
Paclitaxel shows extensive protein binding (up 98%), and less than 6% of drug is recovered 
unchanged in urine. Thus the renal clearance is rather insignificant and the metabolism by 
biliary excretion, and extensive tissue binding is probably responsible for total body clearance 
of paclitaxel (Huizing MT, 1995).
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Figm*e 1-1: Chemical structure of paclitaxel (see text).
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1.2.3 Mechanism of action
1.2.3.1 Microtubular structure
Paclitaxel induces its cytotoxic effect by targeting the microtubules (Schiff PB, 1979). In 
addition to the microtubule’s important role during cell division as the major component of the 
mitotic spindle, they are required for maintenance of cell shape, motility and transport 
between organelles within the cell (Dustin P, 1980; Ro win sky EK, 1990). The Microtubules 
are composed of tubulin heterodimers, each one o f which is itself a dimer composed of two 
very similar globular protein called a  and p tubulin subunit bound tightly by non-covalent 
bonding (Correia JJ, 1991). The cylindrical structure of the microtubule is of made of 13 
protofilaments composed of linear chain of tubulin subunits with a  and P subunits alternating 
along its length and creating a structural polarity with the a  subunit exposed at one end 
(termed minus end) and the p subunit at the other (plus end) (Deny WB, 1998). In the cell 
there is a dynamic equilibrium between the soluble tubulin dimers and microtubular polymers, 
which is vital for their function (figure 2) (Verweij J, 1994).
The study of mechanisms of action and resistance of paclitaxel is hindered by the fact that 
there are multiple tubulin isotypes that are encoded by a large multigene family consisting of 
both functioning and non-functioning genes. The greatest diversity between the p-tubulin 
isotypes occurs in the carboxy-terminal variable region sequence and to a lesser extent in the 
amino terminal variable region (Haber M, 1995). In humans, six p tubulin isotypes have been 
identified which display a distinct pattern of tissue expression. Their classification is as 
follows (Roman numerals represent the tubulin protein class, while Arabic numerals represent 
the gene: class I, HM40; class II, HP9; class III, Hp4; class IV a, Hp5; class IV b, Hp2; class 
VI, H pi. In mammalian cells expression is as follows: class I and Ivb isotypes are 
constitutively expressed, class III and IV a are restricted to brain, class II is found 
predominantly in brain and at low levels in broad range of tissues, and class VI is restricted to 
haematopiotic tissue (Sullivan KF, 1986).
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Figure 1-2: Microtubule’s structure and interaction with paclitaxel (Parekh H, 1997a).
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1.2.3.2 Paclitaxel interaction with microtubules
Unlike the vinca alkaloids, which binds tightly to the free tubulin and prevents its 
polymerization into microtubules, paclitaxel encourages polymerization o f microtubules. It 
binds tightly to the microtubule polymers and prevents the loss of the tubulin subuits, at the 
same time allowing new subunits to be added. In doing so, paclitaxel stabilizes the inherently 
unstable assembly-disassembly process and alter the dynamic equilibrium between soluble 
tubulin dimers and microtubular polymer in favor of the latter, thereby reducing the critical 
concentration of tubulin required forming microtubules (Parekh H, 1997a). The 
polymerization occurred even in the absence of guanosine 5-triphosphate (GTP) and 
microtubule-associated proteins (MAPs), which are otherwise required for tubulin assembly 
(Horwitz SB, 1992; Horwitz SB, 1993). Microtubules assembled under influence of paclitaxel 
are refractory to depolymerization even at 4 and in the presence of calcium, conditions that 
otherwise induce rapid disassembly of microtubules (Horwitz SB, 1992; Horwitz SB, 1993).
Direct photoaffinily labeling has demonstrated that paclitaxel binds preferentially to the beta 
subunit of tubulin with stoichiometry approaching one mole of paclitaxel per one mole of 
polymerized tubulin dimer (Horwitz SB, 1992) (Manfredi JJ, 1984). The binding site of 
paclitaxel was localized to a 31-aminocid region at the N-terminal end of p tubulin subunit 
(Rao S, 1992a). Electron crystallography analysis revealed that the binding site of paclitaxel 
was present near the interprotofilament contact region in the microtubular polymer and not 
near tubulin monomer-monomer or dimer-dimer contact regions (Noagales E, 1995).
The effect of paclitaxel on the microtubules appears to be dose dependent. At high 
concentration (100-500 nM), paclitaxel enhances microtubule polymerization, increases mass 
of microtubules, causes extensive bundling of microtubule with production of spindle asters. 
These changes were observed in the interphase and mitotic phase of cell cycle (Jordan MA, 
1993). However at low paclitaxel concentration (< 9 nM) paclitaxel blocks mitosis at the 
transition from metaphase to anaphase, with no increase in microtubular mass or bundling 
(Jordan MA, 1993). At this concentration, paclitaxel potently suppresses dynamics at the plus 
end of microtubules with no effect at the minus end permitting continued microtubule 
depolymerization at the spindle pole (Derry WB, 1998). Thus paclitaxel causes dysfunctional
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spindles that can not properly polymerize and lead to abnormal chromosome segregation and 
aberrant cytokenesis (Derry WB, 1998). The latter results in cells with abnormal size and 
DNA content, eventually causing cell death. The molecular events that are thought to occur 
distal to binding of paclitaxel to microtubules such as phosphorylation of bcl-2 and bcl-xl and 
lead to cell death will be discussed in details in 1.4.2.
1.2.4 Paclitaxel and induction of mitotic arrest §
The hallmark of Paclitaxel treatment on cells is the induction o f mitotic arrest. Paclitaxel has 
been shown to interact with several important regulators of mitosis that include maturation- 
promoting factor (MPF), Raf-1, and p53. Several studies have demonstrated that the onset of 
mitosis is regulated by MPF complex (King KL, 1995; Nurse P, 1990). This complex consists 
of two subunits, a catalytic subunit, cdc2 kinase, and its regulatory subunit, cyclin B. The 
kinase activity of MPF complex is activated at G2/M transition and inactivated at the onset of 
anaphase. For the activation to occur, cyclin B should accumulate above certain threshold
level followed by dephoshorylation o f cdc2 kinase. At the end o f mitosis, the activity of cdc2
kinase is abolished by proteolysis of cyclin B (King KL, 1995; Nurse P, 1990). Paclitaxel has
.been shown to produce a marked increase in cyclin B1 accumulation and activation of cyclin 
B1 dependent kinase (Ling YH, 1998a). The accumulation of these subunits was shown to 
parallel the mitotic arrest and precedes apoptosis (Ling YH, 1998a). More recently, the signal 
transduction molecule Raf-1 kinase activation has been shown to be important for the passage 
through mitosis (Torres K, 1998). Also, it has been observed that p53 participates in the 
spindle checkpoint process to ensure a correct DNA replication before mitosis (Cross SM,
1995). Paclitaxel activates both molecules, thus effecting the progress through mitosis as 
discussed in sections 1.4.1 and 1.4.2.
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1.3 Molecular aspects o f response to paclitaxel
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1.2.5 Non-microtubular paclitaxel effects
There is some evidence to suggest that paclitaxel induces other cellular changes, besides its 
paclitaxel microtubule-stablizing properties. Paclitaxel has been shown to stimulate the 
lipopolysacharide (LPS) signalling pathway in murine macrophages resulting in secretion of 
tumour necrosis factor a  and down regulation of TNF-a receptor (Ding AH, 1990). This 
effect is independent of its ability to stabilize microtubules, because some derivatives of 
paclitaxel that retain the microtubular polymerizing activity but do not stimulate cytokine 
secretion, Burkhat et al demonstrated that induction of TNF a  gene expression and secretion 
is only seen with paclitaxel and its 7-acetyl derivative and not with other taxanes including 
docetaxel (Burkhat AC, 1994). All the taxanes used in these studies were able to induce cell 
death suggesting that induction of TNF-a or LPS- like activity is separate from the cytotoxic 
effect of paclitaxel. In addition, the transcriptional upregulation of interleukin-1 and 
interleukin-8 following the treatment with paclitaxel has been reported and associated with 
ability of paclitaxel to activate nuclear factor kappa B (NF-kappa B)(Parekh H, 1997a).
Chemotherapeutic agents including paclitaxel induce cell death by a process termed 
apoptosis. The term apoptosis is of Greek origin used to describe the falling of petal from a 
flower or the loss of leaves from a tree. In vertebrates, the term apoptosis is used to describe 
the characteristic the phenotypic and biochemical changes that accompany programmed cell 
death (PCD). The importance of programmed cell death as an essential process for the 
appropriate development and function of multicellular organisms is now well accepted. More 
importantly, It is realized now that failure to appropriately regulate or induce apoptosis may 
lead to suppression of cell death resulting in several pathological processes and 
chemoresistance.
I
There is accumulating evidence to suggest that prolonged mitotic arrest initiates apoptosis 
(Debernardis D, 1997; Donaldson KL, 1994; Ling YH, 1998a); however, little is known about
I
nucleases, first into large 30-50 kilobases, and subsequently into nucleosomal fragments o f 
180-200 base pairs.
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the signalling pathways involved. Several recent discoveries have shed more light on
molecular events distal to binding of paclitaxel to microtubules involving apoptosis regulating
proteins and leading to cell death. In fact, it is realized now that alterations in these apoptosis
regulating proteins may contribute to paclitaxel resistance. In this section an overview of the
.important concept of apoptosis and its regulating proteins will be provided followed by
.discussion of paclitaxel induction cell death. This may provide insight how dysregulation of 
the apoptosis regulating proteins may lead to chemoresistance.
' I
1.3.1 Apoptosis: Genera! overview
The importance of this concept has gained a huge amount of interest following the description 
of the physiological form of cell death termed apoptosis (Kerr JF, 1972; Wyllie AH, 1980).
The process of apoptosis can be subdivided into three different phases: initiation, effector and 
degradation. Whereas the latter two phases are common to all apoptotic processes, the 
initiation phase depends on the type of apoptosis-inducing stimulus. The morphological 
features described by Kerr et al occur during effector phase. The initial changes include cell 
shrinkage due to extrusion of water from the cell, condensation of cells chromatin giving rise 
to the formation of pyknotic nuclei, nuclear fragmentation followed by break up of cells into 
small sealed vesicles called apoptotic bodies. These apoptotic bodies are subsequently 
engulfed and destroyed by neighbouring cells or macrophages without inducing inflammatory 
response during the degradation phase. It is now recognized that the morphological changes 
are closely linked to biochemical changes. The biochemical hallmark of apoptosis during the 
effector phase is the fragmentation of the cells DNA into nucleosome size fragments, which 
can be seen in agrose gel as a DNA ladder (Arends MJ, 1990; Wyllie AH, 1980). The 
fragmentation occurs due to activation of one or more cation-dependent endogenous
.a
f
32
I
' - 'W 'V
1.3.2 Genetics and molecular basis o f apoptosis
Most of the present knowledge of apoptosis in mammals comes from study of the nematode 
Caenorhahditis elegans. In this worm, 1090 cells are generated during development, of which 
131 cells die by an intrinsic death program (Ellis HM, 1986). Three genes, ced-3, ced-4 and 
ced-9, play a crucial role in executing and regulating the death of these cells (Hengartner MO, 
1992; Miura M, 1996; Yuan J, 1993). Both ced-3 and ced-4 are essential for cell death to 
occur and, consequently, mutants lacking either of these genes have extra cells. The ced-9 
gene antagonizes the function of ced-3 and ced-4 by protecting cells from death.
The first important clues indicating that the pathways regulating apoptosis are similar in G 
elegans and mammals came from the discovery that the function o f ced-9 mutation can be 
restored by expression of the human bcl-2 genes (Vaux DL, 1992). Indeed, Subsequent 
cloning of ced-9 showed that its product is similar to bcl-2 (Hengartner MO, 1994). The 
cloning of ced-3 showed that this 503 amino acid protein is homologous to a mammalian 
interleukin- IB-converting enzyme (ICE) (Yuan J, 1993). More recently, ced-4 has been 
shown to be homologous to a mammalian protein termed Apoptotic protease activating-1 
factor (Apaf-1) (Li P, 1997).
1.3.3 ICE and caspases
ICE is a cysteine protease responsible fi>r the proteolytic conversion o f 31 kilodaton (KD) 
inactive cytokine precursor, pro-interleukin IB (proIL-lB), to its 17.5 KD active form 
(Thornberry NA, 1992). ICE is synthesized as a dormant 45 kD proenzyme that resides in the 
cytoplasm, and is proteolytically activated by unknown mechanism. The active form is 
composed of two subunits, one 20 KD and one 10 kD, both which are derived from the 45 
kDa proenzyme following removal of 11 kD N-terminal peptide and a 2 KD linker peptide 
(Thornberry N A, 1992). Cleavage of the proenzyme occurs at aspartic acid residues, 
suggesting that the enzymes involved in processing are ICE-like proteases.
Following the recognition of the similarity between ced-3 and ICE in 1993, a further nine 
related highly conserved ICE-like proteases have been identified. Because all these proteins
33
are cysteine protease (c) that cleave after an aspartic acid residue (aspases), they are termed 
caspases (Alnemri ES, 1996). The caspases exist as inactive zymogen in the cytosol and 
become activated through proteolysis when the cell receives apoptotic signals.
Several lines of evidence suggest that caspases have a direct role in the regulation of apoptosis 
and indeed they are the effector death molecules. Ced-3 is an absolute requirement for 
apoptosis to proceed in c. elegans. The overexpression of gene encoding caspase-1 in Rat-1 
cells was shown to induce apoptosis (Miura M, 1993). Mutation in the catalytic Cys residue of 
ICE completely abolishes its apoptosis inducing activity (Miura M, 1993). Microinjection of 
ICE-c DNA expression vectors into chicken dorsal-root-ganglion also results in cell death 
while microinjection of CrmA, a viral inhibitor of ICE, prevents apoptosis induced by serum 
depletion (Gagliardini V, 1994) (Ray CA, 1992).
Ï
The exact sequence of caspase activation is still unknown. The fact that all caspases are 
cleaved at specific Asp residues, raise the possibility that some of the caspases might 
sequentially activate each other in a cascade (Nagata S, 1997). It has been suggested that 
caspases containing long NH-2 domain such as caspases 8 and 9 play a central role in this 
model and have been termed the initiator protease, which in turn activate an amplifier 
protease such as caspase 1, which in turn activate a machinery protease such as caspaseS.
Enari et al demonstrated that caspase 3 activation is dependent on casjpasel activation in liver 
mice damaged by anti-fas antibody (Enari M, 1996). Further evidence for the cascade theory 
comes from the activation of caspase 8 and caspase 9 by anti-Fas antibody through two 
different mechanisms with subsequent activation of other caspases. Caspase 8 is recruited to 
the death induced signaling complex (DISC) on cell surface through interaction with 
FADD/MORTI and caspase 9 forms a complex with Apaf-1 and cytochrome c in presence o f 
d ATP/ATP. The activated caspase 8 and 9 within these complexes inturn activate caspases 3, 
6, and 7 which lack long NH2 terminal but constitute the main caspase activity in apoptotic 
cells. On the other hand, the observation that caspase 1 null mice have normal phenotype (Li 
P, 1995) and caspase 3 null mice show profound neurological defects (Kuida K, 1996), 
suggest that some members of caspase family (e.g. caspase 1) are redundant cleaving the 
same substrate.
1
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1.3.4 Bch2 family
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The activated caspases appear to target a discrete number of proteins for proteolytic cleavage. 
Some of these substrates that are cleaved during apoptosis include nuclear proteins such as 
poly-adenosine diphosphate, ribose polymerase, DNA dependent kinase, topoisomerase I, 
lamins and 70k D of Ulsn RNP. Cytoskeletal and cytoplasmic components are also cleaved 
including D4-GDI, Fodrin, Pkc and other (Thornberry NA, 1992). The exact mechanism of 
cell death following cleavage o f these substrates remains unknown.
I
The Bcl-2 (B cell lymphoma / leukaemia-2) gene was initially cloned from a 14; 18 
translocation break point associated with 85% of follicular lymphoma and 20% of diffuse B 
cell lymphoma. In this translocation the bcl-2 gene is moved from its normal chromosomal 
location at 18q21 into juxtaposition with heavy chain immunoglobulin promoter on 
chromosome 14 resulting in overproduction of bcl-2 m-RNA and their encoded proteins 
(Tsujimoto Y, 1986). In 1988, Vaux et al reported that overexpression of bcl-2 prolonged the 
survival of interleukin-3 (IL-3) dependent immature pre-B lymphocyte despite the absence of 
IL-3, but without concomitant cell proliferation (Vaux DL, 1988). Subsequently, it was shown 
that microinjection of bcl-2 expression plasmids into Nerve Growth Factor dependent 
sympathetic neurons delayed the rate of cell death upon withdrawal of growth factor (Garcia 
I, 1992). It was also shown that transfection of bcl-2 into haematopoietic cell lines prevented 
cell death upon growth factor withdrawal (Nunez G, 1990). Prompted by these observations 
bcl-2 has been found to protect variety of cells from a variety of apoptotic signals including 
glucocorticoids, y-irradiation, phorbol estera, anti-CD-3 antibody, viral and chemotherapy 
induced cell death (Miyashita T, 1993; Strasser, 1994; Yang E, 1996). Subsequently, Reed et 
al demonstrated that anti-sense mediated reduction in bcl-2 gene expression accelerated the 
rate of cell death in the setting of growth factor withdrawal (Reed JC, 1990).
All of the above observations suggested the critical role of bcl-2 in controlling cell death and 
that bcl-2 blocks a final common pathway leading to cell death. However, bcl2 has little effect
on apoptosis during negative selection or apoptosis in cytotoxic T cell activated killing (Reed 
JC, 1994). Also the observation that bcl-2 function is not required for embryonic development 
raised the possibility that other proteins modulate apoptosis in addition to bcl-2 (Kamada S,
1995; Reed JC, 1994). It is now recognized that bcl-2 belong to a growing family of apoptosis 
regulating gene products. At least fourteen cellular homologues have been described. Broadly,
--these fall into two categories: The anti-apoptotic death antagonist include bcl-2, bcl-xl, Mci-1,
-, •:
bcl-w, Brag-land pro-apoptic cell death promoting proteins bax, bcl-xs, bak, bad, bik, bid,
Hrk) (Reed JC, 1994).
a
1.3.4.2 Bcl-2 homology domains
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1.3.4.1 Localization and the importance of carboxy terminus
,Bcl-2 has been shown to localize mainly in the outer mitochondrial membrane, smooth 
endoplasmic reticulum and peri-nuclear membrane (Krajewski S, 1993; Monaghan P, 1992). 
Other proteins encoded by bcl-2 gene farnily are predominantly localized in the outer 
mitochondrial membrane such as bcl-xl and bax (Yang E, 1996). Most members of bcl-2 
family possess highly conserved stretch of 19 hydrophobic amino acids near the carboxy 
terminus followed by two charged residues which serve to anchor the protein in membranes, 
thus exposing most of the polypeptide to the cytosol, where it Is exposed to protease digestion 
(Kromer G, 1997). The deletion of this transmembrane carboxy terminus abrogates or 
diminishes bcl-2 the death inhibitory effect and prevents the targeting of bcl-2 interacting 
proteins (Zhu W, 1996). The deletion of the crboxy terminus from bax prevents targeting to 
mitochondria and completely abolishes its cytotoxicity in yeast (Kromer G, 1997). These 
observations suggest that, at least for some members, an integral membrane position is 
required for activity.
The bcl-2 family of proteins shares up to four highly conserved domains termed bcl-2 
homology (BH) domains (Zha H, 1996). Most of Bcl-2 family members share BHl (residues
136-155 of bcl-2) and BH2 (residues 187-202 of bcl-2). The substitution of Gly 145 in BHl 
or Trpl88 in BH2 abrogated the death suppressing activity of bcl-2 and prevented bcI-2
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binding to bax without impairing homodimerization with endogenous wild type bcl-2 (Yin 
XM, 1994). In addition, it prevents the interaction targeting proteins such as Raf-1 (Wang HG, 
1996b). Similarly, some mutations in BHl and BH2 domains of bcl-xl have been shown to 
abrogate and disrupt their ability to heterodimerize with bax and bak, but the mutant proteins 
retain most (70-80%) of their death repressor activity, suggesting that these molecules can 
also act independently of each other (Kromer G, 1997).
A third domain BH3 (residues 93-107 of bcl-2) was identified by studying the interaction 
between an anti-apoptotic adenovirus ElB 19K (homologue to bcl-2) and bax (Han J, 1996).
In order for bax to interact with ElB protein, a minimal region of 28 aminoacids distinct from 
BHl and BH2 are needed (Han J, 1996) (Wang K, 1998). This region is designated BH3 and 
is conserved among the various bcl-2 family members. Several observations suggest that this 
domain is uniquely important in the promotion of apoptosis. The two proapoptotic proteins 
Bik and bid have only BH3 domain (Boyd JM, 1995; Wang K, 1996). The deletion of BH3 in 
pro-apoptotic bax and bak disrupt their fimction (Zha H, 1996). In addition to that the 
swapping of a 23-aminoacid segment surrounding BH3 from bax to bcl-2, converted bcl-2 to 
a pro-apoptotic protein (Hunter JJ, 1996b). The sequence alignment studies have shown that 
BH3 domain sequence differs between the proapoptotic and antiapoptotic proteins (Rao L, 
1997).
The fourth domain BH4 (residues 10-30 of bcl-2) is conserved among anti-apoptotic 
homologues, but not found in most pro-apoptotic bcl-2 family proteins except bcl-xs (Kromer 
G, 1997). This observation suggests that BH4 may play a unique role in the function of anti- 
apoptotic proteins. The deletion of BH4 abrogates the anti-apoptotic function of these 
proteins, but it is not required for dimerazation (Hunter JJ, 1996a). Also, BH4 may play role 
in the interaction of bcl-2 and bcl-xl with other non-structurally death-promoting proteins 
such Raf-1, ced-4 (Wang HG, 1996d) (Chinnaiyan AM, 1997b)
■;è
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1.3.4.3 Tertiary structure
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The determination of the three dimensional structure of bcl-xl by X-ray and MRI analysis 
provided an insight to bcl-2 family protein function. It consists of two central hydrophobic 
alpha helices penetrating the lipid hi layer surrounded by five amphipathic helices (Muchmore 
SW, 1996). The alpha helices are connected by a variable region consisting of 60-residue 
flexible loop located between BH-3 and BH-4 domain. An elongated hydrophobic pocket is 
created by close spatial proximity between BHl, BH2, and BH3 domains. Structurally, bcl-xl 
is analogous to bacterial toxins such as diphtheria toxin and colicins, having particularly 
striking similarity in their membrane insertion domain (Kromer G, 1997). Also, the addition 
of recombinant bax to synthetic membrane results in formation of ion channels (Kromer G, 
1997). These observations suggest that many bcl-2 family proteins share the ability to form 
pores in cytoplasmic and nuclear membranes and fonction by regulating signals dependent on 
pH, voltage, or ionic strength.
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1.3.4.4 Function of bci-2 and related proteins
The exact role of bcl-2 and related proteins in the regulation of cell death or survival remains 
unknown. It is thought that these proteins function as regulators of cell death pathways 
proximal to caspases. At the molecular level, it has been suggested that bcl-2 may function as 
an anti-oxidant, a regulator o f endoplasmic reticulum-associated calcium fluxes or an inducer 
of cytosolic acidification (Hockenbery DM, 1993; Lam M, 1994). However, these theories 
were invalidated by demonstration that bcl-2 inhibited apoptosis in cells that lacked 
mitochondria and under nearly anaerobic condition, the induction of nuclear jqpoptosis in 
calcium free media or by calcium depletion, and induction of apoptosis in some models by 
cytosolic acidification (Liu X, 1996; Tsao N, 1996; Zamzami N, 1996). Recent discoveries 
suggest that bcl-2 family proteins may modulate the process of apoptosis by two main 
mechanisms, the alteration o f mitochondrial permeability transition and interaction with 
related and non-related proteins. I
I
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1.3.4.5 Mitochondrial permeability transition and pore formation
This model is based on the critical role of the mitochondria during apoptosis and the sub- 
cellular localization of bcl-2 and some of related proteins to the outer mitochondrial 
membrane. The biochemical and structural changes of mitochondria during apoptosis include 
mitochondrial swelling, disruption of mitochondrial outer membrane; disruption of the 
mitochondrial transmembrane potential and release of protease activators including 
cytochrome c and apoptosis inducing factor (AIF). It is postulated that the opening of large 
pores located at contact sites in mitochondria where the inner and outer membranes abut and 
where various transport processes involving ions and proteins occur lead to generation of 
mitchondrial permeability transition This is followed by dissipation of H+ gradient, osmotic 
swelling due to the high solute concentration o f mitochondrial matrix, rupture of the outer 
mitochondrial membrane and release of cytochrome c (Kromer G, 1997; Reed JC, 1997a).
It has been demonstrated that Bcl-2 and bcl-xl can inhibit both the loss of mitochondrial 
potential and the release of factors from mitochondria into the cytosol that can activate the 
caspases (Susin SA, 1996). In addition to that it has been shown that bcl-2 and bcl-xl 
prevented cytochrome c release upon induction of programmed cell death in intact cells and 
cell-free systems (Kluck RM, 1997; Yang J, 1997). Bcl-2 and bcl-xl could not inhibit 
apoptotic changes induced by cytochrome c after it was released or added exogenously 
suggesting that bcl-2 and bcl-xl exert their function on mitochondria rather than cytosol 
(Kluck RM, 1997). The mechanism of regulation of cytochrome c by bcl-2 and bcl-xl is 
unclear. It is postulated that bcl-xl may function as an ion channel that regulates the 
permeability of mitochondria and could minimize the osmotic stress and in doing so prevent 
cytochrome c release due to mitochondrial matrix swelling and outer membrane rupture 
(Kromer G, 1997; Muchmore SW, 1996).
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1.3.4.6Interaction with related proteins and post-transitional modification
The fate of a cell to undergo apoptosis or not may be determined in part by a balance between 
pro-apoptotic and anti-apoptotic proteins. These proteins are able to form homodimers with
39
î
.self and heterodimers with other proteins by interacting through BH domains discussed above
(Farrow SN, 1996; Rao L, 1997; Reed JC, 1997a). Post-translational modification or
phosphorylation alters the balance between these proteins. For example, Bcl-2 can be
phosphorylated on serine residues within a flexible loop region by various stimuli (Chang BS,
1997). The deletion of this loop domain enhances the anti-apoptotic activity of bcl-2 and
phoshorylation of this loop lead to inactivation of bcl-2 impairing its ability to heterodimerize
with bax inducing apoptotic cell death (Haidar S, 1995). The phosphorylation site of Bcl-2
appears to be one or more of 17 serine residue(s) included in bcl-2 variable region. Haidar et
al mutated several serine residue(s) to homologus alanine residue(s) using overlaping PGR
method. These mutants were transfected into DU 145 prostate cancer cells (lack expression of
bcl-2) to test the ability of these mutants to undergo phosphorylation (Haidar S, 1998). It was
.shown that mutation of Ser 70 of variable region abolishes the ability o f paclitaxel to induce 
bcl-2 phosphorylation of that site. It is postulated that this site may act as a major 
phosphorylation site or binding site for putitive kinase that induces phosphorylation (Haidar 
S, 1998).
IIn addition to that, Bad has been shown to be a target of serine phosphorylation. Bad is a pro­apoptotic protein which heterodimerizes with membrane bound bcl-xl or bcl-2 neutralizing 
their activity and promoting death. In the presence of the survival factor IL-3, bad become 
phosphorylated in two serine residues (Zha J, 1996). It is thought that the targeting of Raf-1 to 
the mitochondria by bcl-2 initiates local signaling that leads to bad phsphorylation (Wang 
HG, 1996a). The phosphorylated bad forms a complex with cytosolic protein 14-3-3
preventing its interaction with bcl-xl located in mitochondria. Upon growth factor withdrawal 
and dephosphorylation, bad is able to dimerize with membrane associated bcl-xl promoting 
cell death (Zha J, 1996).
Another form o f  post-transitional modification is inactivation of bcl-2 family proteins by 
protease. The variable region of bcl-2 is highly susceptible to digestion by protease such as 
trypsin and chymotrypsin. In particular, HIV protease has been shown to cleave bcl-2, which 
may explain cell death during infection (Strack PR, 1996).
I
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1.3.4.7 Interaction with unrelated proteins
Bcl-2 family proteins interacts with up to eleven proteins that have been identified including 
Raf-1, R-Ras and H-Ras, and ced-4, which interact with bcl-2 and bcl-xl but not bax. 
Although the importance of such interactions is not entirely clear, recent discoveries have 
been made.
Ced-9 (nematode equivalent of mammalian bcl-2) has been shown to physically interact with 
ced-4, and that ced-4 can independently bind to ced-3/caspases (Chinnaiyan AM, 1997a; 
Chinnaiyan AM, 1997b). These observations suggest that bcl-2 regulates the activation of 
caspases via ced-4 which acts as an adaptor (Jacobson MD, 1997), Interestingly, the ced-4, 
which normally found in the cytosol, when co-expressed with ced-9 or bcl-xl, is sequestered 
to intracellular membranes where ced-9 and bcl-xl are located (Chang BS, 1997). Conversely,
.when pro-apoptotic members of bcl-r2 family such as bax are co-expressed with bcl-xl, they 
dimerize with bcl-xl, there by displacing ced-4 into cytosol and probably activating the 
caspases (Jacobson MD, 1997).
The signal transduction molecule Raf-1 kinase was shown to bind via its catalytic domain 
(Cat) to bcl-2 in BH-4 dependent manner (Shaham S, 1996; Wang HG, 1996b). Bcl-2 was 
found to target Raf-1 to mitochondria allowing this kinase to contribute to survival by 
phosphorylating the pro-apoptotic protein bad as discussed above. Also, the bcl-2 binding 
protein (BAG-1) was shown not only to bind raf-1 but also increases the activity of kinase 
through protein-protein interaction (Wang HG, 1996c). Thus, it is postulated that dimers o f  
bcl-2 could form a docking site that allow Raf-1 and BAG-1 to interact and result in transient 
reversible activation of the Raf-1 kinase locally in the vicinity of bcl-2 on the surface of 
mitochondria, ER, or nuclear envelope membrane (Reed JC, 1997a)
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1.3.5 P53
The loss and mutation of tumor suppressor gene is the commonest genetic lesion in human 
,cancers occurring in approximately 50% of mainly late stage ovarian cancer (Shelling AN,
1995). P53 is a sequence specific DNA transcription factor that activates the expression of a
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number of well-defined target genes. Wild type p53 can transcriptonaly transactivate genes 
involved in cell cycle arrest e.g. p21, interact with DNA repair machinery GADD45, or 
protein modulating apoptosis e.g. Bax and Fas (Harris CC, 1996). Thus following DNA 
damage, p53 may induce cell cycle arrest allowing DNA repair before proceeding through 
cell cycle or induce apoptosis if the damage is severe (figure 1-3). These two fonctions appear 
to be separable; in tumor cell lines lacking p53 in which inducible restoration of p53 results in 
cell cycle arrest and apoptosis, bcl-2 gene transfer blocks apoptosis but not cell cycle arrest 
(Ryan JJ, 1994; Wang Y, 1993).
1.3.5.1 P53 and cell cycle arrest
Following sublethal damage, p53 protein rises rapidly followed by concomitant activation of a 
number of p53 dependent genes including Gadd45that inhibits the progression of cells into S 
phase, and p21 that acts as a potent inhibitor of cyclin dependent kinase cdk2 that halt the cell 
cycle at Gl/S boundary by binding to proliferating cell number antigen (PCNA) preventing its 
interaction with DNA ploymerase (Harris CC, 1996). Furthermore, p53 regulates the cell 
cycle by interacting with Retinoblastoma (Rb) gene. In the active hypophosphorylated form, 
Rb inhibits cell cycle progression and entry into S phase by forming complexes with and 
inhibiting the activity of the E2F family of transcription factors, which are thought to regulate 
expression of genes necessary for S phase entry (Sellers WR, 1997). Advancement through 
the cell cycle is thought to be mediated by sequential phsphorylation of Rb by G1 cyclin- 
dependent kinases, resulting in release of active E2F, which then proceeds to transcriptionally 
activate genes necessary for S-phase progression. The interaction between p53 and Rb gene is 
based on the action of two genes, mdm2 and p21, which are regulated by p53. It has been 
shown that mdm2 proteins bind to p53 and act as a negative regulator inhibiting wild type p53 
transcriptionaly regulatory activity and creating autoregulatory feedback loop (Harris CC,
1996). Rb binds to carboxyl terminal domain of mdm2 restarting its fonction by altering the 
confirmation of the pocket region. An alternative pathway of p53-Rb interaction is mediated 
by p21, which could inactivate cyclin cdk complexes that target Rb phosphorylation. In 
addition to the well described action of p53 on Gl/S part of cell cycle, there is evidence to
:
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suggest that induction of wild type p53 at high enough levels may arrest cells in G2/M (Cross 
SM, 1995).
1.3.5.2 P53 and apoptosis
Although the exact role of p53 in induction of apoptosis has not been defined, its central role 
has been implied by a series of observations. Expression of wild type p53 has been shown to 
initiate apoptosis in a variety of cell lines in which p53 is either absent or mutated. For 
example expression of p53 in myeloid 32-cell line was shown to rapidly induce apoptosis 
after growth factor withdrawal (Yonish-Rouach E, 1991). In addition when temperature 
sensitive wild type p53 was transfected in CML cell line K562, the cells underwent apoptosis 
when cells were switched to the permissive temperature (Yonish-Rouach E, 1991). Studies of 
p53 transgenic mice have also demonstrated that p53 is required for induction of apoptosis by 
radiation and DNA damaging agents in thymocytes (Lowe SW, 1993). However, p53 
genotype had no effect on glucocorticoid- induced apoptosis in these cells, suggesting both 
p53 dependent and p53 independent mechanism of apoptosis (Macfarlane M, 1996). The 
existence of a p53 independent mechanism is supported by normal development of p53 knock 
out mice (Lowe SW, 1993). These results may suggest that p53 status and role in apoptosis 
may be dependent on tissue type and stimuli inducing apoptosis.
There is some evidence to suggest that p53 modulates apoptosis regulating proteins. It has 
been shown that restoration of p53 in a murine leukemia, M l, cell line was associated with 
increases in Bax m-RNA and protein, accompanied by a decrease in bcl-2 levels (Miyashita 
T, 1996; Miyashita T, 1994). Similar elevation of bax m-RNA occurred after exposure to 
ionizing irradiation of several cell types that express wild type p53. On the other hand, it 
appears that bax induction is cell dependent. A lack of change in bax protein level was 
demonstrated in immature rat thymocyte in p53 wild type and p53 null thymocyte. The Fas 
gene, an apoptosis-intiating cell surface receptor of the tumour necrosis factor receptor 
superfamily, has been recently shown to be upregulated in response to increases in wild type 
p53 activity. However; it has not yet been determined whether this apoptosis-promoting gene 
is product of direct transcriptional target of p53 (Owen-Schaub LB, 1995).
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Figure 1-3: the role of p53 in regulating cell cycle arrest and apoptosis. (See text)
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1.4.1 P53 and Paclitaxel
I
1.4 Paclitaxel and interaction with apoptosis regulating proteins
The role of P53 in Induction of apoptosis following DNA damaging chemotherapeutic agents
is well described (Debernardis D, 1997; Pestell KE, 1998). Although paclitaxel does not
directly damage the DNA, p53 and p21 induction has been demonstrated in some cell lines
(Blagosklonny MV, 1995; Tishler RB, 1995). P21 induction by paclitaxel in some cell lines
.(PC3M) appears to be p53 independent because it occurred in cells lacking p53 expression 
(Blagosklonny MV, 1995). The rise in p53 protein appears to be mediated in large part by 
increase stabilization of protein itself. The increase in p53 and p21 protein levels has been 
associated with paclitaxel’s ability to induce a c-raf-1 cascade (Blagosklonny MV, 1995). 
Recent evidence suggests that p53 and p21 induction at low paclitaxel concentration may be 
raf-1 kinase independent suggesting that a different pathway is activated at low paclitaxel 
concentration (<9 nM) (Torres K, 1998).
1.4.2 Anti-apoptotic proteins andpaclitaxei
Several studies have suggested that paclitaxel induces cell death by post-translational 
hyperphosphorylation of anti-apoptotic proteins (figure 1-4). Initially, Haidar et al showed 
that the treatment of human leukaemia cells with paclitaxel led to bcl-2 phosphorylation 
(Haidar S, 1996; Haidar S, 1995). Subsequently these observations were extended to 
lymphoma cell lines (RS 11846), prostate cell lines (PC3 and LNCap), breast cancer cell lines 
(MCF-7) and leukemia cell line (HL60) (Blagosklonny MV, 1997; Haidar S, 1996). The 
phosphorylated form of bcl-2 is incapable o f forming heterodimers with bax, and a 50% 
reduction in formation of bcl-2 results in apoptotic cell death. Recently, it has been shown that 
paclitaxel induces hyperphosphorylation of bcl-xl abrogating its anti-apoptotic function in a 
manner similar to bcl-2 (Poruchynsky MS, 1998).
The signalling pathways linking the microtubule-paclitaxel interaction and prolonged mitotic 
arrest to bcl-2 phosphorylation and apoptosis remain obscure. Initially, Blagosklonny 
suggested that paclitaxel induced apoptosis seems to have some dependency on Raf-1 kinase
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activity by demonstrating that paclitaxel stimulated the hyperphosphorylation of Raf-1 kinase 
in different cell line (Blagosklonny MV, 1996). The pharmacological depletion of Raf-1 by 
geldanamycin resulted in lack of bcl-2 phosphorylation and cell death, suggesting that Raf-1 
induction is pre-requisite step in bcl-2 phosphorylation. Subsequently, Blagosklonny et al 
showed that in order for paclitaxel to induce Raf-1 kinase, it required the induction of tubulin 
polymerization (Blagosklonny MV, 1997). Raf-1 activation was diminished markedly in 
paclitaxel resistant sublines in which tubulin polymerization did not occur following 
paclitaxel, although other microtubule agents such as vincristine were able to induce Raf-1 
phosphorylation.
Thus, a model has been suggested by this series of experiments. Following microtubule 
polymerization in response to paclitaxel, Raf-1 kinase is activated with subsequent 
phosphorylation of bcl-2 and cell death. Similarly, bcl-xl phosphorylation may be dependent 
on Raf-1 phosphorylation (Poruchynsky MS, 1998). Recently, it has been demonstrated that 
Raf-1 activation is paclitaxel concentration dependent (Torres K, 1998). Disruption of normal 
microtubule occurs at lower paclitaxel concentration (l-9nM) in absence of Raf-1 activation. 
Raf-1 activation correlates with induction of G2-M block, and depletion of Raf-1 resulted in 
accumulation of cells in G2/M phase suggesting that Raf-1 may play a role in the passage 
through mitosis. These observations suggest that paclitaxel mediated cell death may occur 
through two different mechanisms. At low concentration cell death occurs after an aberrant 
mitosis by Raf-1 independent pathway, whereas at high paclitaxel concentration cell death 
may be the result of terminal mitotic arrest occurring by a Raf-1 dependent pathway.
The central role of activation of Raf-1 kinase activity in induction of apoptosis following 
paclitaxel treatment has been challenged -at least in cervical carcinoma- by a recent study. 
Rasouli-Nia demonstrated in twelve unperturbed cervical tumor cell lines exhibiting a range 
of sensitivities to paclitaxel that cells with low levels of endogenous Raf-1 kinase exhibited 
increased sensitivity to paclitaxel (Rasouli-Nia A, 1998). The genetic down regulation o f Raf- 
1 kinase activity by two folds resulted in four-fold enhancement in paclitaxel cytotoxity in 
these cell lines. However, it is unclear whether these results could be extrapolated into ovarian
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tumours as cervical tumours are generally infected by human papilloma virus, which may 
alter their genetics and response to chemotherapy.
On the other hand, bcl-2 phosphorylation was demonstrated to occur in cells expressing a
mutant raf-1 kinase that was not phosphorylated. Thus, the involvement of other kinases in
the signaling pathway between the mitotic arrest stage and bcl-2 phosphorylation has been
suggested. Scatena et al demonstrated that bcl-2 undergoes cell cycle-dependent
phosphorylation during mitosis when there is elevated Cdc2 kinase activity followed by cell
death. In this study the exact nature of the phosphorylating kinase was not identified (Scatena
CD, 1998). The immunoprécipitation experiments revealed an Bcl-2-associated kinase
capable of phosphorylating hlstone HI in vitro but the kinase was likely not cyclin Bl/Cdc2
because cyclin Bl/Cdc2 was not detectable in Bcl-2 immunoprecipitates, nor was
recombinant Bcl-2 phosphorylated in vitro by cyclin Bl/Cdc2. Thus, it was suggested that
paclitaxel may increase cellular susceptibility to apoptosis by amplifying the normal
downstream events associated with mitotic kinase activation. In fact. Ling et al suggested that
.bcl-2 phosphorylation by paclitaxel in cervical and ovarian cell line (SK0V3) is associated 
with mitotic arrest and is not a determinant of progression into apoptosis (Ling YH, 1998b).
In this study, the time course of bcl-2 phosphorylation, mitotic arrest, and apoptosis was 
correlated. It was demonstrated that Bcl-2 phosphorylation was closely associated in time 
with M phase arrest, accumulation of cyclin B l, and activation of Cdc2/cyclinBl kinase, but 
not with apoptosis.
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Figure 1-4: Schematic representation of steps of mechanism ot action of paclitaxel. Following 
passive diffusion of paclitaxel into the cell, it acts on the microtubules.Following induction of 
polymerization of microtubules, signal transduction molecules are activated and lead to 
alterations in apoptotsis regulating proteins and cell death. (See text). (?) other signal 
transduction molecules may be involved. (*) Activation when paclitaxel concentration greater 
than 9 nM. At each level of actionna mechanism of resistance has been descrided and it is
shown in the green boxes.
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1.5 Paclitaxel resistance
Chemotherapy resistance in general can be caused by multiple mechanisms. These 
mechanisms include altered drug uptake, defective metabolic drug deactivation, structural 
changes in drug target, changes in cellular components that interact with target, or changes in 
response of pro-apoptotic or anti-apoptotic proteins that modulate cell death. The resistance to 
paclitaxel can be broadly divided into proximal mechanisms o f resistance including altered 
drug uptake, changes in drug targets, or distal mechanisms related to apoptosis regulating 
proteins such as bcl-2 family of proteins and p53.
1.5.1 Altered drug uptake
Because of the hydrophobic nature of paclitaxel, chemoresistance has been associated with 
induction of multidrug resistance phenotype (MDR) and overproduction of P-glycoprotein 
(PGP). PGP is an integral membrane protein that passes through the membrane 12 times and 
has both its amino and carboxy ends within the cell. A linker region separates the two halves 
of PGP, each of which contains a nucleotide binding site. PGP is thought to function as an 
energy dependent drug-efflux pump that maintains the drug within the cell below toxic level.
Initially expression of the MDR phenotype was detected in Chinese hamster (CHO) selected 
for resistance to paclitaxel in a single step selection (Gupta RS, 1985). Horwitz et al 
demonstrated that highly paclitaxel resistant murine macrophages cell line J7.T1 (900 fold 
resistant) selected by stepwise increasing concentration of paclitaxel expressed MDRl 
phenotype with PGP overproduction (Horwitz SB, 1993). Cell lines that have been selected 
for resistance to other anticancer agents and display multi-drug resistance were shown to be 
crossresistant to paclitaxel. For example, colon carcinoma HCTl 16 (VM) 46, selected for 
resistance to VM-26 and expressing the MDR phenotype was shown to be crossresistant to 
paclitaxel (Long B, 1991). Recently, Bhalla et al reported the isolation of paclitaxel -resistant 
human myeloid HL-60 cells (100 and 1000 resistant to paclitaxel that express MDR-1 gene, 
and were cross-resistant to the other drugs known to be pumped out by PGP (Bhalla K, 1994).
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Similarly, Parekh et al demonstrated that paclitaxel resistance in ovarian cell lines was due to 
overexpression of PGP (Parekh H, 1997b).
Recent studies suggested that MDR phenotype might also be mediated by other proteins. 
Overexpression of a novel 135 kDa membrane glycoprotein distinct from the 170-180 kDa 
PGP has been reported to be responsible for reduced intracellular accumulation of paclitaxel 
in a paclitaxel resistant murine macrophage cell lines (Roy SN, 1985). In some cases, multi­
drug resistance can be mediated by increased transcription of membrane- associate protein 
MRP. To date, there is little evidence to suggest that MRP plays any role in paclitaxel 
resistance (Breuninger LM, 1995; Cole SP, 1994).
1.5.2 Drug target alterations
Alterations in the microtubules causing reduced drug-binding affinities and decreased 
intracellular levels of polymerized tubulin have been associated with paclitaxel resistance.
The study of tubulin alterations can be divided into two phases. The initial studies identified 
alterations in tubulin by detection of changes in electophoretic mobility of tubulin molecules 
or in total amount of tubulin m-RNA or protein present in these cells. Schibler et al reported 
that resistance in paclitaxel dependent Chinese hamster ovary (CHO) cells was due to altered 
forms of a  and p tubulin detected by two-dimensional gel analysis (Schibler MJ, 1986). Also, 
Minotti et al using CHO cells demonstrated that paclitaxel resistance correlated to decreased 
polymerized tubulin (Minotti AM, 1991). Ohta et al reported an increased acétylation of a- 
tubulin subunit in paclitaxel resistant human small cell lung cancer (Ohta S, 1994). Although 
a-tubulin is not known to be a target for paclitaxel, alterations in this subunit may alter the 
topology of the tubulin polymer in such a way that paclitaxel affinity for the microtubules is 
reduced, thus resulting in the development o f paclitaxel resistance.
Subsequent studies used PCR-based mrthodology to analyze the expression of P tubulin 
isotypes and sequence specific target regions without the need for cloning of individual genes. 
However, these studies were hindered by the presence of functional and non-fimctional genes 
encoding for different a  and p isotypes discussed in section 1.2.3.1. Despite that several
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studies have correlated altered expression of tubulin isotypes -  in particular p tubulin isotype- 
to paclitaxel resistance. Increased expression of Mp2, the class II p-tubulin isotype has been 
reported in a murine macrophage cell line with high level of paclitaxel resistance (Rao S, 
1992b). Similarly, paclitaxel resistant human sarcoma mutants displayed reduced expression 
of the P4 and the p5 forms of the P-tubulin isotypes as compared with parental cells 
(Dumontet C, 1996). Kavallaris et al demonstrated differential expression o f p-tubulin isotype 
in paclitaxel resistant ovarian tumours (Kavallaris M, 1997). Using specific oligonucleotides 
and polymerase chain reaction, the expression o f six p- tubulin genes were compared in seven 
untreated primary ovarian tumours and four paclitaxel resistant ovarian tumour bearing 
ascites. Prior to that, specific p tubulin changes were studied in non-small cell lung cancer 
with low level of paclitaxel resistance. These cells displayed increased expression of p-tubulin 
genes: HM40 which encodes the class I isotype, Hp9 which encodes for class II isotype, Hp4 
which encodes for class III isotype, and Hp5 which encodes for class I Va isotype. In ovarian 
tumours with de novo resistance, HM40, Hp4, and HpSgene expression was significantly 
increased compared to untreated tumours. The increased expression of the same specific 
tubulin isotypes in both paclitaxel selected tumour cell lines and clinically derived paclitaxel 
resistant cells suggest that these alterations may be involved in the resistant phenotype. 
Similarly, Ranganathan et al demonstrated increased in Hp4 (class III) and HpS (class IV) 
isotypes in human prostate carinoma cell lines resistant to paclitaxel. (Ranganathan S, 1998).
Further evidence that alterations in p tubulin isotype composition may modulate paclitaxel 
resistance came from a recent study using purified tubulin isotypes. Microtubules composed 
of class III and class IV p tubulin isotypes were found to be 7.4 and 7.7 less sensitive, 
respectively, to the effects of bound paclitaxel than microtubules assembled from 
unfractionated tubulin (Derry WB, 1997). It is postulated that altered expression of distinct 
isotypes could modify tubulin/microtubules dynamics or stability of microtubules in such a 
way that the action of paclitaxel is diminished. The selection of less stable tubulin isotypes 
could offer cells a survival advantage when exposed to microtubule stabilizing drug such as 
paclitaxel.
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More recently, point mutations in p isotubulin have been demonstrated in 1A9 ovarian cell 
line (Giannakakou P, 1997) .In this study the tubulin content and polymerization was equal in 
sensitive and resistant cell lines. There was small increase (1.5 fold) in M40 gene expression 
(class 1 isotype). These genes were found to be mutated in residue p 270 with substitution of 
phenylalanine to valine and amino acid P 364 with substitution from alanine to threonine. It is 
postulated that these point mutations may alter the paclitaxel binding site such that paclitaxel 
binding produces less stable microtubules.
1.5.3 Distal mechanism of resistance
1.5.3.1 P53 alterations and resistance to paclitaxel
Several in vitro studies attempted to address the issue of p53 status and resistance to 
paclitaxel yielding contradictory results. Whal et al reported that in different cell lines 
(HeLa and fibroblast-derived cell lines), the disruption of wild type p53 function resulted 
in seven to nine fold increase sensitivity of cells to paclitaxel compared with cells 
expressing wild type p53 (Wahl AF, 1996). Similarly, Vikhanskaya et al demonstrated 
that disruption o f wild type p53 by transfection with E6 protein of human papilloma virus 
(HPV) type 16 led to 50 fold increase sensitivity to paclitaxel in A2780 ovarian cancer 
cells (Vikhanskaya F, 1998). In contrast, Vasey et al demonstrated that transfection of A 
2780 ovarian cancer cells expressing wild type p53 with a dominant negative p53 mutant 
gene acquired resistance to cisplatin and doxorubicin, but not to paclitaxel (Vasey PA,
1996). Moreover, the introduction of wild type p53 in ovarian cell lines not expressing 
p53 did not change their sensitivity to paclitaxel (Graniela Sire EA, 1995). Subsequent 
study showed that the disruption of wild type p53 by transfection with HPV E6 resulted 
in decrease of apoptosis in ovarian cell line following treatment with paclitaxel (Wu GS,
1996). In addition to that, it was demonstrated that paclitaxel treatment of nine ovarian 
cell lines exhibiting different p53 status showed difference cytotoxicity (Debernardis D,
1997). Overall most of the above results suggest that p53 does not influence response to 
paclitaxel.
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Several prognostic studies in patients treated with platinum based chemotherapy have 
shown that p53 mutations confer poor prognosis with shortening of progression free 
survival and reduction of overall survival rates (Herod JJ, 1996; Marx D, 1998). 
Recently, Sorensen et al correlated p53 status analyzed at DNA level with response rate 
and disease free survival in patients treated with paclitaxel. In total 45 patients were 
randomized to be treated with paclitaxel and cisplatin combination or cisplatin and 
cyclophosphamide combination (Smith-Sorensen B, 1998). When relapse free survival 
was estimated in the 33 patients (73%) who had detectable p53 gene alterations, there 
was a significantly better outcome for patients treated with paclitaxel based combination 
compared to the cyclophosphamide arm. Moreover, there was an association between 
p53 status and prognosis for patients who received platinum-based combination but not 
for the paclitaxel arm.
1.5.3.2 Bcf-2 family
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Taken together, these observations suggest that paclitaxel mediated cytotoxicity in
ovarian cancer is not influenced by p53. Since p53 mutations occur in about 50% of
patients presenting with ovarian cancer and these mutations influence the outcome 
.cisplatin treatment, the use of first line paclitaxel and cisplatin treatment may help to 
improve the outcome as has been shown by the GOG 111 trial and intergroup study 
discussed in section 1.1.3.
Several experimental models have shown that bcl-2 family proteins can modulate the 
sensitivity to paclitaxel in different cancer cell lines. Liu et al investigated the role of Bcl-xL 
in resistance to chemotherapy-induced apoptosis in ovarian carcinoma. Two human ovarian 
cell lines A2780 and SKOV3 and tumour lysates from human ascitic samples were analyzed 
for bcl-xl expression by Western blotting. The A2780 cell lines expressed low endogenous 
levels and displayed sensitivity to cisplatin and paclitaxel while SK0V3 cell lines expressed 
high endogenous levels of bcl-xl and resistance to chemotherapy (Liu JR, 1998). All the
tumour lysates from ascitic fluid expressed high levels of bcl-xl. When the chemotherapy
- I
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sensitive A2780 cell line were transfected with bcl-xl, it became resistant to paclitaxel and 
cisplatin (Liu JR, 1998). Similarly, the overexpression of bcl-xl or bcl-2 by transfection of 
human leukaemic cells (HL60) inhibited paclitaxel induced apoptosis without affecting its 
antimicrotubule or cell cycle effects (Ibrado AM, 1997) and high levels o f bcl-xl were shown 
to reduce free bax levels by hetrerodimerization.
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In contrast, the pro-apoptotic proteins appear to enhance paclitaxel cytotoxicity. The 
transfection of MCF7 breast cancer cells that express high levels of bcl-xl with pro-apoptotic
protein bcl-Xs induced a marked increase in chemosensitivity to paclitaxel (Sumantran VN,
1995). Similarly, Strobel et al suggested that bax may play an important role in paclitaxel
induced apoptosis. Ovarian cancer cell (SW626) with p53 deficiency were transfected with c
DNA encoding for murine bax resulting in significant enhancement of cytotoxicity to
paclitaxel, vincristine, and doxorubicin, but not carboplatin. The presence of high levels of
bax itself was not sufficient to trigger apoptosis without additional stimulus (Strobel T, 1996).
The exact mechanism of how bax transfection augment paclitaxel induced apoptosis remain
unclear, however several paclitaxel mediated events were enhanced including G2/M phase
arrest, tubulin polymerization and phosphorylation. More recently it has been demonstrated
.that there is an increased accumulation of paclitaxel in bax-overexpressing cells, an effect due
to diminished drug efflux (Strobel T, 1998a). Similarly, the enhancement of apoptotic
.pathway function through stable expression of the pro-apoptotic protein bad is in order to 
sensitize human epithelial ovarian cancer cells to chemotherapy has been studied. Expression 
of HA-bad in six separate clonal transfectants from two different ovarian cancer cell lines was 
found to significantly enhance the cytotoxic effects of paclitaxel, vincristine, and, to a lesser 
extent, etoposide. Importantly, this effect was associated with binding of HA-bad to bcl-xl 
and concomitant disruption o f bax: bcl-xl interaction.
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Taken together, these data suggest two main options to circumvent resistance to paclitaxel 
other than MDR reversal. The first the development of small molecules which mimic the 
effects of pro-apoptotic proteins such as bax and bad that may represent a new class of drugs 
capable of preventing or reversing resistance to chemotherapy agents such as paclitaxel 
(Strobel T, 1998b). The second is the development of antisense bcl-2 or bcl-xl oligonucleotide
:to reduce their protective effects. In fact, the antisense bcl-2 oligonucleotide is already in 
clinical studies (Webb A, 1997) (Reed JC, 1997b)
On the other hand, the prognostic significance of bcl-2 family in the prediction o f response to 
chemotherapy and survival in solid malignancy has been controversial and mostly 
inconsistent with in vitro studies. Most prognostic studies in ovarian cancer treated with 
cisplatinum suggested that high bcl-2 expression correlated with better prognosis. Herod et 
demonstrated that high bcl-2 expression detected by immunohistochemical staining in 45 
patients with advanced ovarian cancers treated with platinum based chemotherapy was 
associated with improved survival (Herod JJ, 1996). Similarly, Diebold et al and Henriksen 
showed that high bcl-2 expression in patients with advanced ovarian cancer was predictive of 
better outcome (Diebold J, 1996; Henriksen R, 1995). All these studies concentrated on bcl-2
expression alone without correlating bcl-2 expression to other pro-apoptotic proteins such as 
bax that is clearly important in determining the fate o f the cell. Marx et al examined the issue 
of differential expression of bcl-2 and bax in 215 ovarian cancers using immunohistochemical 
staining. Although bcl-2 expressing tumours had better prognosis, bax-expressing tumour had 
worse outcome in terms of overall survival. The overall survival in patients with bcl-2 
positive/ bax negative tumours was significantly longer than bcl-2 and bax negative tumours 
(Marx D, 1997). On the other hand, Tai et al analyzed the expression of pro-apoptotic protein 
bax expression by immunohistochemistry and m-RNA transcript levels in 45 newly diagnosed 
ovarian cancer patients. Ovarian tumours expressing high levels of bax had higher response 
rates and had a clear disease free survival advantage independent o f other prognostic factors 
(Tai YT, 1998).
Several explanation has been put forward to explain the inverse relationship between bcl-2 
expression and prognosis. The first is that the interaction between the pro-apoptotic and anti- 
apoptotic are complex and dynamic, hence, the attempt to assess a single protein will be 
misleading. For example, bcl-2 predominates in well differentiated colorectal tumours and 
declines, as the tumour becomes undifferentiated. In contrast, bcl-xl tends to predominate in 
undifferentiated tumours. Similarly, for these studies to be meaningful, the anti-apoptotic 
proteins should be correlated to pro-apoptotic proteins. It has been demonstrated that
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1.6 Aims of the study
aggressive metastatic breast cancer had reduction in bax with reduced bcl-2 levels. Thus, low
levels of bcl-2 were offset by reduction in bax and probably resulted in a survival advantage.
The second is that immunohistochemical staining of histological biopsies provide a snap
.picture, which is technique and operator dependent.
iI
The first aim of this thesis was to test in vivo the hypothesis that significant alterations in the 
expression of the apoptosis regulating proteins occur to account for the development of 
resistance to paclitaxel. To achieve this aim, paclitaxel sensitive and resistant xenografts were 
established form CHI and CHI resistant cell lines respectively. The CHI cell lines were 
chosen because of lack of expression of MDR phenotype, which would help to eliminate one 
mechanism of resistance to paclitaxel. In addition, both CHI paclitaxel sensitive (CHl/TS) 
tumours and CHI paclitaxel resistant tumours (CHl/JR) express wild type p53 allowing the 
assessment of its central role in the regulation of other death inducing proteins described in 
vitro. Following the establishment of these xenografts, the sensitivity and resistance to 
paclitaxel was examined in vivo. Subsequently, intra-tumoural paclitaxel concentrations were 
measured following paclitaxel administration to rule out any uptake defects. Then, the effect
of paclitaxel on the cell cycle and proliferation, and induction of cell death was compared in 
both types of tumours. Finally, the changes in levels of apoptosis regulating proteins
IIfollowing paclitaxel treatment were assessed by western blotting. It was essential to take into consideration the dynamic nature of all these parameters, so they were assessed at 24, 48, and 
72 hours following paclitaxel administration.
Because of the importance of cisplatin in the management of ovarian cancer, it was important 
to assess its effect on these tumours. Hence, the response of both tumours, changes in cell 
cycle and proliferation, induction of cell death, and changes in apoptosis regulating proteins 
were studied following cisplatin treatment. Thus, we were able to compare and contrast the 
effect of paclitaxel and cisplatin on all these parameters.
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The importance of studying these proteins stems from their role in controlling the most distal 
steps of induction cell death following chemotherapy treatment, therefore, providing a 
suitable targets for molecular therapy. We have chosen to conduct this study in vivo because 
of two main reasons. Firstly, in vivo studies have the advantages of taking into consideration 
the tissue-tissue interactions, and drug delivery which are major determinants of tumour 
growth. Secondly, there is a lack of in vivo studies addressing these issues despite the 
abundance of in vitro studies. Consequently, the present study will help to determine if the 
changes in apoptosis regulating proteins occur in vivo.
The second aim of the thesis was to test the hypothesis that the overexperssion of a given anti-
.apoptotic protein can modulate the response to paclitaxel and cisplatin in vivo. To that effect, 
xenografts of CHI ovarian cancer cells transfected with anti-apoptotic protein bcl-xl were 
established and subsequently treated with cisplatin and paclitaxel. Similarly, the intra-tumour 
paclitaxel concentration was determined in these tumours and compared to the parent CHI 
tumour to rule any uptake defects. The importance of this experiment would be to examine 
whether the alteration in expression of a single effector distal protein could modulate the
: -response to chemotherapy, which would further strengthen their possible role as target for 
molecular therapy.
With these experiments, we aimed to:
1. Demonstrate in vivo the effect of paclitaxel on cell cycle and proliferation, and induction 
of apoptosis.
2. Compare and contrast the mechanisms of action, apoptosis induction, and the effect on 
apoptosis regulating protein of paclitaxel and cisplatin in resistant and sensitive tumours.
3. Determine whether in acquired resistance, there is any alteration in the expression or 
induction of apoptosis regulating proteins.
4. Determine whether overexpression in vivo of a given anti-apototic gene, bcl-xl, could 
result in development of resistance to paclitaxel.
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Chapter 2; Materials & Methods
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2.1 Cell lines and establishment of xenografts
2.1.1 Solution & Buffers
(1) Duibecco’s Modified Eagle Medium (DMEM) without sodium pyruvate and with 
4500mg/l glucose. (Gibco catalogue number (cat no.) 41965-039). Stored at 4°C.
(2) Foetal Bovine Serum (FES) {Imperial Laboratories, Andover, UK). Stored a t-20 to -40
r .
(3) L-glutamine (200 MM lOOX Gibco cat no. I I 140-035). Stored at -20  XJ.
(4) Modified Eagle Medium non-essential amino acids (lOOX Gibco cat. No.11140-0335). 
Stored at 4 T7.
(5) Hydrocortisone 25 mg o f hydrocortisone dissolved in 5 ml 95% ethanol and stored at 4 f). 
When Required 0.5ml of stock is added to 12 ml Earles s balanced salt solution.
Filtered and 1.1 ml per 500 ml bottle.
(6) Trypsin (Life Technologies, U.K.).
(7) Ethyelenediaminatetraacetic acid (EDTA) (Sigma).
2.1.2 Cell lines and culture conditions
The CHI ovarian carcinoma cell line was derived from a moderately differentiated human 
ovarian carcinoma (Hills CA, 1989), and has been shown previously to be relatively sensitive 
to cisplatin, and paclitaxel. The paclitaxel resistant subline of CHI (CHl/TR) was provided 
courtesy of Dr Kelland, and was generated by continuous exposure to paclitaxel at escalating 
concentrations up to 20 nM. The 96 hrs I C 5 0  of CHI and CHl/TR to paclitaxel were 0.66nM, 
and 7.93nM respectively, making the CHl/TR cell line 12 fold resistant to paclitaxel 
compared to parent cell line (Rogers P, 1996). Both cell lines were maintained in DMEM 
supplemented with 10% fetal calf serum, 2mM of L-glutamine, 5 ml of MEM non-essential 
amino acids and 0.5 mg/ml of hydrocortisone. Both cell lines expressed wild type p53 
sequence, with no overexpression of PGP (PestellKE, 1998; Rogers P, 1996).
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2 .1.3 Preparation of cell line for implantation
The cells were harvested by trypsinisation for 5 minutes at 37 C using 0.02% EDTA/0.05% 
trypsin and centrifuged at 500 g for 15 minutes. Cells were washed once in phosphate 
buffered saline (PBS), and then resuspended in 2ml of DMEM containing 10% foetal calf 
serum. Cells were then injected in 0.2ml volume containing approximately 5x10^ cells
2.1.4 Establishment of CHI and CHI paclitaxel resistant xenograft
2.1.4.1 Experimental animals
60
 :   . _
Specific pathogen-free 4-6 week old athymic nude (nu/nu) mice were used. The mice were 
housed in sterilized filter topped cages kept in laminar flow isolators and were fed sterilized 
food and water. All procedures involving the animals were performed under sterile conditions 
in a laminar flow hood. All studies were performed according to the approval of the Institute 
of cancer research Animal Ethics Committee and according to UKCCCR guidelines.
3-
2.1.4.2 Establishment o f Xenografts
In total ten nude mice were injected subcutaneously in the right inguinal region with 
SxlO^cells of either CHl/TS or CHl/TR cells. When the tumours reached 10-15mm in 
diameter they were serially passaged by subcutaneous (s.c.) implantation of expiants of 
xenografted tissue. The passage was done by implanting a small non-necrotic fragment of 
harvested tumours subcutaneously in right inguinal and the wound was sutured by a metal 
clip. The tumours were passaged for at least four times before conducting the growth 
experiments. All these procedures were done with mice fully anaesthetized by halothane.
2.2 Biological growth experiments
The aim of this experiment was to confirm the sensitivity and resistance pattern of CHl/TR 
and CHl/TS cells in vivo.
2.2.1 Drugs
A) Paclitaxel {BristolMyers Squibb, Wallingford, Connecticut, and U.S.A.) was dissolved in 
a vehicle containing 50% polyoxyethy 1 ated castor oil (Cremophor EL) and 50% ethanol, 
and further diluted in 5% glucose in water.
B) Cisplatin {Johnson Matthey Technology Centre, Reading, Berks, UK) was dissolved in 
0.9%NaCl.
2.2.2 Methodology
50 nude mice were implanted with CHl/TS tumours and 50 nude mice were implanted with 
CHl/TR tumours. The take rate which is defined as the number of tumours that grew 
progressively after implantation and could be serially passaged were 75% and 50% for 
CHl/TS and CHl/TR respectively.
The tumours were measured once per week in two dimensions (length and width) using 
calipers. A baseline weight of each animal was taken and subsequently weighed once per 
week. When the tumor diameter size reached 8±2 mm, the mice were randomized into three 
groups of five for each line:
A) Group 1 controls (no treatment)
B) Group2 treated with paclitaxel 25mg/kg in 0.2ml IP on days 0,4,and 8.
C) Group 3 treated with cisplatin 4mg/kg in 0.2ml IP on days 0,4, and 8.
The end point was reached when tumour is 20 mm in diameter, or 60 days post treatment. The 
tumour volume was calculated using formula Tv = a x b  ^x tc/6, where a is the length 
measurement of longest axis, and b is width perpendicular to the length. The biological 
growth curves were generated by plotting the relative tumour volume against time.
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The specific growth delay of CHl/TS and CHl/TR tumours treated with cisplatin or 
paclitaxel was calculated by formula:
Specific growth delay = TD treated -  TD control
TD control 
TD= tumour doubling time.
2.3 Paclitaxel uptake and pharmacokinetic stud ies
The aim of this experiment was to assess the paclitaxel concentration levels and 
pharmacokintetic parameters of CHl/TS, and CHl/TR following intraperitoneal (i.p.) 
administration of 25mg/kg of paclitaxel using High Performance Liquid Chromatography 
(HPLC).
2.3.1 Methodology
Three tumours per time point were harvested from athymic nude mice bearing CHl/TS, and 
CHl/TR xenografts at 1, 3, 6, and 24 hours following administration of 25mg/kg i.p. 
paclitaxel. All tumours were snap frozen with liquid nitrogen for subsequent use.
At the time of analysis, the tumours were disrupted by Polymix homogenizer with a tight- 
fitting ground glass pestle after the addition of 2ml of PBS per gram of tissue. Paclitaxel was 
extracted from tumours by adding 2.5 ml of acetonitrile: then the samples were vortexed for 
30 seconds and centrifuged at 400 g for 10 minutes. The supernatants were collected and 
dried under nitrogen flow at 37 °C. The dry residues were reconstituted in 200pi of 
acetonitrile, methanol, and de-ionized water solution (4:1:5) by vortexing for 30 seconds.
They were then centrifuged at 400g for 5 minutes, and 100 pi of supernatants was injected 
into the HPLC column.
The standards were prepared from untreated control tumours that were homogenized as 
above. Paclitaxel was added to tumour tissue and serial dilutions from 5000 ng/ml to 50 ng/ml 
were made.
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2.3.1.1 HPLC measurement
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Paclitaxel concentration in tumour tissue was measured by means of the reversed-phase 
HPLC method. The HPLC system consisted of a Waters 240 UNICAM module equipped with 
aUV detector and a Supelcosil (Supelco) 1.5 cm x 4.6mm 5 pm (Cl 8) column. TheUV 
detection was done at 227 nm, with a limit of sensitivity of 0.125 pg/ml. The mobile phase 
consisted of 10 ml of ammonium acetate, 490 ml of de-ionized water, 100 ml of ethanol, and 
400 ml of acteonitrile per liter. The tissue extracts were chromatographed at flow of 1 ml/min. 
The peak heights in microvolts of paclitaxel standards and tissue extracts were measured. A 
Standard curve of concentration ranging from 50 to 5000 ng/ml versus peak values was 
generated using paclitaxel standard. The correlation coefficient was used to evaluate the 
linearity of the standard curve. The tissue paclitaxel concentration was derived from the 
standard curve by linear regression using Prism2 of Graph Pad software.
2.3.1.2 Pharmacokinetic analysis
Concentration-time curves were plotted using mean concentration of paclitaxel per time point 
for each tumour type. These curves were then used to calculate the following tissue 
pharmacokinetic parameters Cmax, ti / 2  Lambda z, AUClast, and AUCINF. The calculation was 
done using Win non lin professional software (non-compartemental analysis). AUC from time 
0 to the last sampling point was computed for tissue concentration data by using trapezoidal 
method.
2.4 Chemotherapy induced pharmacodynamics: Study design
The aim of this experiment was to design a xenograft model from CHl/TS and CHl/TR 
tumours to study the cell cycle changes, induction of apoptosis, and dynamic changes of bcl-2 
family of proteins, p53, and p21, Raf-1 following paclitaxel and cisplatin treatment. All these 
parameters were assessed at 24, 48, and 72 hrs following treatment because of their dynamic 
nature.
2.4.1 Buffers S,Solution
(1) Bromodeoxyuridim (Sigma, B-9285)
(2) TrisrHCL (50 mM) andNaCl buffer
0.6057g Tris-HCL + 0.8766g NaCl/100 de-ionized water (dd. H20) adjusted to pH 7.6
(3) Sodium Orthovanadate (100 mM) (Na V04) (Sigma)
18.4 mg ofN a V04/ 1ml ddH20
(4) Phenylmethylsulfonylfluoride PMSF (20m M) (Sigma, P-7626)
(5) Sodium Dodecyl Sulphate (SDS) (20%) (Sigma) 
lOmg SDS/ 50 ml ddH20
{6)Aprotinin (lOmg/ml) (Sigma, A-6279)
(l)Leupeptin (lOmg/ml) (Sigma, L-9783)
(8) NonidetP-40 {NP40) (Sigma, N-6507)
(9) Lysis buffer
10 ml 50 mM Tris-HCL, 150 mMNaCl, lOOpl 100% NP40, lOOpl 20%SDS, 500pL 
NaV04 (100 mM), 2pL Aprotinin (lOmg/ ml), 2plLeupeptin (lOmg/ ml) was made in 
place immediately prior to use.
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2 .4 .2  Methodology
Forty two athymic nude bearing CHl/TS tumours and forty two athymic nude mice bearing 
CHl/TR were randomized into three groups when the tumour size was 8+2 mm in diameter. 
The groups and the treatment for each cell line were as follows:
1) 18 mice received paclitaxel 25mg/kg i.p. and they were sacrificed in groups of six mice at 
24h, 48h, 72h after treatment.
2) 18 mice received cisplatin 4mg/kg i.p. and they were sacrificed in groups of six mice at 
24h, 48h, 72h after treatment.
3) 6 mice received no treatment and they were sacrificed at 24h after start of experiment.
All mice were injected with 100mg/kg of bromodeoxyuridine (Brd Urd) made up in 0.9% 
NaCl saline (lOmg/ml) five hours before harvesting of tumours to facilitate the cell cycle 
kinetics by flow cytometry. Subsequently, the tumours were harvested and divided in to three 
sections:
1) First section was section was immersed in ice-cold 70% ethanol to be used for flow 
cytometry.
2) The second section was immersed in 10% formalin before making of paraffin section.
3) The third lysed with ice-cold lysis buffer and used for protein extraction.
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2.5 Measurement of cell k inetics by bromodeoxvuridine/anti- 
bromodeoxvuridine method
There are several methods that can be used to assess proliferation and cell kinetic 
measurement, each having advantages and disadvantages. Most methods such as mitotic 
index, S phase fraction from the DNA histogram, or Ki-67 and PCNA staining provide a 
snapshot assessment of the cells in a particular phase of cell cycle or cells actively 
proliferating. Techniques which include the use of DNA precursors such as 
bromodeoxyuridine (Brd Urd) are recognized to be better, in cell kinetic terms, because they 
measure the functional aspects of the cell proliferation. The assessment of proliferation by 
Brd Urd technique using flow cytometry is based on incorporation of Brd Urd (detected by 
monoclonal antibody) relative to DNA content measured by propidium iodide (PI). Thus 
allowing measurement of cell kinetics and more importantly the movement of cohort cells in 
any phase of cycle in labelled and unlabelled cells using appropriate computer generated 
regions.
The flow cytometric analysis involved two steps: obtaining the nuclei from ethanol fixed 
tumours and dénaturation procedure of DNA for Brd Urd detection.
2.5.1 Obtaining nuclei from ethanol fixed tumours
The tumour samples were removed from the 70% ethanol and minced into small (Imm^) 
fragments, then dissociated by addition of 5 mis of pepsin solution (0.4 mg/ml/in O.IM HCL) 
to each sample and incubated at shaking water (37 °C) water bath for 30 minutes. The 
samples were then drawn into 1ml pipette and continued disassociation until only connective 
tissue remained. The suspension was filtered through 35 pm nylon mesh into conical- 
bottomed 10ml tube. The nuclei were pelleted by centrifugation at 500g for 5 minutes and 
then washed and resuspended in PBS.
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2.5.2 Dénaturation of DNA and Brd Urd detection
The freshly prepared nuclie were pelleted by centrifugation at 500 g for 5 minutes and then 
resuspended in 1 ml of 2 M HCL. The suspension was incubated at room temperature for 30 
minutes to denature the DNA after which 5 ml of PBS was added and the nuclei centrifuged at 
500 g for 5 minutes. The pelleted nuclei were washed twice with PBS, then resuspended in 
labelling solution containing 1ml of 0.5% Tween 20/1% BSA/PBS and 20 pi of Anti-Brd Urd 
FITC-conjugated monoclonal antibody (Becton-Dickinson, cat. no.347583) and incubated for 
30 minutes. The suspension was then washed twice in 1ml 0.5% tween 20/1% BSA/PBS and 
resuspended in 1 ml of PBS containing 20pg/ml propidium iodode (PI) (Sigma) and 100 
pg/ml RNAse (Sigma).
2.5.3 Flow cytometry
Flow cytometric measurements were made on a Coulter EPICS Elite ESP (Beckman coulter. 
High Wycombe, UK) using a Spectra-Physics argon-ion laser tuned to produce 200 mW at 
488 nm. The DNA content was measured as red fluorescence (>630 nm) from PI. A display o f 
the peak versus the area of the signal red fluorescence was used to gate out any debris or any 
clumped nuclei (Ormerod, 1990).
A display of green representing cells incorporating Brd Urd during DNA synthesis 
(fluorescein, 520 nm) versus red (DNA) was recorded in bivaraite histogram. A separate 
histogram of DNA fluorescence was also recorded. The percentage of tumour cells in each 
phase of the cell cycle was analyzed on multicycle-cell analysis program (Phoenix flow 
systems, CA, USA) that deconvolves a DNA histogram into G l, S, and G2/M phases. A 
region was set on the histogram to exclude the host cells from the analysis.
Several regions were created in the bivaraite histogram; a) region containing all cells, b) 
region containing all cells with Gl DNA content, c) region containing the Brd Urd labelled 
Gl phase cells, d) region containing labelled in S phase, e) region containing cells with G2
DNA content. The labelling index was expressed as the percentage of tumour cells that had 
taken up Brd Urd (Ormerod MG, 1994). Because some cells would have divided to produce 
two daughter cells, labelled cells which appear in Gl phase were halved and subtracted from 
the total number of labelled cells and from the total cell number. The relative movement was 
calculated by subtracting the mean DNA of Gl population from that of the labelled cells and 
dividing it by Gl population from that of the labelled cells and dividing it by Gl subtracted 
from G2 (Ormerod MG, 1994).
2.5.4 Detection of apoptotic ceils by flow cytometry
Cells dying of apoptosis from G l give a sub-Gl (hypoploid) peak in the DNA histogram that 
correlate with DNA degradation. The sub-Gl debris in all 84 samples was measured from the 
DNA histogram to give cmde estimation of apoptosis and subsequently correlated with values 
obtained from TUNEL assay.
68
' ■ ' ' - " -   . .
2.6 TdT ■ mediated d UTP-biotin nick end labelling (TUNED assay of 
apoptosis in paraffin-wax embedded sections
The detection of apoptosis by TUNEL assay is based on specific binding of terminal 
deoxynucleotidyl transferase (TdT) to 3-OH ends of DNA produced during DNA 
fragmentation. Following the exposure of nuclear DNA on histological sections by proteolytic 
treatment, TdT is used to incorporate biotinylated deoxyuridine at sites of DNA breaks. The 
signal is amplified by Avidin-biotin peroxidase conjugate enabling conventional 
histochemical identification by light microscopy.
■i
2.6.1 Solution & BUFFERS
■I
1) Phosphate Buffered Saline, pH  7.3 (PBS)
(Tablets- lo tablets per 1000 ml de-ionized water, each tablet contain 7.33 g sodium 
chloride (NaCL), 2.36g di-sodium hydrogen phosphate, and L32g sodium di-hydrogen 
orthophosphate.
2) Tris buffered saline 
0.606 g Tris base + 0.88g NaCl/ 100 mis di-water adjusted to pH 7.6
3) Cobalt chloride (50m M)
0.119-g cobalt chloride in 10 mis di-water. 200 aliquots stored at -20°C.
3) Reaction buffer (X5)
1 M sodium cacodyl ate (3.2g) + 125 mM Tris HCl (3.15g) + 0.025mg/ml BSA in di­
water.
4) Reaction mixture (RM)
Each lOOpI- 0.75pl TdT, 0.50///Biotin 16dutp, lO.OOpl cobalt chloride, 20.00pl [X5] 
reaction buffer.
5) pepsin solution
0.5g pepsin (molecular biology grade: Sigma P-7012) was dissolved in 100 ml of de­
ionized water, and diluted in 0.1 M HCL to give a final pH OF 2.0. The enzyme solution 
was stored in 500 pi aliquotos at -20 °C in eppendorf tubes.
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2 .6 .2  Paraffin sections
.The harvested tumours were fixed in 10% neutral buffered formalin and embedded in paraffin 
wax. Sequential adjacent sections (3pm) were cut from the paraffin-tumours onto slides 
coated with 3-aminopropyltriethoxysiIane (Sigma), dried at 37 °C overnight, and stored at 
room temperature in standard slide shelving until use.
2.6.3 Labelling of paraffin sections
Three micron paraffin sections were dewaxed in xylene twice and then immersed in
increasing dilutions of Industrial Methylated Spirits (IMS) (100% x3, 95% xl, 80% x l, and
70% x l) and hydrated in de-ionized water x2. The endogenous peroxidase was blocked by
immersing in 1% H202 for 15 minutes and then washed in de-ionized water x3. Each section
was incubated with lOOpl of 0.5% pepsin (pH 2) for 30 minutes in humidified chamber at 37
°C. The digestion with pepsin was terminated by rinsing for 1 minute, then washing for 5 
.times in de-ionized water and Tris buffered saline (pH 7.6) for 5 minutes x2. Each section was 
covered with lOOpl of reaction mixture (RM) and incubated in humidified oven for 1 hour at ;37 °C. After incubation, the sections were washed with de-ionized water x2 and PBS X3, 
then, incubated for 30 minutes with Streptavidin Biotin Complex conjugated to horseradish 
peroxidase (Strep ABC/HPR Dako) diluted 1:400 in PBS, 1% BSA, and 0.5% tween 20. After 
washing sections in PBS/Tween 20 for three times, the peroxidase activity were demonstrated 
with 0.5% diaminobenzidine (DAB; Sigma) and 0.07% imidazole for 30 seconds, then 100 pi 
of H2 O2  was added and sections were incubated for a further 10 minutes. The sections were 
then washed in running tap water for 5 minutes and then immersed in 0.5% copper sulphate 
and 0.9% sodium chloride in de-ionized water for 1 minute. After washing in running tap for 
5 minutes, the sections were counterstained with Mayers haematoxylin for 60 seconds,
washed in tap water, dehydrated through increasing concentration of IMS (as above) followed
.by xylene, cleared and mounted in DPX.
2.6.4 Determination of apoptotic index (Ai)
Every slide was examined carefully a using a standard light microscope (x40 objecive) (Nikon 
Optiphot II, Japan) with 10x10 eyepiece graticule. A total of 3000 cells were counted 
randomly and percentage of positively labelled cells was determined to obtain AI.
2.7 Western Blot o f total protein extracts of tumours
2.7.1 Protein recovery for Western blotting
The tumors were harvested and homogenized in 2mI of ice-cold lysis buffer by an electrical 
homogenizer and left on ice for 15 minutes with occasional mixing. The mixture was 
centrifuged at 12,000 g at 4°C for 20 minutes. The supernatant was carefolly removed and an 
aliquot of 50pl placed into a labeled tube (for protein concentration measurement by BC A 
assay) and the rest was placed in another appropriately labelled tube. Then samples were 
stored at -70 °C.
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2.7.2 Protein concentration estimation by Pierce protein BCA assay
Protein concentration estimation was done using Pierce protein BCA assay. In this assay, 
proteins react with Cu^^to yield Cu^ Cu+ reacts selectively with bioinchoninic acid of BCA 
to yield an H20 Soluble purple reaction product that absorbs light strongly at 562 nm. This 
assay was used because of its compatibility with detergents present in lysis buffer.
Initially Bovine Serum Albumin (BSA) (Pierce, cat no. 23209) standards were prepared. 
Then, BCA reagents were prepared by mixing 50 vol. Reagent A (Pierce cat no. 23223) with 
1 vol. Reagent B (Pierce cat no. 23224) -  stable for day at room temperature. The samples 
were diluted between 1/20 to 1/50 for cellular total protein samples. Duplicates of 50pl 
sample or standard were pipetted into a small test tube, and 1 ml of BCA reagent was added. 
The samples were vortex mixed. The samples and standards were incubated at 37 for 30
■minutes, and then allowed to cool for 10 minutes. The absorbance of standard and samples 
were measured at 562 nm. The absorbance of the standards at 562 nm was plotted against 
protein concentration and a standard curve was generated. The sample protein concentration 
was determined from the standard curve by linear regression using Prism 2 program of Graph 
pad software.
2.7.3 Western blotting of cellular total protein extracts
2.7.3.1 Gel electrophoresis
Precast gels were obtained from Novex (cat no. EC60485, Germany) with 8-16% gradient 
separating gel. The gel specification
Tris-glycine Gel matrix, L5 mm gel thickness, 8 cm x 8 cm gel 
Size, cassettes size 10 cm x 10 cm, and 15 well configuration.
2.7.3.2 Buffers & Solutions
1) Laemmli sample buffer (x2)
20 ml glycerol (20%), 10 ml mercaptoethanol (10%), 23ml of 20% SDS (4.6%), 6.25 ml 
of 1 M Tris (pH 6.8), 5 ml bromophenol blue (0.1%) diluted to 100 ml with de-ionized 
water. Aliquot into 250pl and freeze at -20°C until required.
2) Running buffer (lOx, Novex, cat no, LC 2675)
29 g Tris (0.2 M), 144 g Glycine (1.9 M), 10 g SDS (1%).
80 ml of running buffer was added to 720 ml of de-ionized water.
3) Transfer buffer (25x, Novex, cat no. LC 3675)
12 mM Tris, 96 mM Glycine
20ml of Transfer buffer is added 430 of de-ionized water and 50 ml of methanol.
4) Casein blocking buffer (pH 7.6)
0.5% Casein (2.5g) (Biochemical, cat no 4402034), 0.02% thimerosal (O.lg) (Sigma).
The mixture is dissolved in 500ml of PBS and heated to 60°C until Casein dissolves, then 
allowed to cool and adjusted to pH 7.6.
ê
___________________________
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(2) Bax
(3) B c I-x 1 s /l
(4) P53
2.7.3.3 Antibodies
The primary antibodies used were as follows:
(1) Bcl-2
Source: Santa Cruz Biotechnology
,Antibody Type: polyclonal rabbit N-19 (cat no. Sc-492)
Epitope: Amino acids 4-21 of bcl-2 
Dilution: 1:1000
Duration of incubation: Overnight incubation.
■ÿ;Source: Santa Cruz Biotechnology 
Antibody Type: Polyclonal rabbit (cat no. Sc-493)
Epitope: Amino acids 11-30 of bax 
Dilution: 1:500
Duration of incubation: Overnight incubation
Source: Santa Cruz Biotechnology 
Antibody Type: Polyclonal rabbit (cat. no. Sc-634)
Epitope: Aminoacid sequence mapping at amino terminus of Bcl-x of 
human origin.
Dilution: 1:500
Duration of incubation: Overnight incubation 
Source: Santa Cruz Biotechnology
Antibody Type: monoclonal mouse (DO-1) (cat. no. Scl26)
Epitope: Amino acid residues 11-25 of human origin 
Dilution: 1:500
Duration of incubation: Overnight incubation
i
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(4) P21 II
Source: Santa Cruz Biotechnology 
Antibody Type: Polyclonal rabbit C-19 (cat no sc-397)
Epitope: Amino acid mapping at the carboxy terminus of human p21.
Dilution; 1:500
(2) Anti-mouse
Source: Amersham
Antibody Type: HPR-Iabelled anti-mouse antibody 
Dilution: 1:1000
Duration of incubation: Overnight incubation
(5) Raf-1 I
3.ÎSource: Santa Cruz Biotechnology 
Antibody Type: Polyclonal rabbit C-12 (cat no sc-133)
Epitope: Amino acid mapping at the carboxy terminus.
Dilution: 1:500
Duration of incubation: Overnight incubation •I'v'
ÎThe secondary antibody were as follows:
(1) Anti-rabbit
Source: Santa Cruz Biotechnology
Antibody Type: Anti-rabbit IgG-HPR labelled (cat.no. sc-2004)
Dilution: 1:1000
.Duration of incubation: 45 minutes
■I
I
Duration of incubation: One hour 4-
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2.7.3.4 Methodology
The protein extracts were diluted with ddH20 so that all the samples contained the same 
protein concentration (40-60pg). The samples were diluted 1:1 with laemmli buffer, and 
heated at 95°C for 3 minutes. 5 pg of rainbow marker was diluted with 1:1 laemmli buffer and 
heated at 95°C for 1 minute. Both samples and rainbow marker were allowed to cool and kept 
on ice until use.
Equal amount of proteins 40 pg were loaded into 15 wells of a 8-16% polyacrylamide gel.
The gels were run under constant current of 30 mA per gel using running buffer. Following 
completion of separation of proteins, they were transferred onto nitrocellulose filter. The 
transfer step was carried in cold room (4“C), under constant current of 300 MA and using 
running buffer. Subsequently, the electroblotting efficiency and equal protein content per lane 
were verified by staining of membranes with 0.1% Ponceau S. The membranes were blocked 
using blocking buffer for 60 minutes at room temperature. Following this step the membranes 
are ready for immunodetection.
2.7.3.5 Immunodetection of specific proteins on nitrocellulose filters
Initially the nitrocellulose filters were washed with PBS containing 0.1% Tween 20 (PBST), 
then the filters were exposed to the appropriate antibody diluted in blocking buffer as above. 
All antibodies were incubated overnight to enhance detection of proteins. Following 
incubation with primary antibody, the nitrocellulose filters were washed with PB ST for 15 
minutes once and 5 minutes three times. Then the filters were exposed to the appropriate 
secondary antibody for one hour. Then the filters were washed with PB ST as above.
The proteins were detected using Enhanced Chemiluminescent (ECL) and autoradiography 
films in dark room. The filter was exposed to mixture of 5 mis of reagent A and 5 mis o f 
reagent B for 60 seconds. The reaction was terminated by the removal of the filter from the 
mixture, and quickly exposed to autoradiography film for 1,2,5 minutes.
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21.3.6 Imagequantification
The expression o f different apoptotic proteins were assessed in two ways;
(1) The effect of paclitaxel treatment on bcI-2 family of proteins, p53, p21, and Raf-1 in 
CHl/TS and CHl/TR tumours was compared at 24, 48, 72 hours. The pre-cast gels were 
loaded with CHl/TS control, CHl/TR control, protein samples of the six CHl/TR 
xenografts treated with paclitaxel, and protein samples of the six CHl/TS xenografts 
treated with paclitaxel to perform this comparison.
(2) The effect o f cisplatin and paclitaxel on expression of the above proteins in CHl/TR 
xenograft was compared because of different response of these xenografts to the two 
drugs. The pre-cast gels were loaded with CHl/TR control, protein samples of the six 
CHl/TR xenografts treated with cisplatin, and protein samples of the six CHl/TR 
xenografts treated with paclitaxel.
The imagequantification of protein bands was done using Imagequant Molecular Dynamics 
software. The imagequntification provided a value reflecting the band density of the protein 
probed for each individual sample. The band density values were expressed as ratio folds 
increase or decrease from the control proteins. Prior to that, the controls for CHl/TR and 
CHl/TS xenografts were blotted and probed for different proteins above. The expression of 
the probed proteins in the control samples was found to be almost equal. Hence, one control 
was chosen for each group and used throughout the experiments.
2.7.3.7 Characterization o f bcl-2~related proteins
In addition to the 26 kilodalton (KD) bcl-2 band, two other bands with molecular weight of 27 
KD and 30 KD bcl-2 related bands. To further characterize these bands, 50 pg of tumour 
lysate of three paclitaxel treated CHl/TS tumours lysates were either incubated with or 
without 2 units o f alkaline phosphotase at 37 °C for 4 hours. Then, 40 pg were loaded into 
pre-cast gels and immunoblotted with anti-bcl-2 antibody. The tumour lysates were prepared 
with same lysis buffer described in section 2.4.1, but Sodium Orthovanadate was omitted 
because it inhibits the action of alkaline phosphates.
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2.8 Growth studies of xenografts of bcl-xl transfected CH1 paclitaxei 
sensitive cells
.The aim of this experiment was to assess the effect of the transfection of the anti-apoptotic
bcl-xl on the responsiveness of CHl/TS tumours to cisplatin and paclitaxel.
2.8.1 methodology
Cell line of CHI tumour cells transfected with bcl-xl was provided courtesy of Dr. Kelland.
The bicistronic plasmid vector pIRES-P (code number 250, EMBL accession number
Z75185) was used to express bcl-xl in CHI cells (figure 2-1) (Sharp SY, 1998). This vector
expresses a single bicistronic mRNA driven from the human cytomegalovirus immediate
early enhancer/promoter and uses the internal ribosome entry site from encephalomyocarditis 
.virus to direct translation of the downstream pac gene encoding for puromycin acetyl 
transferase. Xenografts of CHI cells transfected with bcl-xl (CHI/bcl-xl) and xenografts CHI 
cells transfected with vector only (CHl/F 280) were established using the same procedures in 
section 2.1.4 were used to establish these xenografts. These xenografts were passaged at least 
for three times before conducting the growth experiments. The level of expression of bcl-xl 
protein CHl/bcl-xl xenografts was assessed by western blotting and expressed as fold 
increase from CHl/TS tumours.
Subsequently, 105 athymic nude mice were divided into three equal groups and implanted 
with either CHl/TS, CHl/bcl-xl, or CHl/F 280 tumours. The take rates were 75%, 60%, and 
65% for CHl/TS, CHl/bcl-xl, and CHl/F 280 tumours respectively. The tumours were 
measured once per week in two dimensions (length and width) using calipers. A baseline 
weight o f each animal was taken and subsequently weighed once per week. When the tumor 
size reached 8 ±2 mm, the mice were randomized into three groups of six for each line:
D) Group 1 controls (no treatment)
E) Group2 treated with paclitaxel 25mg/kg in 0.2ml IP on days 0,4,and 8.
F) Group 3 treated with cisplatin 4mg/kg in 0.2ml IP on days 0,4, and 8.
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The end point reached when tumour is 20 mm in diameter, or 60 days post treatment. The 
tumour volume and specific growth delay was calculated as described previously.
I
2.9 Paclitaxel uptake and pharmacokinetic studies of CH1/bcl-xl
It was important to rule out any uptake defect that contributes to the pattern of response of 
CHl/bcl-xl tumours to paclitxel. Hence, Three tumours per time point were harvested from 
athymic nude mice bearing either CHl/bcl-xl or CHl/TS tumours at 1, 3, 6, and 24 hours 
following administration of 25mg/kg i.p. Then intra-tumoural concentration of paclitxel in 
CHl/bcl-xl tumours was measured and compared to parent tumour CHl/TS tumours using the 
method described in section 2.3.1.
I
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Figure 2-1: The puromycin-resistant bicistronic 1RES vector containing the complete coding 
sequence for MRPI (F250 vector).
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2 .1 0  S ta t i s t i c a l  a n a ly s i s
2.10.1 Biologicaf growth studies
Following the calculation o f the mean relative tumour volume and standard error of the mean 
(SEM), it was blotted against time (days), and no fiirther statistical analysis was carried out.
2.10.2 Fiow cytometeric studies and prolifération
The mean percentage values and SEM of cells in sub G l, Gl, S, and G2/M phases were 
calculated in control untreated tumours and CHl/TS tumours following cisplatin and 
paclitaxel treatment at 24, 48, and 72 hours. In addition, the mean percentage values and SEM 
of labeling index and mean relative movement values were calculated in control tumors, and 
in CHl/TS and CHl/TR tumors following capsulation and paclitaxel treatment at 24, 48, 72 
hours. The Mann-Whitney test was used to detect significant statistical difference (p <0.05) 
for each group of values compared to the control. The Mann-Whitney test, also called the rank 
sum test, is a nonparametric test compares two unpaired groups. It assumes that the data is 
representative of a population with each subject was selected independently, but the 
populations do not need to follow any particular distribution.
2.10.3 Apoptotic studies
The mean values and SEM of apoptotic indices were calculated for control tumours, and 
CHl/TS and CHl/TR tumours following paclitaxel and cisplatin treatment at 24, 48, and 72 
hours. The Mann-Whitney test was used to detect significant statistical difference (p <0.05) 
for each group of values compared to the control.
2.10.4 Apoptosis regulating proteins
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IFollowing the estimation of each protein level per tumour by densitometry, the levels were, 
then, expressed as ratio increase or decrease to control. The mean values and SEM of these I
ratios were calculated for each protein. The statistical differences between levels of protein 
expression were compared in CHl/TS and CHl/TR tumours at 24, 48, and 72 hours.
»
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Chapter 3: Results
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3.1 B io lo g ic a l  g ro w th  s tu d i e s
3.1.1 C H I paclitaxel sensitive (CHl/TS) xenografts
83
The average growth rates of CHl/TS and CHl/TR tumours following paclitaxel (25mg/kg) 
and cisplatin (4mg/kg) treatment on days 0,4,and 8 are shown in figure 3-1. CHl/TS tumours 
demonstrated sensitivity to paclitaxel with complete disappearance of all the tumours 4 days 
post last dose of treatment. Three mice were still tumour free 52 days post treatment, in one 
mouse tumour began to grow slowly 24 days post treatment, and the fifth mice was culled at 
day 43 post treatment because of toxicity with no evidence of growing tumour. The doubling 
time of untreated control CHl/TS tumours was 2.9 days and a growth delay of paclitaxel 
treated CHl/TS tumours was more than 60.1 days. Similarly, cisplatin induced complete 
disappearance of CHl/TS tumors 4 days post last dose of treatment. Four mice were still 
tumour free 52 days post treatment, and in one mouse the tumour began to grow slowly 24 
days post treatment. The growth delay for these tumours was, also, more than 60.1 days.
.13.1.2 C H I Paclitaxel resistant (CHl/TR) xenografts
The average growth rates of CHl/TR tumours following paclitaxel and cisplatin treatment are 
shown in figure 3-2. CHl/TR tumours displayed no response to paclitaxel with tumours 
reaching the end-point size and weight 16 days post last dose of treatment in all five mice.
The doubling time of control untreated CHl/TR tumours were 3 days and the a growth delay 
of paclitaxel treated CHl/TR tumours were 8.7 days. Following cisplatin treatment there was 
partial response of CHl/TR tumours in all mice that was maintained on average for 21 days 
post treatment indicating partial resistance to cisplatin with a growth delay of 32.4 days.
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Figure 3-1:Averge growth curves of CH1/TS tumours following paclitaxel (25mg/kg) 
and cisplatin (4mg/kg) given on days 0,4, and 8.
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Figure 3-2: Average growth curves of CH1/TR tumours following paclitaxel 
(25 mg/kg) and cisplatin (4 mg/kg) on days 0,4,8.
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3.2 Paclitaxei uptake studies and pharmacokinetic analysis
The chormatographic analysis of samples showed that paclitaxel eluted with a mean retention 
time of 9.5 minutes. The mean paclitaxel concentrations and concentration versus time curves 
of CHl/TS, and CHl/TR tumours are shown in table 3-1 and figure 3-3 respectively. There 
was no significant difference in mean intra-tumoural paclitaxel concentration of CHl/TS, 
CHl/TR 1, 3, 6, or 24 hours post treatment. In particular, the difference of paclitaxel 
concentration noted at 1 hour post treatment with values of 0.22pg/ml, 0.067pg/ml, 
respectively, was not significant (p=0.4) The mean paclitaxel concentrations 6 hours post 
treatment were almost equal and represented the mean peak values for both tumours.
The pharmacokinetic parameters measured are summarized in table 3-2.The intratumour 
paclitaxel Cm»x occurred at 6 hours post treatment with similar values of 3.18 and 3.46p,g/ml 
in CHl/TS, CHl/TR tumours respectively. The calculated AUCo- ) . 2 4  value for CHl/TS was
100.8 hr X fxg/ml, however, there was an increase of 8% in AUCo- > 2 4  values for CHl/TR as 
shown in table 3-2. The terminal T 1 / 2  values of CHl/TS, and CHl/TR were 15.2, and 28.5 
respectively.
The above results suggest that there are no major differences in either intratumoural paclitaxel 
concentrations or pharmacokinetics to account for the resistant pattern observed in CHl/TR 
tumours as demonstrated in biological growth studies previously. Thus, these results confirm 
that there are no alterations in paclitaxel uptake and suggest that the observed resistant 
phenotype is due to more distal mechanisms.
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Figure 3-3; Intratumoural paxiitaxel concentration versus time of 
- o -  CH1/TS and CH1/TR following administration of 25 mg/kg of 
paclitaxel i.p.
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Time (hrs) CHl/TR (pg/ml) CHl/TS (pg/ml)
1 0.067+0.021 0.22+0.09
3 3.56+0.45 3.42+0.13
6 6.93+0.52 6.36+0.47
24 4.47+0.54 2.8+0.28
Table 3-1: the intra-tumoural concentration of paclitaxel in CHl/TS, and CHl/TR 
tumours following treatment with 25 mg/kg of paclitaxel i.p.
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Parameters CHl/TR CHl/TS
Cmax (ng/ml) 3462 3181
AUClast (ng/ml x hr) 121997.8 100798
Ti/ 2  Lambda z (hr) 28.51 15.16
AUCINF (ng/ml x hr) 152931.07 80957.95
Table 3-2: the pharmacokinetics parameters measured in CHl/TS and CHl/TR 
tumours following treatment with 25 mg/kg of paclitaxel i.p.
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3 .3  F lo w  c y to m e tr y
3.3.1 CH1/paclitaxe! sensitive
3.3.1.1 Post paclitaxel treatment
IThere were 18 athymic nude mice bearing CHl/TS tumours that were treated by single dose of paclitaxel 25mg/kg i.p. and sacrificed in groups of six mice at 24hr, 48hr, 72hr following 
treatment. There were six control untreated mice. Table 3-3 shows the mean percentage (%) 
values of cells in S phase and G2/M phase, labelling index (LI), and calculated relative 
movement through S phase (RM) of treated and controls xenografts. The characteristic feature 
of the DNA histograms (figure 3-4) is accumulation of cells in G2/M phase of cell cycle. This 
effect was apparent at 24 hours post treatment with mean percentage o f cells in G2/M of 
17.54 (p=0.11), but became more marked at 48 hrs and 72 hrs post treatment with mean % of 
cells in G2/M of 24.23% (p=0.0159) and 32.37% (p=0.0095) respectively. Interestingly, there
'was an increase in % of cells in S phase with mean % of cells of 40.2 (p=0.0317), 36.02
(p=0.0303), and 36.98% (p=0.0087) at 24, 48, and 72 hours respectively. These observations 
.are consistent with previous in vitro studies.
The green (Brd Urd uptake by cells actively synthesizing DNA at time of injection) versus red 
(DNA content) histograms demonstrated that movement of cells through S phase is 
unhindered following paclitaxel treatment (figure 3-5). This is reflected in relative movement 
values (table 3-3) with control, 24h, 48h,and 72h values of 0.68, 0.70, 0.69, and 0.69 
respectively. The percentage of tumour cells labelled with BrdU (LI) was largely unaltered at 
24 hours and 48 hours post treatment with control, 24 hr, 48 hr mean % values of 26.9, 29.43 
(p=0.4206), 24.15 (p=0.9048) (table 3-3). However, 72 hr post paclitaxel treatment there was 
inhibition of S phase proliferation with decreased in mean % of LI value to 19.9 (p=0.0303).
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3.3.1.2 Post cisplatin treatment
Eighteen athymic nude mice bearing CHl/TS tumours were treated by single dose of 
cisplatin 4mg/kg i.p. and sacrificed in groups of six mice at 24hr, 48hr, 72hr post treatment. 
There were six control untreated mice. Table 3-4 shows the mean percentage values of cell in 
S phase and G2/M, labelling index, and relative movement through S phase following 
cisplatin treatment. The characteristic feature of DNA histograms (figure 3-6) is accumulation 
of cells in S phase. This effect was apparent at 24 hours (p=0.03) post-cisplatin treatment and 
became more marked at 48 and 72 hours with mean percentage of cells in S phase 54.37% 
(p=0.0173) and 51.98% (p=0.0087) respectively. There was a statistically significant increase 
in mean percentage of cells in G2/M (18.22%) at 72 hours post cisplatin treatment. These 
observations were previously demonstrated in ovarian cancer cell lines including CHI and 
other cell lines following cisplatin treatment (Ormerod MG, 1996).
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The green versus red histogram (figure 3-7) demonstrated slowing down in the movement of 
cells through S phase with little corresponding hindrance at Gl-S phase transition. The 
control untreated tumours incorporated sufficient amount Brd Urd and showed steady cell 
cycle distribution pattern. Three out of six tumours 24 hours post treatment and five out o f  six 
tumours 48 hours post treatment had no or poor incorporation of Brd Urd. This part of the 
experiment was repeated twice to exclude any methodological errors, however the same 
results were obtained. The S phase proliferation is markedly inhibited in the tumours that 
incorporated Brd Urd with mean percentage values of LI of 14.8% and 5.8% for three 
tumours at 24 hours and one tumour at 48 hours post treatment respectively (table 3-4). In 
addition the RM values of these tumours reflected the marked retardation of movement
through S phase with mean values of 0.41 and 0.47 at 24 hrs and 48 hrs post treatment
respectively. These observations suggest that the lack of Brd Urd uptake in the other tumours
may be due to complete inhibition of DNA synthesis. In contrast at 72 hours post cisplatin
treatment there was sufficient incorporation of BrdUrd with an increase in LI (46.34%)
suggesting an escape fi-om temporary effect of cisplatin on DNA synthesis. However, the RM
.through S phase at 72 hours post cisplatin treatment was still retarded with value of 0.58
(p = 0 .002).
f t ;
3.3.2 CH1/TR paclitaxel resistant xenografts
The DNA histogram of most of these xenografts showed multiple Gl peaks suggesting the 
presence of multiple subclones within the tumours. Because of that specific values of G l, S 
phase, and G2/M values were difficult to obtain. However, in descriptive terms the DNA 
histograms and red versus green histogram reflected the response of these tumours to 
paclitaxel and cisplatin. In addition, an estimate of percentage of Gl and G2/M cell cycle 
phases were obtained by generating region on the DNA histograms using the WinMIDI 
program. This enabled the calculation of G2 to Gl ratio was to obtain an estimate of the 
changes in G2/M phase of cell cycle in CHl/TR tumours following paclitaxel treatment.
3.3.2.1 Post-paclitaxel treatment
The same number of mice and design was used as in section 3.3.1.1. The LI, RM, G2/G1 
values of CHl/TR tumours following paclitaxel treatment are summarized in table 3-5. The 
DNA histograms (figure 3-8) demonstrated no cell cycle alterations in these tumours 
following paclitaxel treatment, in particular there was no G2/Mblock. The G2/G1 ratio of the 
CHl/TR control xenografts and at 24, 48, and 72 hours post paclitaxel treatment were 0.3, 
0.35, 0.37, and 0.35 respectively. In contrast the G2/G1 ratio of the CHl/TS controls and at 
24, 48, 72 hours post paclitaxel treatment were 0.3, 0,39, 0.56, 1.19 respectively. Moreover, 
the green versus red histograms (figure 3-9) shows no change in the LI and RM between 
untreated control and treated tumours as shown in table 3-5. These observations confirm the 
resistance of these tumouns to paclitaxel.
3.3.2.2 Post-cisplatin treatment
The same number of mice and design was used as in section 3.3.1.2. The LI, RM values of 
CHl/TR tumours following cisplatin are summarized in table 3-6. The DNA histograms of 
CHl/TR treated with cisplatin displayed the S phase slow down previously demonstrated in 
CHl/TS tumours (figure 3-10). Similarly, the green versus red histogram demonstrate the pile 
up of cells in early S phase with RM values of control and treated tumours at 24h, 48h, and
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72h of 0.69, 0.42(p=0.0022), 0.52 (p=0.0043), and 0.68 (p=0.93) respectively (figure 3-11). In 
contrast to CHl/TS tumours there was no inhibition of proliferation with mean percentage LI 
of control, and treated tumours at 24, 48, and 72h values of 30.55,40.68, 49.48, and 30.88. 
These observations are consistent with partial resistance of CHl/TR xenografts demonstrated 
previously in the biological growth studies.
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Control 24h 48h 72h
G2% 11.88 ±1.03 17.54 ±2.61 24,23±3.51* 32.37 ±5.8**
S phase 
(%)
27.4 ±0.92 40.2 ±3.62* 36.02±2.42* 36.98±2.25*
LI (%) 26.09 ±1.72 29.43 ±4.55 24.15 ±3.05 19.19±2.48*
RM 0.68 ±0.007 0.71 ±0.021 0.70 ±0.01 0.69 ±0.017
Table 3-3 : the mean percentage values and standard error of the mean (SEM) of cell cycle 
G2/M and S phases, labelling index (LI), and mean values of relative movement through S 
phase (RM) of CHl/TS tumours following treatment with paclitaxel (*)=P <0.05, (**)=p 
<0.01, (***)= P <0.0001.
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Control 24h 48h 72h
G2% 11.88 ±1.03 11.3 ±0.72 7.83 dhO.98 18.22+2.14*
S phase % 27.4 ±0.92 40.7 ±2.89* 54.37±4.08** 51.98+4.66**
LI% 26.09 ±1.72 14.28±6.45* 5.18 ±5.18+ 46.34 ±2.45
RM 0.68 ±0.007 0.41 ±0.012 0.47±0.47+ 0.58 ±0.013**
Table 3-4; The mean percentage values and standard error of the mean (SEM) of cell G2/M 
and S phases, labelling index (LI), and mean values of relative movement through S phase 
(RM) of CHl/TS tumours following treatment with cisplatin. (*)=P <0.05, (**)= P <0.01, 
(***)= P <0.0001. (+) Represent value from single tumour (see text).
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Control 24 hr 48 hr 72 hr
LI% 30.55 ±0.69 32.02 ±2.07 32.7 ±1.9 29.26 ±1.27
RM% 0.69 ±0.04 0.63 ±0.25 0.65 ±0.015 0.67 ±0.007
G2/G1 0.3 0.35 0.37 0.35
Table 3-5: the mean percentage values and standard error of the mean (SEM) labelling index 
(LI), relative movement through S phase (RM) of CHl/TR tumours following treatment with 
paclitaxel, and the mean values of G2/G1 ratios. (*)=P <0.05, (**)= P <0.01, (***)-p 
<0.0001.
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IControl 24 hr. 48 hr. 72 hr.
L I% 30.55 ±0.69 40.68 ±3.68 49.48 ±5.22 30.88 ±2.53
RM % 0.69 ±0.04 0.42 ±0.027** 0.52 ±0.028** 0.68 ±0.04
Table 3-6: the mean percentage values and standard error of the mean (SEM) labelling index 
(LI), and relative movement through S phase (RM) of CHl/TR tumours following treatment 
with cisplatin. (*)=P <0.05, (**)= P <0.01, (***)= P <0.0001.
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Figure 3-4: DNA histograms of CHl/TS tumours following paclitaxel treatment showing 
accumulation of cells in G2/M phase of cell cycle, (A) Control, (B) 24 hrs post-treatment, (C) 
48 hrs post-treatment, (D) 72 hours post treatment.
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Figure 3-5: Red (DNA) vs. green (Brd Urd uptake) histograms of CHl/TS tumours following 
paclitaxel treatment showing unhindred movement of through S phase, -D-on the histograms 
refer to cells that have undergone division. (A) Control, (B) 24-hrs post-treatment, (C) 48 hrs 
post-treatment, (D) 72 hours post treatment.
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Figure 3-6; DNA histograms of CHl/TS tumours following cisplatin treatment showing 
accumulation of cells in S phase. (A) control, (B) 24 hrs post-treatment, (C) 48 hrs post­
treatment, (D) 72 hours post treatment.
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Figure 3-7: Red (DNA) vs. green (Brd Urd) histograms of CHl/TS tumours follow.ng 
cisplatin treatment showing pile up cells in early S phase. Gl-D refers to cells that took up 
Brd Urd and divided, then entered G1 phase of cell cycle. (A) Control, (B) 24 hrs post­
treatment, (C) 48 hrs post-treatment, (D) 72 hours post treatment.
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Figure 3-8: DNA histograms of CHl/TR tumours following paclitaxel treatment showing no 
alterations in the cell cycle. (A) Control, (B) 24 hrs post-treatment, (C) 48 hrs post-treatment, 
(D) 72 hours post treatment.
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Figure 3-9: Red (DNA) vs. green (Brd Urd) histograms of CHl/TR tumours following 
paclitaxel treatment showing no alteration in cell cycle. (A) control, (B) 24 hrs post-treatment, 
(C) 48 hrs post-treatment, (D) 72 hours post treatment.
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Figure 3-10: DNA histograms of CHl/TR tumours following cisplatin treatment showing 
accumulation of cells in early S phase. (A) Control, (B) 24 hrs post-treatment, (C) 48 hrs post­
treatment, (D) 72 hours post treatment.
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Figure 3-11; Red (DNA) vs. green (Brd Urd) histograms of CHl/TR tumours following 
cisplatin treatment showing pile up of cells in early S phase. (A) control, (B) 24 hrs post­
treatment, (C) 48 hrs post-treatment, (D) 72 hours post treatment.
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3.4 Apoptosis
The main method for detection of apoptosis in this study was labelling of paraffin embedded 
sections by TUNEL assay. There were no discrete sub-Gl peaks that are frequently 
demonstrated in vitro and correlated with DNA degradation. However, the careful 
examination of DNA histograms showed that there were sub-Gl debris that exhibited a 
pattern in both treated and untreated sensitive and resistant tumours. These sub-Gl debris 
were estimated from the DNA histograms using the WinMEDI program and correlated with 
apoptotic index (AI) obtained by TUNEL assay. Despite the usefiilness estimating of sub-Gl 
debris as supporting evidence for apoptosis, it remains a crude method for detection of 
apoptosis because it may consist of apoptotic and necrotic cells. Thus the results here are 
interpreted with caution and in correlation with results from the TUNEL assay.
3.4.1 Detection of apoptosis by TUNEL assay
3.4.1.1 CHl/TS Tumours
The mean percentage apoptotic indexes of CHl/TS tumours are summarized in table 3-7. 
Figures 3-12, 3-13, and 3-14 provide representative CHl/TS tumour slides labelled by 
TUNEL assay of control tumours, and paclitaxel and cisplatin treated tumours respectively. 
The sensitivity of CHl/TS tumours to cisplatin and paclitaxel is demonstrated by a 
statistically significant increase in AI following treatment. Cisplatin induced an increase in AI 
with mean percentage values for control, and treated tumours at 24, 48, and 72 hours of 0.83, 
13.7 (p=0.002), 20.4(p“ 0.002), 19.4(p-0.002) respectively. Similarly, there was an increase in 
mean percentage AI following paclitaxel treatment vnth values at 24, 48, and 72 hours o f 8.6 
(p=0.002), 9.3 (p=0.002), 6.5(p=0.002) respectively. The difference in increase of AI between 
cisplatin and paclitaxel could be explained in part by presence of large number of cells in 
mitotic arrest that may subsequently undergo apoptosis as shown in figure 3-13. The mean 
percentages of cells in mitotic arrest for control tumours and at 24, 48, and 72 hours following 
paclitaxel treatment were 1, 9.6, 6.4, and 4.2 respectively.
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3.4.1.2 CHl/TR tumours
The mean apoptotic indexes of CHl/TR tumours are summarized in table 3-7. Figures 3-15, 
3-16, and 3-17 provide representative CHl/TR tumour slides labelled by TUNEL assay of 
control tumours and paclitaxel and cisplatin treated tumours respectively. Following 
paclitaxel treatment of CHl/TR tumours, there was statistically non-significant increase in AI 
with mean % values of control, and treated tumours at 24, 48, 72 hours of 0.99, 1.79 
(p=0.064), 1.91(p=0.093), and 1.93(p=0.093) respectively. Furthermore, cells displaying 
mitotic arrest were seen very occasionally in small number of slides (less than 1%). These 
observations confirm the resistance of these tumours to paclitaxel and the lack of induction of 
apoptosis. On the other hand, cisplatin induced statistically significant increase in apoptosis in 
CHI/TR tumours with mean percentage of AI at 24, 48, and 72 hours of 10.4(p=0.002), 
7.9(p=0.002), and 7.4(p=0.002). In comparison to CHl/TS tumours, cisplatin induced less 
apoptosis in CHl/TR tumours consistent with inherent partial resistance to cisplatin that has 
been previously demonstrated in the biological growth studies.
3.4.2 Measurement of sub-Gi debris
The results of sub-Gl debris measurement are summarized in table 3-8. There was a small 
sub-Gl debris peak for CHl/TS and CHl/TR controls with mean values of 3.27 and 2.3 
respectively. There was marked statistically significant increase in sub-Gl debris in CHl/TS 
following paclitaxel and cisplatin treatment. The mean % of sub-Gl debris following cisplatin 
treatment was 13.6, 29.42, and 15.12 (p-0.002) at 24, 48, and 72 hours respectively. The 
mean % of sub-Gl debris following paclitaxel treatment was 8.45, 17.62, and 16.42 (p-0.002) 
at 24, 48, and 72 hours respectively. Interestingly, The rise in sub-Gl values was more 
marked following cisplatin treatment and in keeping with apototic indexes measured by 
TUNEL assay.
There was less marked increase in sub-Gl debri in CHl/TR tumours following cisplatin and 
paclitaxel treatment. The mean % of sub-Gl debris values following paclitaxel treatment of 
CHl/TR tumours were 6,83, 6.25, and 7.01 (p=0.002). Despite the statistical significance of
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these values, the increase in sub-Gl debris in CHl/TR tumours following paclitaxel treatment 
is much less than the values obtained following treatment of CHl/TS tumours with paclitaxel 
These observations are in keeping with results of AT estimation by TUNEL assay. There was 
a statistically significant increase in mean % of sub-Gl with values of 12.5, 9.45, and 9.28 at 
24, 48, 72 hours post treatment respectively. Similarly this increase in sub-Gl debris in 
CHl/TR tumours is less than values obtained following the cisplatin treatment of CHl/TS 
tumours in keeping with biological growth studies and estimation of A.I results that suggest a 
degree of partial resistance
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Control 24 hr 48 hr 72 hr
CHl/TS/Tx 0.83 ±0.15 8.6+1.08** 9.3 ±0.98** 6.5 ±1.31**
CHl/TR/Tx 0.99+0.16 1.79 ±0.77 1.9 12+0.39 1.93 ±0.28
CHl/TS/Cis 0.83 ±0.15 13.17+0.58** 20.4 ±3.21** 19.4 ±4.54**
CHl/TR/Cis 0.99 ±0.16 10.4 ±1.1** 7.9+0.81** 7.4 ±0.84**
■iI
f*
i
%
Table 3-7: Mean % of apoptotic index and standard error of mean (SEM) of CHl/TS and 
CHl/TR tumours treated with both paclitaxel (Tx) and cisplatin (Cis). (*)=P <0.05, (**)- P 
<0.01, (***)-P <0.0001.
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Control 24 hr 48 hr 72 hr
CHl/TS/Tx 3.27 ±0.85 8.45 ±0.54** 17.62 ±3,37** 16.42 ±5.28**
CHl/TR/Tx 2.3 ±0.56 6.83 ±1.014** 6.25 ±0.58** 7.017 ±0.94**
CHl/TS/Cis 3.27 ±0.85 13.6 ±1.7** 29.42 ±6.33** 15.12 ±5.73**
CHl/TR/Cis 2.3 ±0.56 12.5 ±2.54** 9.45 ±1.27** 9.28 ±1.93**
Table 3-8; Mean % of sub-Gl values and SEM of CHl/TS and CHl/TR tumours treated with 
both paclitaxel (Tx) and cisplatin (Cis). (*)=P <0.05, (**)= P <0.01, (***)= p <0.0001.
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3-12: Representative photomicrograph (x40) of control (untreated) CHl/TS tumour showing 
few darkly stained apoptotic bodies.
I l l
3-13: Representative photomicrographs (x40) of CHl/TS tumours treated with paclitxel 
showing darkly stained apoptotic bodies and numerous cells in mitotic arrest. (A) 24 hrs 
following treatment, (B) 48 hrs following treatment, (C) 72 hrs following treatment (overleaf).
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Figure 3-13(cont.) - (C) CHl/TS tumour 72 hrs following paclitaxel treatment.
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3-14: Representative of photomicrographs (x40) of CHl/TS tumours treated with cisplatin 
showing numerous darkly stained apoptotic bodies. (A) 24 hrs following treatment, (B) 48hrs 
following treatment, (C) 72 hrs following treatment (overleaf).
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Figure 3-14 (cont.) - (C) CHl/TS tumours 72 hrs following cisplatin treatment
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»3-15: Representative of photomicrographs (x40) of control (untreated) CHl/TR tumour 
showing f two darkly stained apoptotic bodies.
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3-16: Representative photomicrographs (x40) of CHl/TR tumours treated with paclitaxel 
showing few darkly stained apoptotic bodies.(A) 24 hrs following treatment, (B) 48 hrs 
following treatment, (C) 72 hrs following treatment (overleaf).
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Figure 3-16(cont.) - (C) CHl/TR tumours 72 hrs following paclitaxel treatment.
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3-17; Representative photomicrographs (x40) of CHl/TR tumours treated with cisplatin.(A) 
24 hrs following treatment, (B) 48 hrs following treatment, (C) 72 hrs following treatment 
(overleaf).
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Figure 3-17 (cont.) - (C) CHl/TR tumour 72 hours following cisplatin treatment.
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3 .5  A s s e s s m e n t  o f  a p o p to s i s  r e g u la t in g  p r o te in s  b y  W e s te r n  b lo tt in g
The changes in apoptosis regulating protein p53, p21, bax, bel-2, bcl-xl, and Raf-1 were 
studied CHl/TS and CHl/TR tumours following treatment with paclitaxel (25 mg/kg i.p) and 
cisplatin (4mg/kg i.p.). The established xenograft model allowed the dynamic assessment of 
the relative expression of these proteins at 24, 48, and 72 hours post treatment using western 
blotting. The levels of expression of these proteins were compared in two ways as discuss in 
section 2.7.3.6. Briefly, Because of the different response to paclitaxel, the effect of paclitaxel 
on the expression of these proteins was compared in CHl/TS and CHl/TR tumours. The 
CHl/TR tumours displayed a moderate sensitivity to cisplatin; hence the effect of cisplatin 
and paclitaxel on apoptosis regulating proteins in CHl/TR tumours was compared.
Here, the changes in the levels of each protein will be discussed separately, but taking into 
account the different interactions between these proteins. The mean fold increase or decrease 
in levels of proteins above in CHl/TS and CHl/TR tumours are summarized in tables 3-9 and 
3-10. The mean fold increase or decreases in levels of proteins above in CHl/TR tumours 
following cisplatin treatment are summarized in table 3-11.
3.5.1 P53
CHl/TS and CHl/TR cell lines are known to express wild type p53 (Pestell KE, 1998). 
Paclitaxel induced significant increase in p53 levels in CHl/TS tumours (figure 3-18 and table 
3-9) with mean fold increases from the control of 4.7, 3.4, and 4.3 at 24, 48, and 72 
respectively. In contrast, paclitaxel induced slight increase in p53 in CHl/TR tumours with 
p53 levels of 1.3, 1.5, and 1.4 at 24, 48, and 72 hours respectively. The difference in induction 
of p53 between CHl/TS and CHl/TR was statistically significant (p=0.002) at 24 hrs, 48 hrs, 
and 72 hrs. Interestingly, cisplatin induced significant increase in p53 levels (figure 3-19) in 
CHl/TR with mean fold increases of 2.2, 2.55, and 3.9 (p=0.002) at 24, 48, and 72 hours 
respectively.
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3.5.2 P21
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P21 is downstream protein that is transactivated by p53 protein as discussed in section 1.3.5.1.
The induction of p53 by paclitaxel in CHl/TS tumours resulted in similar rise in p21 levels 
(figure 3-20 and table 3-9) with fold increases from control of 1.46, 3.84, 3.6 at 24, 48, and 72 
hours respectively. Paclitaxel resulted in slight changes in p21 levels in CHl/TR tumours of 
1.37, 0.82, at 24, 48 hours respectively, however, at 72 hours there was more significant 
increase with increase from control of 2.2 fold. Although there was marked in induction of 
p53 protein in CHl/TR tumours by cisplatin, the level o f induction of p21 was less (figure 3- 
21 and table 3-11) with fold increases from control of 1.5, 1.1, and 1.9 at 24, 48, and 72 hours 
respectively. II
3.5.3 Bax
Bax protein (21 KD) transactivation by p53 protein has been demonstrated in ovarian cancer
cell lines in vitro following paclitaxel treatment as discussed in sections 1.3.5.2 and
-1.4.1 (Jones NA, 1998). In this study, despite the marked induction of p53 in paclitaxel treated
CHl/TS tumours, there was only slight induction of bax at 48 hours following paclitaxel 
treatment (figure 3-22and table 3-10) with fold increases from control of 0.86, 1.21, 1.17 at 
24, 48, and 72 hours respectively. There was no induction of bax protein in CHl/TR tumours 
following paclitaxel treatment levels of 0.99, 0.84, and 0.85 at 24, 48, and 72 hours 
respectively. Similarly, there was no induction of bax protein in CHl/TR tumours following 
cisplatin treatment with levels of 0.9, 1.02, and 1.0 at 24, 48, and 72 hours respectively (figure 
3-23 and table 3-11).
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3.5.4 B C L-2
The anti-apoptotic protein bcl-2 has been shown to be phosphorylated foliowing paclitaxel 
treatment in vitro and that phosphorylation leads to inactivation of bcl-2 and cell death as 
discussed in 1.4.2. The bcl-2 protein normally runs at molecular weight of 26 KD on SDS- 
PAGE under reducing conditions (Blagosklonny MV, 1997). In most cell line such as breast 
cancer cell line MCF-7, prostate cancer cell line PC3, and HL-60 leukemia, bcl-2 
phosphorylation results in retardation of electrophoretical mobility of the original band with 
appearance of 27 KD bcl-2 band (Blagosklonny MV, 1996).
Figure 3-24 shows the immunoblotting of bcl-2 in CHl/TR and CHl/TS tumours following 
paclitaxel treatment. The 26 KD band is faintly expressed in CHl/TR control untreated 
tumours and more prominent in CHl/TS control tumours. In addition to the regular 26 KD 
bcl-2 band, two other bands at 27 KD and 30 KD were demonstrated. This pattern has been 
described previously. Tang et al detected the presence of 26, 27, and 30 KD bands in prostate 
cancer cell lines PC3 and DU 145 using the same anti-bcl-2 antibody used in the present study 
(sc-492, Santa Cruz) (Tang DG, 1998). Tang et al demonstrated that 27 KD band is the 
phosphorylated isoform of the 26 KD band, but the significance of 30 KD band was not 
known. Guan et al detected in colonic cell line the presence of 30 KD band, in addition to the 
26 KD band and demonstrated that the 30 KD band is the phosphorylated form of the original 
band (Guan RJ, 1996). Of note that in the latter two studies no chemotherapy was 
administered suggesting that these phosphorylated forms are endogenously expressed.
In this study, both 27KD and 30 KD bcl-2 bands were detected in CHl/TS control tumours 
suggesting that these proteins are endogenously expressed, although 30 KD bcl-2 band is 
more prominent (figure 3-24). The densitometery of the 30 KD band following paclitaxel 
treatment showed no significant alteration in its levels in CHl/TS and CHl/TR tumours. The 
ratio level to control in CHl/TS tumours were 1.2, 1.8, and 1.14 and in CHl/TR tumours were 
1.1, 0.87, and 0.85 at 24, 48, and 72 hours respectively (table 3-10). The quantification of 27 
KD band by densitometery was difficult to perform because of its position close to the 26 KD 
band. However, two main observations could be made. The first is that the 27 KD band is
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present almost solely in the CHl/TS treated with paclitaxel. The second is that the 26 KD 
band became faint with increased prominence of 27 KD band following paclitaxel treatment. 
These observations suggested that the 27 KD band may represent phosphorylated form of the 
original 26 KD band, the pattern o f which is affected by paclitaxel treatment. The 27 KD was 
further characterized by incubation of paclitaxel treated CHl/TS tumour lysate with alkaline 
phosphostase. The lysis buffer used to prepare these tumour lysates had no Sodium 
Orthovanadate that inhibit alkaline phosphatase action. The alkaline phosphatse treatment 
resulted in marked increase in 26 KD band with decrease in intensity of 27 KD band 
suggesting that the latter band is phosphorylated form of the 26 KD band (figure 2-26).
Following the treatment of CHl/TR tumours with paclitaxel. The 26 KD band is expressed 
faintly in CHl/TR tumours at 24, and 48hours and becoming more prominent at 72 hours with 
very faint expression of 27 KD band (figure 3-24). Following the treatment of CHl/TR 
tumours with cisplatin (figure 3-25), the 26 KD band could be seen faintly and the 27 KD 
band was not detected. The densitometery the 30 KD band showed no significant alteration at 
24, 48, and 72 hours with ratio to control values of 0.71, 1.02, and 1.27 at 24, 48, and 72 
hours.
Taking together these observations suggest that 27 KD bcl-2 band represented the 
phosphorylated form of 26 KD bcl-2 band which is present endogenously and further altered 
by paclitaxel treatment. It appears that paclitaxel treatment decrease the 26 KD band and 
increase the phosphorylated (inactive form) 27 KD band.
3.5.5 BCL-XL
The anti-apoptotic protein bcl-xl has been shown to be phosphorylated following paclitaxel 
treatment in vitro, which lead to bcl-xl inactivation and lead to apoptosis (Poruchynsky MS, 
1998). The immunobltting pattern of bcl-xl in CHl/TR and CHl/TS follows paclitaxel 
treatment as shown in figure 3-27. In the present study there was no evidence of 
phosphorylation in either cell line following paclitaxel treatment. However, there was a 
decline of the level of the anti-apoptotic protein bcl-xl in CHl/TS but not CHl/TR tumours
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.treated with paclitaxel with the ratio bcl-xl levels to control in CHl/TS tumours of 0.63 
(P=0.09), 0.54 (P=0.026), and 0.35 (P=0.026) at 24, 48, and 72 hours, in contrast, the ratio to 
of bcl-xl levels to control in CHl/TR were 0.83, 0.98, and 0.83 at 24, 48, 72 hours 
respectively (table 3-10). Figure 3-28 shows the immunoblotting pattern following treatment 
of CHl/TR with paclitaxel and cisplatin. Cisplain induced similar decrease in bcl-xl levels. 
With ratio to control levels of 1.0 (P=0.4), 0.73 (P=0.13), and 0.46 (P=0.015) at 24, 48, 72 
hours respectively.
3.5.6 R aM
Following treatment of different cell lines with paclitaxel, it was demonstrated that c-Raf-1 
phosphorylation occurs (Blagosklonny MV, 1997). More recently, it has been demonstrated 
that low concentration paclitaxel can induce mitotic arrest and cell death without 
phosphorylation of c-Raf-1. Figure 3-29 shows immunoblotting for Raf-1 of CHl/TS and 
CHl/TR tumours following the treatment with paclitaxel. There is no evidence of 
phosphorylation of 74,000 Raf-1 protein.
Protein 24 hrs 48 hrs 72 hrs
P53/CH1-TR 1.27±0.19 1.12+0.14 1.42+0.17
P53/CH1-TS 4.73±0.64 3.42+0.29 4.33+0.39
P21/CH1-TR 1.37+0.13 0.82+0.1 2.2+0.18
P21/CH1-TS 1.46+0.45 3.84±0.65 3.6+1.2
Table 3-9: The ratios of p53 and p21 levels to control in CHl/TS (paclitaxel sensitive) and 
CHl/TR (paclitaxel resistant) at 24, 48, 72 hrs following the treatment with paclitxel.
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aProtein 24 hrs 48 hrs 72 hrs
Bax/CHl-TR 0.99+0.06 0.84+0.12 0.85+0.12
Bax/CHl-TS 0.87+0.09 1.21+0.06 1.17+0.075
Bcl-2/CHl-TR 1.1+0.08 0.87+0.28 0.85+0.07
Bcl-2/CHl-TS 1.21+0.18 1.8+0.24 1.14+0.12
BcI-xl/CHl-TR 0.83+0.046 0.98+0.13 0.83+0.19
Bcl-xl/CHl-TS 0.63+0.077 0.54+0.09 0.35+0.09
a
I's
?
S
Table 3-10: The ratios of apoptotic proteins levels to control in CHl/TS (paclitaxel sensitive) 
and CHl/TR (paclitaxel resistant) at 24, 48, 72 hrs following the treatment.
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Protein 24 hrs 48 hrs 72 hrs
P53 2.23+0.15 2.55+0.23 3.3+0.07
Bcl-xl 1.022+0.12 0.73+0.14 0.46+0.013
Bax 0.91+0.05 1.02+0.12 1.0+0.04
Bcl-2 0.71+0.07 1.02+0.25 1.27+0.3
P21 1.51+0.11 0.95+0.17 1.9+0.49
'I
li
Table 3-11: The ratios of apoptotic protein levels to control in CHl/TR tumours at 24, 48, and 
72 hrs following cisplatin treatment.
---------------
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Figure 3-18; Immunoblotting of p53 (53 KD) in CHl/TS and CHl/TR tumours following 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control 
Lane 2: CHl/TS control
Lanes 3-8: CHl/TR tumours treated by paclitaxel.
Lanes 9-14: CHl/TS tumours treated by paclitaxel.
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Figure 3-19: immunoblotting of p53 (53 KD) in CHl/TR tumours following cisplatin and 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control
Lane 2-7: CHl/TR tumours treated with cisplatin 
Lane 8-13: CHl/TR tumours treated with paclitaxel.
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Figure 3-20: Immunoblotting of p2I (21 KD) in CHl/TS and CHl/TR tumours following 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control 
Lane 2: CHl/TS control
Lanes 3-8: CHl/TR tumours treated by paclitaxel.
Lanes 9-14: CHl/TS tumours treated by paclitaxel.
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Figure 3-21: immunoblotting of p21 (21 KD) in CHl/TR tumours following cisplatin and 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control
Lane 2-7: CHl/TR tumours treated with cisplatin 
Lane 8-13: CHl/TR tumours treated with paclitaxel.
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Figure 3-22: Immunoblotting of bax (21 KD) in CHl/TS and CHl/TR tumours following 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control 
Lane 2: CHl/TS control
Lanes 3-8: CHl/TR tumours treated by paclitaxel.
Lanes 9-14: CHl/TS tumours treated by paclitaxel.
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Figure 3-23; immunoblotting of bax (21 KD) in CHl/TR tumours following cisplatin and 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control
Lane 2-7: CHl/TR tumours treated with cisplatin 
Lane 8-13: CHl/TR tumours treated with paclitaxel.
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Figure 3-24: Bcl-2 immunoblotting in CHl/TS and CHl/TR tumours following paclitaxel 
treatment at 24, 48, and 72 hrs showing the 26 KD bcl-2 band and the related 27 and 30 KD 
bands.
Lane 1. CHl/TR control 
Lane 2: CHl/TS control
Lanes 3-8: CHl/TR tumours treated by paclitaxel.
Lanes 9-14: CHl/TS tumours treated by paclitaxel.
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Figure 3-25 immunoblotting of bcl-2 in CHl/TR tumours following cisplatin and paclitaxel 
treatment at 24, 48, and 72 hrs showing the parent 26 KD bcl-2 band and related 30 KD band. 
Lane 1; CHl/TR control
Lane 2-7: CHl/TR tumours treated with cisplatin 
Lane 8-13: CHl/TR tumours treated with paclitaxel.
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Figure 3-26: Characterization of bcl-2 related bands by addition of alkaline phosphatase in 
three CHl/TS tumours.
Lanes 1-3: Tumour lysates with alkaline phosphatase.
Lanes 4-6: Tumour lysates with no alkaline phosphatase.
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Figure 3-27: Immunoblotting of bcl-xl (31 KD) in CHl/TS and CHl/TR tumours following 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1: CHl/TR control 
Lane 2: CHl/TS control
Lanes 3-8: CHl/TR tumours treated by paclitaxel.
Lanes 9-14: CHl/TS tumours treated by paclitaxel.
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Figure 3-28: immunoblotting of bcl-xl (31 KD) in CHl/TR tumours following cisplatin and 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1; CHl/TR control
Lane 2-7: CHl/TR tumours treated with cisplatin 
Lane 8-13: CHl/TR tumours treated with paclitaxel.
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Figure 3-29; Immunoblotting of Raf-1 (74 KD) in CHl/TS and CHl/TR tumours following 
paclitaxel treatment at 24, 48, and 72 hrs.
Lane 1; CHl/TR control 
Lane 2: CHl/TS control
Lanes 3-8: CHl/TR tumours treated by paclitaxel.
Lanes 9-14: CHl/TS tumours treated by paclitaxel.
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3.6 Biological growth studies of CH1/bcl-xl xenografts
In this experiment, the growth studies of CHl/TS, CHl/bcl-xl, and C H I/F 250 (vector 
control) xenografts were performed separately following paclitaxel and cisplatin treatment. 
The results from these three experiments are represented following paclitaxel and cisplatin in 
figure 3-30 and 31 respectively.
The control untreated CHI, CHl/bcl-xl, and CHl/F 250 tumours have similar growth pattern 
with doubling time of 2.6, 3.4, and 4.6 days respectively. The CHI tumours displayed marked 
sensitivity to paclitaxel with complete disappearance of tumours 6 days post last dose of 
treatment and growth delay more than 66.4 days. The CHl/bcl-xl tumours showed initial 
partial response to paclitaxel, which was maintained for 18 days post last dose o f treatment, 
subsequently these tumours began to grow rapidly with specific growth delay o f 34.9 days. 
The CHI/ F 250 tumour showed a prolonged good partial response, which was maintained for 
52 days post last dose of treatment and the calculated growth delay for these tumours was
51.1 days.
Similarly, cisplatin induced complete response in CHl/TS tumours with complete 
disappearance of all tumours 12 days post last dose of treatment and growth delay of more 
than 66.4 days. The CHl/bcl-xl tumours displayed a very short partial response to cisplatin, 
which was maintained for three days only post last dose of treatment followed by rapid 
growth of the tumours with specific growth delay o f 24.6 days only. Interestingly, the CHl/F 
250 tumours displayed some resistance to cisplatin with the good initial partial response 
achieved that was maintained for 22 days followed by growth of these tumours and growth 
delay of 26.6 days.
141
5000-1
4000-
3000-
B 2000 -
000 -
> 4 ^20 807060504030100
Time (days)
Figure 3-^8: Average growth curves of CH1, CH1/bcl-xl, CH1/F250 tumours 
following paclitaxel (25 mg/kg i.p.) treatment. - D -  CH1/control,
CH1/bcFxl/control ’ —0 -C H 1 /F  250/control 
CH1/paclitaxel Rx ’ -o-C H 1/bcl-xl/paclitaxel Rx
CH1/F 250/paclitaxel Rx
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Figure 3-29: Average growth curves of CH1, CH1/bcl-xl, and 
c m /F 2 5 0  tumours following cisplatin treatment - o -  CH1 /control
cm /b cl-x l/con tro l, —O - CH1/F 250/control
-m -  C m /cisplatin  Rx. , - e -  Cm/bcl-xl/cisplatin Rx.
Cm/F 250/cisplatin Rx
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Figure 3-32: immunoblotting of bcl-xl in CHl/TS tumours and CHl/bcl-xl. 
Lanes 1-3: Three CHl/TS tumours.
Lanes 4-6: Three CHl/bcl-xl tumours.
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3.7 Paclitaxel uptake studies and pharmacokinetic analysis o f CHl/bcl-xl 
tumours
This experiment was done as part of uptake study presented in section 3.2. The mean 
paclitaxel concentrations and concentration versus time curves of CHl/bcl-xl, and CHl/TS 
tumours are shown in table 3-12 and figure 3-33 respectively. There was no significant 
difference in mean paclitaxel concentration of CHl/TS, and CHl/bcl-xl tumours at 1, 3, 6, or 
24 hours post treatment. The mean paclitaxel concentration 6 hours post treatment were 
almost equal and represented the mean peak values for the both types o f tumours as shown 
table3-12. Similarly there was no significant difference in the pharmacokinetics parameters 
measured as shown in table 3-13.
The above results suggest that there are no major differences in either intratumour paclitaxel 
concentration or pharmacokinetics to account for resistant pattern to paclitaxel and cisplatin 
observed CHl/bcl-xl tumours as demonstrated in biological growth studies presented in 
section 3.6. This is consistent with in vitro studies that have shown that bcl-xl uptake does not 
affect paclitaxel uptake and, more importantly, does not interfere with microtubular 
polymerization (Ibrado AM, 1997; Liu JR, 1998). Taking together the observation from this 
study and other studies suggest that the expression of bcl-xl resulted in the development to 
chemotherapy.
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Figure 3-33: Intra-tumoural paclitaxel concentration versus time of 
of cm -b c l-x l and CHl/TS after treatment with 25mg/kg i.p. 
of paclitaxel.
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Time (hrs) CHl/TS (^ig/ml) CHl/BCL-XL (pg/ml)
1 0.22+0.09 0.36+0.14
3 3.42+0.13 2.4+0.66
6 6.36+0.47 6.8410.46
24 2.8+0.28 3.89+0.48
Table 3-12: the inta-tumour concentration of paclitaxel in CHl/TS, and CHl/bcl-xl tumours 
following treatment with 25 mg/kg of paclitaxel
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Table 3-13: the pharmacokienitcs parameters measured in CHl/TS, and CHl/bcl-xl tumours 
following treatment with 25 mg/kg of paclitaxel i.p.
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Parameters CHl/bcl-xl CHl/TS
Cnux (ng/ml) 3417.0 3181
AUClast (ng/ml x 
hr)
113325.8 100798
Ti/ 2  Lambda z (hr) 22.1625 15.1624
AUCINF (ng/ml x 
hr)
118881.03 80957.95
-I.'!".
Chapter 4: Discussion of results.
:
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4.1  In tr o d u c tio n
As outlined in section 1.5, the resistance to paclitaxel has been attributed in previous studies 
to three main mechanisms which include altered drug uptake due to expression of MDR 
phenotype, altered microtubule polymerization and content, and alteration in apoptosis 
regulating proteins (Bhalla K, 1994; Horwitz SB, 1993; Kavallaris M, 1997; Parekh H,
1997b). It has been suggested that understanding of resistance to chemotherapy is dependent 
on elucidation of the molecular mechanisms by which anti-cancer drugs induce apoptotic cell 
death. Over the last few years several in vitro studies have demonstrated the importance o f 
apoptosis regulating proteins in the induction and modulation of response to paclitaxel (Liu 
m , 1998; Liu QY, 1997; Strobel T, 1996; Wahl AF, 1996). The induction o f cell death by 
paclitaxel involve these alteration of several apoptosis regulating proteins including p53, p21, 
the pro-apoptotic protein bax, and the anti-apoptotic proteins bcl-2 and bcl-xl (Blagosklonny 
MV, 1995; Blagosklonny MV, 1996). In addition, these studies demonstrated the role o f  the 
signal transduction molecule Raf-I in connecting the polymerization of the microtubules and 
the alteration in apoptotis regulating proteins (Blagosklonny MV, 1997).
The present in vivo study focused on the role of the apoptosis regulating proteins in induction 
of cell death and acquired resistance to paclitaxel. This required a methodological approach 
that progressed through several steps. Firstly, establishment of successful xenografts of CHI 
paclitaxel sensitive (CHl/TS) and CHI paclitaxel resistant xenografts (CHl/TR) from their 
respective cell lines and the conformation of pattern of resistance and sensitivity in vivo. 
Secondly, the assessment of paclitaxel uptake in CHl/TS and CHl/TR tumours because 
differences in intra-tumoural concentration may contribute to the development of 
chemoresistance. Thirdly, flow cytometric analysis of cell cycle alteration and proliferation 
following paclitaxel treatment. Fourthly, the confirmation that paclitaxel induces apoptosis in 
vivo. Finally, the changes in apoptosis regulating proteins were assessed by western blotting. 
In all these steps the effect of paclitaxel was compared and contrasted with an important 
chemotherapeutic agent in management of ovarian cancer, cisplatin. This allowed an in vivo 
evaluation of differences in the mechanisms o f action and induction of cell death between 
cisplatin and paclitaxel.
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4.2 The establishment of xenografts and confirmation of sensitivity
After the evaluation of differences in the expression of apoptosis regulating proteins 
following cisplatin and paclitaxel treatment between the paclitaxel sensitive and resistant 
tumours, the second part of the study was devoted to assess the effect o f overexpression of 
one of these proteins (anti-apoptotic protein bcl-xl) on the response to paclitaxel and cisplatin 
chemotherapy in vivo.
3
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A previous in vitro study has shown that the CHl/TS cell line displayed sensitivity to 
paclitaxel and cisplatin (Rogers P, 1996). However CHl/TR cell line was resistant to 
paclitaxel but retained its sensitivity to cisplatin (Rogers P, 1996). In this study, the biological 
growth studies clearly demonstrated that the CHl/TS tumours displayed marked sensitivity to 
both cisplatin and paclitaxel with maintained complete responses and growth delay o f more 
than 60.1 days (figure 3-1). In contrast, the CHl/TR tumours had a differential response to 
paclitaxel and cisplatin (figure 3-2). The CHl/TR tumours were resistant to paclitaxel with no 
responses in any tumour, while cisplatin induced partial responses in all tumours that was 
maintained on average for 21 days post. This represented the first demonstration that this 
phenotype of acquired resistance to paclitaxel with partial sensitivity to cisplatin developed in 
vitro could be reproduced in vivo.
sI
4.3 Paclitaxel uptake studies
Paclitaxel is hydrophobic drug that enters the cell by passive diffusion (Parekh H, 1997a). 
Chemoresistance to paclitaxel has been associated with induction of multi drug resistance 
phenotype (MDR) and overproduction of P-glycoprotein (PGP) or overexpression o f a novel 
135 KD membrane glycoprotein distinct from the 170-180 KD PGP (Horwitz SB, 1993; Roy 
SN, 1985). Hence, it was important to first assess paclitaxel uptake in CHl/TS and CHl/TR 
tumours by measuring the intra-tumour concentration of paclitaxel by High Performance
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Liquid Chromatography (HPLC) to rule out the presence of major drug efflux mechanisms in 
CHl/TR tumours.
It has been shown previously in vitro that CHl/TS and CHl/TR cell lines do not express P- 
glycoprotein with no major differences in paclitaxel uptake (Rogers P, 1996). In the present 
study, the paclitaxel uptake studies confirmed the in vitro data with no significant difference 
intra-tumoural concentration of paclitaxel between CHl/TS and CHl/TR tumours at 1,3,6, 
and 24 hours following administration of 25 mg/kg of paclitaxel intrapertionally (table 3-1). 
In fact, by 24 hours following paclitaxel treatment, the CHI/TR tumours were able to tolerate 
higher concentration of intra-tumour paclitaxel concentration suggesting that the resistance is 
due to other mechanisms. Similarly, there was no difference all in the pharmacokinetic 
parameters in both tumours (table 3-2).
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Taking together the in vitro and in vivo results demonstrate no significant differences in intra- 
tumoural paclitaxel concentration between the CHl/TR and CHl/TS tumours to account for 
the changes in the growth response to paclitaxel. These observations allowed us to focus on 
potential distal molecular mechanisms of resistance.
3:
4 .4  M e a s u r e m e n t  o f  c e ll  k in e t ic s  b y  f lo w  c y to m e tr y
33The Measurement of cell kinetics by bromodeoxyuridine/anti-bromodeoxyuridine method Îusing flow cytometry provided an in vivo demonstration on different effects of paclitaxel and
. . f t -cisplatin on cell cycle and proliferation. In addition, it allowed a comparison of paclitaxel’s
effect on CHl/TS and CHl/TR tumours.
’:3'
4.4.1 Comparison of mechanisms of action of paclitaxel and cisplatin In
■ftCHl/TS tumours
f t 3I
4.4. t 1  Paclitaxel
The cell cycle analysis results clearly demonstrate that cells are blocked in G2/M phase 
following the treatment of CHl/TS tumours with paclitaxel. The G2/M block was first
detected at 24 hrs and became more marked at 48 and 72 hours post-treatment as shown in 
table 3-3 and figure 3-4. These results are consistent with the initial description G2/M phase 
blockage following paclitaxel treatment by Schiff et al and numerous in vitro studies that have 
followed (RowinskyEK, 1988; Schiff PB, 1979; Schiff PB, 1980).
33
Although the CHl/TS cells treated vsnth paclitaxel were able to traverse the S phase with no 
hindrance (demonstrated by the mean relative value movements (table 3-3) and green (Brd 
Urd uptake) versus red (DNA) bivariate histograms, figure 3-5, there was an increase in the 
mean percentage of cells in S phase with decrease in labelling index at 72 hours post 
treatment. These observations suggest that there is partial inhibition of DNA synthesis 
sufficient to increase percentage in S phase and decrease proliferation at 72 hours without 
hindering the movement through the S phase. Similar observations have been made in vitro 
and in a study of surgical specimens. Zaffaroni et al demonstrated an increase in S phase 
fraction and G2/M block following incubation of A2780 ovarian cell lines with paclitaxel for 
24 hours (Zaffaroni N, 1988). Millenbaugh et al studied the effect of paclitaxel treatment on 
17 three-dimensional histocultures of surgical specimens. It was demonstrated that paclitaxel 
produced partial inhibition of Brd Urd incorporation (LI) in about 40% of tumours where
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incomplete DNA synthesis occurred with induction of apoptosis in about 90% of tumours
(Millenbaugh NJ, 1998). The incomplete inhibition of DNA synthesis is also consistent with
.data in the literature showing that paclitaxel treated cells can proceed with DNA synthesis. 
The mechanism by which paclitaxel inhibits DNA synthesis is unclear, however it has been 
demonstrated that paclitaxel inhibits the initiation of DNA synthesis in fibroblasts stimulated 
by thrombin and epidermal growth factor (Crossin KL, 1981).
Wahl et al suggested that at late times after exposure to paclitaxel (> 40hr) fibroblasts with 
intact p53 showed an increased G1 population with decrease in Brd Urd labelled cells, 
suggesting that cells arrest transiently in G1 in the second cell cycle after the completion o f 
mitosis (Wahl AF, 1996). The G1 inhibition has only been shown in normal cells, and in 
particular there is no evidence for its occurrence in ovarian cancer cell lines. In the present 
study the CHl/TS expressed wild type p53, however there was no demonstrable increase in 
G1 cells at any time point.
Taken together these observations suggest that paclitaxel affects all phases of cell cycle, 
however, maximum sensitivity appear to be at G2/M phase. Donaldson et al demonstrated by 
phase synchronous treatment in fibroblasts that paclitaxel sensitivity is low in G1 and 
increases with progress through the cell cycle with cells in G2/M being most sensitive than 
proliferating cells (Donaldson KL, 1994). Also, in the study by Millenbaugh et al, it was 
demonstrated that the tumour sensitivity to DNA inhibitory effect is opposite to apoptotic 
effect, suggesting that partial inhibition of DNA synthesis does not lead to the induction o f 
apoptosis (Millenbaugh NJ, 1998). The cells held in G2/M block and mitotic arrest are most 
sensitive to paclitaxel and eventually undergo apoptosis (Donaldson KL, 1994).
#
Following the treatment of CHl/TS tumours with cisplatin, there was an accumulation o f 
cells in S phase that was apparent at 24 hours and most marked at 48 and 72 hr (table 3-4 and 
figure 3-6. In addition, at 72-hr post treatment there was an accumulation of cells in G2. 
These observations are consistent with previous in vitro studies that have demonstrated early
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f.inhibition of DNA synthesis (12 h), accumulation of cells in S phase, and slow-down in the 
traverse of cells through the S-phase of their cycle. Subsequently, there is a dose-dependent 
arrest in G2 (Demarcq C, 1992; Sorenson CM, 1990; Sorenson CM, 1988). It has been 
proposed that in G2 the cells reach a point of decision at which they overcome the G2 block, 
divide and then remain in cycle or remain in G2 and die (Sorenson CM, 1990; Sorenson CM, 
1988). I
Three tumours harvested 24 hr post-treatment and five tumours at 48 hr post-treatment had no 
uptake of Brd Urd (table 3-4). The tumours that took Brd Urd showed marked slow down of 
transition through the S phase as reflected by RM and marked decrease in LI table 3-4 and 
figure 3-7, which suggest that the tumours that did not take Brd Urd had complete inhibition 
of DNA synthesis. At 72 hrs, despite the accumulation of cells in S phase at 72 hours and the 
statistically significant retardation of movement through S phase, all the tumors took Brd Urd 
with an increase in LI. These results are consistent with in vitro data which show significant 
early inhibition of DNA synthesis even at the earliest time point of 12 hours, vrith DNA 
synthesis returning between 2 to 5 days when minimal (0.25-0.5 pg/ml) to intermediate (0.5-1 
tig/ml) toxic concentration of platinum used (Sorenson CM, 1988).
I
4.4.2 The effect of paclitaxel on CH1/TR tumours
In contrast to the characteristic cell cycle effects of paclitaxel on CHl/TS tumours, there was 
no demonstrable cell cycle perturbation following the treatment of CHl/TR tumours with 25 
mg of paclitaxel i.p. (table 3-5 and figures 3-8 and 3-9). Because there were multiple G1 
peaks, it was difficult to obtain the percentage of cells in different phases of cell cycle. 
However, the percentage of cells in G1 and G2 phase were estimated, in order to calculate the 
changes in G2; G1 ratio over 72 hours following paclitaxel treatment as discussed in section ft
2.5.3. As shown in table 3-5, there was no difference between the control and treated CHl/TR 
,tumors in the ratio of G2: G1 that has been shown to increase in CHl/TS tumors. Similarly,
there was no alteration in DNA synthesis, movement through the S phase, or inhibition of 
proliferation. The inability of paclitaxel to induce any cell cycle changes is consistent with
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resistance of CHl/TR tumours to paclitaxel as demonstrated by growth studies and suggest a 
failure of paclitaxel-microtubule interaction to trigger cell cycle arrest or apoptosis.
Interestingly, the CHI/TR tumours displayed sensitivity to cisplatin with accumulation of 
cells in S phase as shown in figure 3-10 and 3-11. All tumours took up Brd Urd and there was 
retardation o f movement through S phase but there was no inhibition of proliferation as in 
table 3-6. These observations are suggestive of incomplete DNA synthesis at treatment dose 
of 4mg/kg consistent with partial response of these tumours to cisplatin as previously 
indicated by biological growth studies.
4.4.3 Summary
• Following paclitaxel treatment, the CHl/TS tumours displayed G2/M phase blockage with 
inhibition of proliferation at 72 hours. Following cisplatin treatment CHl/TS displayed 
accumulation of cells in S phase, accumulation of cells in G2 phase at 72 hours, and 
inhibition of proliferation at 24 and 48 hours.
• Following paclitaxel treatment, CHl/TR tumours there was no G2/M phase blockage or 
any cell cycle perturbation. Following cisplatin treatment, the CHl/TR tumours displayed 
accumulation of cells in S phase, but with no inhibition of proliferation and consistent 
partial response of these tumours to cisplatin.
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4 .5  C o n f irm a tio n  o f  in d u c t io n  o f  ce ll d e a th
The cell cycle alterations induced by cisplatin in CHl/TS and CHl/TR tumours and paclitaxel 
in CHl/TS tumour are indicative of the ability o f both drugs to interact with their cellular 
targets and induce cell cycle arrest. However, it was important to determine whether these cell 
cycle changes were associated with apoptosis. Apotosis was assessed by labelling of paraffin 
section using TUNEL assay and the results were correlated with data from DNA histograms, 
which estimated sub-Gl debris.
4.5.1 Induction of apotosis In CHl/TS following paclitaxel and cisplatin 
treatment
4.5.1.1 Paclitaxel
Numerous in vitro studies have demonstrated that paclitaxel induces both mitotic arrest 
followed by apoptosis (Blagosklonny MV, 1996; Poruchynsky MS, 1998) (Bhalla K, 1993). 
Two previous in vivo studies used murine ovarian and mammary carcinoma xenografts 
demonstrated that paclitaxel induced mitotic arrest and apoptosis (Milas L, 1995; Milross CG,
1995). More importantly, these two studies showed sequence dependence in that apoptosis 
followed mitotic arrest.
The results from the present study confirm that paclitaxel induce G2/M block (section 
4.4.1.2), mitotic arrest, and apoptosis in vivo following the administration o f 25 mg/kg o f 
paclitaxel. The results in table 3-7 and figure 3-13 show clearly that there is a statistically 
significant increase in percentage mean apoptotic index (A.I) at 24, 48, 72 hr. The maximum 
AI value was reached at 48 hr (9.3% ±0.98) which represented a slight increase from AI value 
at 24 hr (8.6 ±1.08 %). The difference between these two values was not statistically 
significant. There was a decline in AI value by 72 hr (6.5 ±1.31%) and the difference between 
AI value at 48 and 72 hr was statistically significant (p=0.04). These findings are consistent
with observations made by Milross et al that demonstrated that following the treatment of 
murine ovarian cancer xenografts (OCA-1) with single dose of 40 mg/kg paclitaxel, there was ft:!
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4.5.1.2 Cisplatin
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an increase in AI from control untreated levels of 2% to 12% at 24 hrs, and 10% at 48 hrs, 
followed by a decline to 4% at 72 hrs (Milross CG, 1995). Another study used a single 60 
mg/kg paclitaxel in OCA-1 xenografts induced higher AI at 24hr (17%), followed by a 
decline at 48 hrs (9%) and 72 hrs (5%) (Milas L, 1995). Similarly, the sub-Gl debris values 
were consistent with AI values with increase in mean percentage sub-Gl debris from 
3.27+0,85 (control) to 8.45±0.54, 17.62 ±3.37, 16.42 ±5.28 at 24,48, and 72 hrs.
In addition morphological evidence showed that paclitaxel effectively arrest cells in mitosis
.(figure 3-13). The mean percentage of cells arrested in mitosis as determined by morphology 
increased from control value less than 1% to a peak value of 9.6%, followed by a decline to 
6.4 at 48 hr, and 4.2 at 72 hr. These results are consistent with two previous in vivo studies 
mentioned above that showed that peak values occur early around 9 hours post paclitaxel 
treatment, followed by a decline in to reach background values at 72 hrs. ■Î
The changes in apoptotic index and mean percentage cells in mitotic arrest at 24, 48, 72 hours 
are represented in figure 4-1. The kinetic profile of apoptosis induced by paclitaxel follows 
that of mitotic arrest as determined by morphology, which is consistent with previous finding 
suggestive that mitotic arrest precedes induction of apoptosis. However, the flow cytometric 
analysis of DNA content indicated that CHl/TS cells had an increasing mean G2/M content 
72 hours following paclitaxel treatment. These observations suggest that some of the cells 
arrested in G2/M may escape paclitaxel effect without undergoing apoptosis.
The present study confirms that cisplatin induces apoptosis in vivo (table 3-7, figure 3-14). 
There was a statistically significant increase in apoptotic index at 24, 48, 72 hrs with mean 
percentage values of 13.7%, 20.4%, and 19.4%. These values suggest that cisplatin is more 
effective than paclitaxel in inducing apoptosis. Similar results were obtained by Milross et al 
in OCA-1 murine tumours and demonstrated that cisplatin induces higher and more sustained 
apoptotic peaks at an earlier time point (Milross CG, 1995).
a
14.5.2 Induction of apoptosis in CH1/TR tumours foilowing paclitaxei and 
cisplatin treatment
In contrast to CHl/TS tumours, there was no significant induction apoptosis in CHl/TR 
tumours (table 3-7 and figure 3-16). In addition there was no significant increase in ceils in
I
mitotic arrest from control. However, there was a statistically significant increase in sub-GI 
.debris as shown in table 3-8. The results of Sub-Gl debris should interpreted with caution as
it may contain some necrotic cells. It is noteworthy that the mean increase in the sub-Gl 
.debris in CHl/TR tumours was significantly less than mean increase in sub-Gl in CHl/TS
.tumours. These data confirm a complete failure of paclitaxel to trigger an apoptotic response 
in CHl/TR tumours and consistent with a lack of effect on tumour growth.
■
On the other hand, cisplatin was able to induce apoptosis in CHl/TR tumours, albeit less 
effectively than in CHI/TS tumours (table 3-7 and figure 3-17). The apoptotic index rose 
from 0.99% (control) to 10.4% (24hr), 7.9% (48 hr), and 7.4% (72 hr). Similarly the 
statistically significant increase in sub-Gl after the treatment of CHl/TR tumours with 
cisplatin was less marked than CHl/TS tumours. Again, these data are consistent with partial 
resistance observed in growth studies.
4.5.3 Summary of apoptosis detection studies
1
■.
%
Paclitaxel induced mitotic arrest and apoptosis in CHl/TS tumours and these processes 
probably occur in sequence. Similarly, cisplatin induced significant apoptosis in CHl/TS, 
Paclitaxel failed to induce mitotic arrest or apoptosis in CHl/TR tumour, which is 
consistent with the lack of response in growth studies and lack of G2/M arrest. Cisplatin 
induced apoptosis in CHl/TR tumours, albeit at lower levels compared to CHl/TS
tumours which is consistent with the growth and cell cycle studies. I
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Figure 4-1; C hanges in percentage of ceils in mitotic arrest, G2/M biock, 
and apoptotic index (Ai) over 72 hrs foilowing the treatment of CH1/TS 
tumours with paclitaxei.
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4.6.1 P53 induction and p21
■I
4.6 Apoptosis regulating proteins and paclitaxel mechanisms of action and 
resistance
.The role of apoptosis regulating proteins in the development of chemoresistance is well 
described (Kromer G, 1997; Reed JC, 1994; Reed JC, 1997a). However paclitaxel interaction 
with apoptosis regulating proteins has almost exclusively been demonstrated by in vitro 
studies, and little is known about its effect on these proteins in vivo. By the establishment of 
successfiil CHl/TS and CHl/TR xenografts, we were able to study the dynamic changes in 
apoptosis regulating protein at 24,48,72 hr. The apoptosis regulating proteins assessed were 
p53, p21, bax, bcl-2, bcl-xl, and the signal transduction molecule Raf-1. Because o f the 
contrasting response of CHl/TS and CHl/TR to paclitaxel, the effect of paclitaxel on the 
expression o f these proteins was compared in CHl/TS and CHl/TR tumours. The CHl/TR 
tumours displayed a moderate sensitivity to cisplatin; hence the effect of cisplatin and 
paclitaxel on apoptosis regulating proteins in CHl/TR was compared. The following 
discussion from this point on will not include the effect of cisplatin on CHl/TS tumours. A:
Several in vitro studies have shown that, in wild type p53 cell lines, paclitaxel induces p53 
protein, which is largely mediated by an increase in p53 protein stability mediated by Raf-1 
activation at high paclitaxel concentration (>9nm) and non-Raf-1 dependent mechanism at 
low paclitaxel concentration (Blagosklonny MV, 1995; Torres K, 1998). In the present study, 
p53 protein induction following paclitaxel in CHl/TS tumours was demonstrated in vivo. 
There was significant sustained increase in p53 protein level over 72 hours (table 3-9 and 
figure 3-18). In contrast, paclitaxel induced only a slight increase in p53 in CHl/TR tumours 
(figure 3-18). More importantly, cisplatin was able to induce significant p53 levels in CHl/TR 
(figure 3-19). These changes are summarized in figure 4-2. The observation that cisplatin was 
able to induce significant levels of p53 suggest that p53 induction pathway is intact in
CHl/TR tumours and the lack of significant induction by paclitaxel is probably due to a
.defect proximal to p53 The defect may be localized to microtubules or signal transduction 
events post-tubulin polymerization.
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P53 plays a central role in the regulation o f proteins involved in cell cycle arrest such as p21. 
In vitro studies have demonstrated that paclitaxel induces the accumulation of p21 in both p53 
wild type and p53-null cancer cells (Blagosklonny MV, 1995). In the present study, we were 
able to demonstrate that there was down stream activation of p21 in CHl/TS tumours 
following paclitaxel administration. The induction of p53 by paclitaxel in CHl/TS tumours 
resulted in a similar rise in p21 levels (table 3-9 and figure 3-20). Paclitaxel resulted in 
minimal changes in p21 levels in CHl/TR tumours (figure 3-20). Although there was marked 
in induction o f p53 protein in CHl/TR tumours by cisplatin, the level of induction of p21 was 
less (figure 3-21) with fold increases from control of 1.5, 1.1, and 1.9 at 24, 48, and 72 hours 
respectively. The changes in p21 are summarized in figure 4-3. Thus, at least in CHl/TS 
tumours, p21 protein appears to be p53 dependent. The lack of significant p21 induction in 
CHl/TR tumours following cisplatin despite the significant p53 induction may be due to 
defect in signaling pathway distal to p53.
The exact role of p53 and p21 in the cellular response to mitotic spindle damage by paclitaxel 
remain to be elucidated. P53 induced by paclitaxel has been shown to be involved in G1 and 
G2 checkpoints. It has been demonstrated that paclitaxel blocks cell cycle progression in Gl, 
but only in normal cells (Wahl AF, 1996). P53 facilitates the progression of normal cells 
through mitosis and subsequent arrest in G l, hence it has been suggested that the disruption of 
wild type p53 in normal cells may result in increased in sensitivity to  paclitaxel (Wahl AF,
1996). In most of the in vitro studies involving ovarian cancer cells, the disruption of p53 
results in either no change or decreased sensitivity to paclitaxel (Debernardis D, 1997). In the 
present study there was a marked induction of p53 and p21, but there was no Gl phase arrest 
in CHl/TS tumours treated with paclitaxel (Wu GS, 1996).
Recently, it has been suggested that p53 may play a role during mitotic checkpoint that
■ 1ensures the maintenance of diploidy, and its induction may represent a response to
a
abnormalities in mitotic spindle such as abnormal chromosome segregation (Torres K, 1998). 
Cross et al has shown that mouse cells devoid of the p53-dependent spindle checkpoint are 
capable of completing subsequent cell cycle phases including DNA synthesis, without
complete chromosome segregation (Cross SM, 1995). On the other hand, it has been shown 
that p21 accumulation in both p53 wild type and p53-null cancer is not involved in mitotic 
arrest and -in fact- it occurs as consequence of mitotic arrest (Barboule N, 1997).
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In addition, p53 has been shown to regulate other apoptosis regulating proteins. In some cell
types p53 has been shown to upregulate the expression of pro-apoptotic protein bax and down
regulate the anti-apoptotic proteins bcl-2 and bcl-xl (Miyashita T, 1996; Miyashita T, 1994).
Thus, p53 may induce cell cycle arrest allowing repair before proceeding through cell cycle or
induce apoptosis if the damage is severe. However, most of the in vitro and prognostic studies
suggest that p53 is a determinant o f cell induction of death or survival. This is may be
.particularly relevant in low clinically relevant paclitaxel concentrations where p53 induction 
does not occur.
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Figure 4-2: Mean p53 level changes ± SEM of CHl/TS and CHl/TR tumours 
following paclitaxel (pac) treatment and CHl/TR tumours following cisplatin (cis) 
treatment. The values at 24, 48, and 72 hrs are expressed as a ratio to control, at time 0 
the ratio to control value is taken as 1.
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Figure 4-3: Mean p21 level changes ± SEM of CHl/TS and CHl/TR tumours 
following paclitaxel (pac) treatment and CHl/TR tumours following cisplatin (cis) 
treatment. The values at 24, 48, and 72 hrs are expressed as a ratio to control, at time 0 
the ratio to control value is taken as 1.
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4,6.3 The anti-apoptotic protein bcl-2
In the present study, the immunoblotting of CHl/TS tumours revealed 26KD bcl-2 band and 
two other bands at MW 27 KD and 30 KD (figure 3-24). These two bands were detected in 
CHl/TS control tumours suggesting that these proteins are endogenously expressed, although 
30 KD bcl-2 band was more prominent. It is noteworthy that the control CHl/TR tumours 
expressed the 26 bcl-2 faintly with no expression of 27 KD band. These observations are 
consistent with observation made by Tang et al and Guan et al described in section 3.5,4.
There were no major alterations in 30 KD bcl-2 band following paclitaxel treatment in 
CHl/TS tumours (table 3-10). However, there was decrease in intensity of 26 KD bcl-2 band
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4.6.2 The proapoptotic protein bax
Several in vitro studies have demonstrated that paclitaxel in some cell types is able to induce 
the pro-apoptotic protein bax through p53 induction pathway (Miyashita T, 1996; Miyashita 
T, 1994) (Jones NA, 1998). In contrast paclitaxel was not able to induce bax in other cell l;types (Liu QY, 1997). In the present study, there was marked induction of p53 proteins in ACHl/TS tumours, but there was no significant increase in bax levels in CHl/TS except for 
mild elevation of bax protein at 48 hrs with mean fold increase of 1.21 (table 3-10 and figure 
3-22). In CHl/TR tumours there was no bax induction following either paclitaxel or cisplatin 
treatment (figure 3-23). These changes in bax levels are summarized in figure 4-4.The 
possibility of earlier than 24 hour bax protein peak induction can not be excluded. Similarly 
the possibility that other pro-apoptotic proteins such as bak or bad are induced can not be %excluded.
3The anti-apoptotic protein bcl-2 has been shown to be phosphorylated in vitro following 
paclitaxel treatment leading to loss of anti-apoptotic properties and cell death (Blagosklonny 
MV, 1997; Blagosklonny MV, 1995; Blagosklonny MV, 1996). The molecular weight of bcl- 
2 protein 26 KD protein and its phosphorylated form in most cell run on SDS-PAGE under 
reducing condition at Mw of 27 KD.
with increase in intensity of phosphorylated 27 KD band (figure 3-24). The further 
characterization of 27 KD and 30 KD bands by the incubation of CHl/TS protein samples 
with alkaline phosphatase led to attenuation of 27 KD bcl-2 band and intensification of the 26 
KD bcI-2 band (figure 3-26). These observations suggest that 27 KD bcl-2 band is the 
phosphorylated form o f bcl-2.
In contrast, the paclitaxel treated CHl/TR tumours express the 30 KD bcl-2 band prominently 
with no significant alteration over 72 hours following treatment (3-24). The expression o f  the 
two other bands varied over 72 hours following paclitaxel treatment. At 24 and 48 hours, 
there was faint expression of 26 KD bcl-2 band with no expression of 27 KD band. By 72 
hours following the treatment, the CHl/TR tumours developed very prominent 26 KD bcI-2 
band with faint expression of 27 KD band. Interestingly, the CHl/TR tumours that have 
demonstrated relative sensitivity to cisplatin showed that presence of bcl-2 30 KD and faint 
expression of 26 Kd bcl-2 band, with no expression 27 KD band (figure 3-25).
These observations rise several important points about bcl-2 mechanism:
(a) It remains obscure how the phosphorylated form of bcl-2 death induces cell death. Most in 
vitro suggest suggested that the inactivation of bcl-2 by phosphorylation result in the 
alteration in the balance between the pro-apoptotic and anti-apoptotic proteins 
(Blagosklonny MV, 1996). This result in increase of pro-apoptotic proteins such as bax 
with induction o f bax. However, a recent study has challenged this theory and suggested 
that the phosphorylation of bcl-2 correlated with ability of paclitaxel to induce mitotic 
arrest and with apoptosis as discussed in section 1.4.2. (Ling YH, 1998)
(b) The initial low endogenous level of expression the 26 KD bcl-2 in CHl/TR tumours with 
marked increase by 72 hours following paclitaxel treatment and lack o f significant 
phosphorylation may suggest that bcl-2 is functioning as survival pormoting protein 
which is not amenable to phosphorylation. It is not clear whether this pattern of expression 
in the resistant tumour is due to inherent defect at the protein level or due a more proximal 
defect as discussed in section 4.6.
(c) In the present study, we have demonstrated that the phosphorylated 27 KD band exist 
endogenously, which may reflect a degree of background apoptosis or mitotic. The
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endogenous expression of phosphorylated band is consistent with previous reports.
However, the administration of paclitaxel resulted in the relative expression of the 
unphosphorylated and phosphorylated bands.
4.6A The anti-apoptotic protein bcl-xl
It has been demonstrated that bcl-xl may undergo phosphorylation following paclitaxel 
treatment (Poruchynsky MS, 1998). However, in the present study there was no evidence of 
bcl-xl phosphorylation in either CHl/TS or CHl/TR tumours following paclitaxel treatment. 
However, there was statistically significant decline in bcl-xl levels in CHl/TS tumours 
following paclitaxel treatment. Following treatment with paclitaxel, the ratio bcl-xl levels to 
control in CHl/TS tumours was 0.63,0,54, and 0.35 at 24, 48, and 72 hours (table 3-10, 
figure 3-27). In contrast, there was no similar decline in bcl-xl levels in CHl/TR tumours 
following paclitaxel treatment with the ratio to of bcl-xl levels to control in CHl/TR of 0.83,
0.98, and 0.83 at 24, 48, 72 hours respectively. Interestingly, Cisplatin induced a decrease in 
bcl-xl level in CHl/TR tumours. With ratio to control levels of 1.0, 0.73, and 0.46 at 24, 48,
72 hours respectively (figure 3-28). These changes in bcl-xl level are summarized in figure 4- 
5.
The decline in bcl-xl level may be due to the ability of bcl-2 family members -including bel- f  
xl to form heterodimers with pro-apoptotic proteins leading to the alteration of balance of 
these proteins (Kromer G, 1997; Reed JC, 1997a). The reduction in bcl-xl level has been 3 |
previously shown to occur due to hetcardimerization with pro-apoptotic proteins such as bax, 
bak, or bad (Ottilie S, 1997; Simonian PL, 1997; Wang K, 1998). In this study, The total 
levels of bax protein have been shown to be unchanged over 72 hours, however the induction 
of other pro-apoptotic proteins such as bik, bak, or bad can not be ruled out. In addition, the 
decline in total levels of bcl-xl has been shown to be due to down regulation of bcl-xl m- 
RNA. Paclitaxel treatment of prostate cell line (LNCaP cell) led to almost total down- 
regulation of bcl-xL protein in the absence o f alteration of bax, bak, or bcl-2 levels, which 
was paralleled by a similar decrease in the level of bcl-xL mRNA, as demonstrated by reverse fi 
transcription-PCR (Liu QY, 1997).
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4.6.5 Signal transduction molecule: Raf-1
I
Taken together the results from the present study and other studies suggest that the decline in 
bcl-xl levels may be induced by different chemotherapeutic agents such as paclitaxel and
';Acisplatin. O f particular importance that the decline in bcl-xl levels in CHl/TR tumours 
occurred with cisplatin where a response has been demonstrated by growth studies, cell cycle 
analysis, induction of apoptosis, but not following paclitaxel administration where no such 
observation were made. These observations suggest that there is no inherent defect in bcl-xl 
protein and that the pathway involved in its down regulation was able to function following
. %induction of cell death signal by cisplatin. Moreover, it suggests that the alteration in levels o f 
bcl-xl may be a major determinant of cell death or survival following chemotherapy
treatment.
It has been shown that the polymerization of microtubules leads to initiation of signaling 
cascade involved in alterations in p53, p21, bcl-2, and bcl-xl (Blagosklonny MV, 1997). The 
induction of p53 and p21 and phosphorylation of bcl-2 and bcl-xl was shown to be dependent 
on the signal transduction molecule c-Raf-1 (Blagosklonny MV, 1997; Blagosklonny MV,
1995; Poruchynsky MS, 1998). In the present study, there was no evidence of c-Raf-1 
phosphorylation in either CHl/TS or CHl/TR tumours (figure3-29). A recent study suggested 
that c-Raf-1 phosphorylation may be dependent on paclitaxel concentration. The in vitro 
studies have shown that paclitaxel concentration greater than 9nM is needed before 
phosphorylation of c-Raf-1. Since a fixed dose of paclitaxel was used in this study, 
phosphorylation of c-Raf-1 can not ruled out with higher dose of paclitaxel, although the 
strain of nude mice used in this study do not tolerate significantly higher doses of drug in the 
schedule rate of administration used. :: j
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4.6.6 Summary of alteration in apoptosis regulating proteins following 
paclitaxel treatment
• Following paclitaxel treatment of CHl/TS tumours, there was evidence of induction of 
p53 and p21, bcl-xl down regulation, and phosphorylation of bcl-2. However, there was 
no bax or Raf-1 induction.
• Following treatment of CHl/TR tumours, there was no significant induction of p53, p21, 
or alterations in bcl-xl, bcl-2, bax, or Raf-1. However, cisplatin still induced p53 and 
down regulated bcl-xl in CHl/TR tumours with no bcl-2 phosphorylation or bax 
induction. These observations suggest that p53 pathway is intact in CHl/TR tumours, but 
paclitaxel fails to trigger the observed damage seen in CHl/TS tumours.
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Figure 4-4: Mean bax level changes ± SEM of CHl/TS and CHl/TR tumours 
following paclitaxel (pac) treatment and CHl/TR tumours following cisplatin (cis) 
treatment. The values at 24, 48, and 72 hrs are expressed as a ratio to control, at time 
0 the ratio to control value is taken as 1.
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treatment. The values at 24, 48, and 72 hrs are expressed as a ratio to control, at time 0 
the ratio to control value is taken as 1.
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4 .7  P r o p o s e d  m o d e l f o r  a c q u ir e d  r e s i s t a n c e  o f  C H 1/TR  tu m o u r s
Based on the observations of this in vivo study and other in vitro studies (Blagosklonny MV, 
1997; Blagosklonny MV, 1995; Blagosklonny MY, 1996; Horwitz SB, 1993), a model could 
be proposed to explain the resistance o f CHl/TR tumours. There was no difference in 
paclitaxel uptake between paclitaxel resistant and sensitive tumours suggesting a more distal 
defect to account for the resistance o f CHl/TR tumours. In CHl/TR tumours, there was a 
failure to induce G2/M arrest and apoptosis. In vitro studies have shown that microtubules 
polymerization is needed for activation of a signal transduction molecule such as Raf-1 
kinase, which in turn is involved in induction of p53 and p21 and phosphorylation 
(inactivation) of bcl-2 (Blagosklonny MV, 1997). It could be postulated that the lack of 
successful polymerization of microtubules may result in the lack o f initiation o f down stream 
pathways involved in apoptosis, including p53 and p21 induction, bcl-2 phosphorylation, and 
bcl-xl down regulation. The demonstration that these pathways can still be induced by 
cisplatin suggest that they remain intact, and further suggests that lack of response to 
paclitaxel is due to a proximal step possibly at the level of polymerization of microtubules.
4.8 Alteration of response to paclitaxel by overexpression of anti-apoptotic 
protein bcl-xl
Bcl-xl is a member o f bcI-2 family o f  proteins, and shares significant homology with bcl-2 in 
its BHl and BH2 regions. By alternate splicing, the gene encodes for two important protein 
isoforms of which the longer bcl-xl is an anti-apoptotic protein, whereas the shorter isoform 
bcl-xs is pro-apoptotic (Yang E, 1996).
Several in vitro studies have shown that the overexpression of the anti-apoptotic protein bcl- 
xl results in inhibition o f apoptosis due to various stimuli including paclitaxel (Minn AJ,
1995; Tang C, 1994; Yang E, 1996). Furthermore, bcl-xl overexpression has been shown to 
inhibit paclitaxel-induced apoptosis in A2780ovarian cancer cell line, human acute myeloid 
leukaemia HL-60, prostate cell line (Ibrado AM, 1997; Liu JR, 1998). It has been postulated
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that anti-apototic effect of overexpression bcl-xl is due to the formation of heterodimers 
between pro-apoptotic and anti-sqpoptotic proteins that alter their balance as discussed 
previously.
In the present study, we established successful xenografts of CHI paclitaxel sensitive cell 
transfected with bcl-xL In three separate experiments, the established CHl/TS, CHl/TS-bcl- 
xl, and CH1/TS-F250 (transfected by vector only) xenografts were treated with either 
paclitaxel or cisplatin. Figure 3-30 and 3-31 represents the growth curves of these three types 
of xenografts following paclitaxel and cisplatin. These results demonstrate that bcl-xl may 
modulate tumour response to paclitaxel. There was an initial partial response to paclitaxel but 
these tumours began to grow rapidly 12 days following last dose of treatment, while the 
CHl/TS and CHl/TS-250 demonstrated marked persistent sensitivity to paclitaxel. The 
specific growth delays were 66.4, 51,1, 34.9 days for CHl/TS, CH1/TS-F250, and CHl/bcl-xl 
respectively reflecting these tumours sensitivity to paclitaxel. The immunoblotting of bcl-xl 
protein showed that there was a three-fold increase in bcl-xl protein CHl/bcl-xl compared to 
CHl/TS tumours (figure 3-33). The initial response to paclitaxel may be explained by the 
possibility of heterogeneous expression on bcl-xl within the tumour following transfection; 
thus cell expressing no or small amount may undergo cell death leaving resistant focus of 
cells expressing of bcl-xl that grow rapidly subsequently.
The paclitaxel uptake studies showed that there was no significant difference in intra-tumour 
paclitaxel concentration between CHl/TS and CHl/bcl-xl, hence excluding any drug efflux 
mechanism contributing to resistant phenotype. These results are consistent with previous in 
vitro studies which demonstrated that bcl-xl overexpression does not alter paclitaxel uptake 
and more importantly does not affect tubulin polymerization following paclitaxel treatment 
(Ibrado AM, 1997). The observations from this study and previous in vitro suggest that high 
endogenous levels of bcl-xl may represent a distal mechanism which opposes drug induced 
apoptosis. The mechanisms by which bcl-xl inhibit cell death remain unclear, however it has 
been suggested that overexpressed bcl-xl reduce the amount of free bax induced by paclitaxel 
resulting prevention o f cell death.
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The hypothesis that bcl-xl may represent a distal mechanism of resistance is strengthened by 
results following treatment of CHl/bcl-xl by cisplatin treatment of treatment. The CHl/bcl-xl 
tumours displayed a very short partial response to cisplatin, which was maintained for three 
days only post last dose of treatment followed by rapid growth of the tumours with growth 
delay of 24.6 days only. The CHI tumours showed marked sensitivity to cisplatin with growth 
delay of more than 66.4 days. However, CHl/F 250 tumours displayed some resistance to 
cisplatin with a good initial partial response achieved that was maintained for 22 days 
followed by growth of these tumours and growth delay of 26.6 days. The partial resistance 
displayed by CH1/F250 may be explained on the basis that cisplatin act on DNA where the 
DNA viral vector is incorporated; hence it may influence the response to cisplatin.
Overall these in vivo results are consistent with previous in vitro results suggesting that the 
overexpression of anti-apoptotic protein bcl-xl may result in modulation of response to 
chemotherapy -  in particular paclitaxel- by acting through a distal mechanism. This 
observation could gain clinical significance because of demonstration that ovarian cancer cells 
with de novo in previous in vitro studies high levels of bcl-xl, which may represent a target 
for modulation.
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5.1 P a c li ta x e l  a n d  a p o p to s i s :  Im p l ic a t io n s  fo r  r e s i s t a n c e
Paclitaxel has established an evolving role in the management of ovarian cancer. The 
demonstration in this in vivo study and several in vitro studies that cisplatin and paclitaxel 
have different cellular targets suggest that the combination o f both drugs may overcome the 
resistance to either of them. The biological growth studies have demonstrated that cisplatin 
induced response in CHl/TR tumours where there was resistance to paclitaxel. Similarly, the 
demonstration in vitro that p53 status influences the outcome in terms of response and 
survival when cisplatin used, but not with paclitaxel suggest that combination chemotherapy 
may be more useful. In fact, at least two randomized trails using combination cisplatin and 
paclitaxel adjuvant treatment have shown survival advantage for patients treated with 
combination chemotherapy, further strengthening this argument (McGuire WP, 1996; Stuart 
G, 1998). However, the emergence of resistance to paclitaxel is likely to become an 
increasing problem, and thus a reason for failure of the therapy of ovarian cancer. 
Understanding the molecular pathways involved in the development of resistance to paclitaxel 
may provide suitable targets for novel therapies to help to circumvent resistance to paclitaxel.
Previous in vitro studies have identified three main mechanisms of resistance to paclitaxel. 
The first two mechanisms operate proximally and include the expression of MDR phenotype 
and the alterations in polymerization of the microtubules. The third mechanism operates 
distally, involving an expanding family of apoptosis regulating proteins which include p53, 
the pro-apoptotic protein bax, and the anti-apoptotic proteins bcl-2 and bcl-xl. The ability of 
paclitaxel to induce bcl-2 phosphorylation, induce bax expression, and down regulate bcl-xl 
has been shown to induce cell death in vitro. Hence, these apoptosis regulating proteins were 
the focus of the present in vivo study as they may either represent oncogenes responsible for 
acquired resistance, or alternatively potential targets for molecular intervention to circumvent 
resistance to paclitaxel.
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5.1.1 Apoptosis regulating proteins: Changes with acquired resistance
More importantly, we demonstrated that the cell cycle alterations induced in CHl/TS 
tumours following paclitaxel and cisplatin treatment, and in CHl/TR tumours following
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Despite the abundance of in vitro studies, there is a paucity of information in vivo regarding 
paclitaxel's mechanism of action and the basis for acquired resistance. An ideal scenario 
would be to study xenografts established from cells of patients before and following the 
development de novo resistance to avoid cell selection pressures induced by in development 
of acquired resistance in vitro (Kaye SB, 1996a). However, this approach is hindered by 
difficulty of obtaining adequate samples, propagation o f cells, and establishing successful 
xenografts. Nevertheless, the present study provided an insight to mechanism of action and 
resistance of paclitaxel using xenografts o f cell lines which had acquired resistance in vitro.
In the present study, we demonstrated that following intraperitonial delivery sufficient intra- 
tumoural paclitaxel concentrations were achieved to induce cytotoxicity, with no significant 
uptake difference between the sensitive and resistant tumours. In this model therefore, an 
MDR-like phenotype is not responsible for resistance to paclitaxel.
The cell cycle analysis and proliferation studies provided an insight into the mechanisms of 
action of paclitaxel and cisplatin in vivo. In CHl/TS tumours paclitaxel induced G2/M arrest 
with inhibition of proliferation at 72 hours following treatment. In contrast, cisplatin induced 
accumulation o f cells in S phase with an early inhibition o f cell proliferation. These 
observations reflect the damage induced by paclitaxel and cisplatin on their known targets, the 
microtubules and DNA, respectively, and are consistent with in vitro studies (Demarcq C, 
1992; Ormerod MG, 1996; Rowinsky EK, 1990). Furthermore, it was demonstrated that in 
paclitaxel resistant tumours (CHl/TR) there were no cell cycle alterations following 
paclitaxel, although accumulation of cells in S phase was still obsereved following cisplatin. 
This would be consistent with a phenotype of acquired resistance to paclitaxel where the drug 
for whatever reason, failed to induce G2/M arrest, yet the same cells remained sensitive to 
DNA damage with capacity to induce cell cycle arrest.
.'■■til
cisplatin treatment only, were accompanied by significant apoptosis. The failure of paclitaxel 
to induce G2/M arrest and apoptosis in CHl/TR tumours despite adequate levels of the drug 
are suggestive of an acquired inability to trigger apoptosis.
I
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The contribution of apoptosis regulating proteins to the induction of cell death and resistance 
by paclitaxel was evaluated. We demonstrated that following paclitaxel treatment of CHl/TS 
tumours, there was significant induction of p53, evidence bcl-2 phosphorylation, and down 
regulation of bcl-xl. Again, these observations are consistent with in vitro studies that are 
associated with an ability of paclitaxel to induce cell death. Following paclitaxel, the CHl/TR 
tumours failed to demonstrate significant p53 induction, bcl-2 phosphorylation, or down 
regulation of bcl-xl. This raises a question as to whether these differences between sensitive 
tumours in expression of apoptosis regulating proteins following paclitaxel are due to an 
upstream defect or an inherent defect in expression of these proteins. The demonstration that 
cisplatin was able to induce significant levels o f p53, down regulate bcl-xl, and induce cell 
death in CHl/TR tumours suggests that the acquired resistance to paclitaxel is not associated 
with an inherent defect in the distal pathways, but instead due to an upstream defect possibly
at the level of microtubules. It is known that successful polymerization of microtubules is'required for induction of cell death, induction o f p53 and p21 and phosphorylation of bcl-2 
(Blagosklonny MV, 1997).
Î
It has been suggested by several in vitro studies that induction of p53 by paclitaxel may result 
in significant induction of the pro-apoptotic protein bax, and that this may contribute to a p53- 
dependent mechanism of cell death (Miyashita T, 1996; Miyashita T, 1994). However, in the 
present study, we observed no significant induction of bax despite a significant induction of 
p53. A similar observation has been made in vitro where induction of other pro-apoptotic i
Î
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proteins other than bax were found, such as bak (Liu QY, 1997). The role o f p53 in regulating 
pro-apoptotic genes in response to paclitaxel remains an area for fiiture study.
There has been recent debate about the role of phosphorylation of the anti-apoptotic protein 
bcl-2 following paclitaxel, and in particular whether this inactivates
bcl-2 and contributes directly to cytotoxic drug-induced cell death. While we detected 
evidence for phosphorylation of bcl-2 in CHl/TS cells after paclitaxel, we failed to see 
significant phosphorylation (activation) of Raf-1 kinase which is thought to be the mediator of 
paclitaxel induced phosphorylation of bcl-2. An absence of phosphorylated bcl-2 was seen in 
control untreated CHl/TR resistant versus CHl/TS sensitive cells, with a complete failure of 
paclitaxel to trigger subsequent phosphorylation of bcl-2. This may relate to differences in 
endogenous expression of bcl-2 which could account for a failure to trigger apoptosis. 
Alternatively, there may be a difference in cell kinetics in the resistant tumours with a failure 
to undergo any mitotic arrest which could be related to an acquired tubulin defect, resulting in 
a failure to see any phosphorylated bcl-2. This would be the case if as Ling et al suggest that 
the phosphorylation of bcl-2 is a marker o f M-phase events and not a determinant of 
apoptosis.
Overall, in this model, we failed to see significant endogenous differences in apoptosis 
regulating proteins in the CHl/TR tumours to account for acquired resistance to paclitaxel. 
Indeed, their continued expression in response to cisplatin further supports the argument that 
acquired resistance to paclitaxel occurs because of a failure to trigger changes in levels of 
these proteins, rather than inherent differences in their expression. The likely level o f  this 
could be at the microtubules where an acquired defect in tubulin structure, such as 
overexpression or point mutations of p-tubulin isotypes which have been recognized 
(Giannakakou P, 1997; Horwitz SB, 1993; Kavallaris M, 1997), fails to allow a cytotoxic 
message to be delivered to cells. Assays are available to measure the polymerization of 
microtubules in vitro (Blagosklonny MV, 1997; Kavallaris M, 1997), and studies are now 
undergoing to see if polymerization of CHl/TR Cells is in any way altered compared with 
CHI cells.
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5 .1 .2  A p o p to s i s  r e a u la t in q  p r o t e i n s :  O v e r e x p r e s s io n  m o d u la t in g  r e s i s t a n c e
In the second part of this study, we demonstrated that the overexpression of the anti-apoptotic 
protein bcl-xl resulted in development of resistance both to paclitaxel and cisplatin. This 
observation was particularly important because it demonstrated that these proteins do control 
a common pathway controlling cell death, and further underline their importance as possible 
targets for molecular therapy.
Other potential molecular therapeutic interventions may include:
(1) Downregulation of anti-apoptotic proteins such as bcl-xl and bcl-2 by the development of 
antisense oligonucleotide to bcl-2 or bcl-xl. The aim of this approach would be to reduce 
the balance of anti-apoptotic proteins, thus rendering the cell more susceptible to an 
apoptotic stimulus, either endogenously or following chemotherapy. In fact, the antisense 
bcl-2 oligonucleotide is already in clinical trails and has shown promising results in 
lymphoma (Reed JC, 1997b; Webb A, 1997).
(2) Overexpression of pro-apoptotic proteins such bax or bad using gene therapy. Such an 
approach has already been shown to improve chemosensitivity to paclitaxel in vitro 
(Strobel T, 1996; Strobel T, 1998b). It is proposed to conduct more experiments where by 
the pro-apoptotic protein bax is overexpressed in both CHl/TR and CHl/bcl-xl cells to 
see whether the previously demonstrated resistance in these tumours. This is particularly 
important because if the overexpression of bax were able reverse resistance to paclitaxel 
in both CHl/TR cells (where there is no endogenous difference in levels of anti-apoptotic 
proteins, except perhaps an absence in levels of phosphorylated bcl-2), and in CHl/bcl-xl 
cells (where overexpression of anti-apoptotic protein induced resistance to paclitaxel). If 
resistance were overcome in both cells, this would support a strategy of up regulating 
tumour levels o f pro-apoptotic proteins as a general approach to bypass multiple 
mechanisms o f resistance.
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Finally, the signal transduction pathway between microtubule polymerization and alteration 
in apoptosis regulating proteins remains obscure. Ultimately this may provide a clue as to the 
basis of acquired resistance to paclitaxel in CHl/TR cells, and further studies of Raf-1 kinase 
are merited. A better understanding of this pathway of may provide important new targets for 
molecular intervention.
i
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